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ABSTRACT 
Nercapturic acids are urinary metabolites which signal exposure to 
genotoxic compounds. Carefully designed hapten-protein conjugates 
and a judicious screening strategy has enabled the generation of 
compound and class-specific antibodies which bind mercapturic acids. 
S-phenylmercapuric acid (S-PMA) is a highly specific and sensitive 
marker of benzene exposure A monoclonal antibody reactive with S-
PIIA has been generated. The immobilised antibody retains 
immunoreactivity and can he used to enrich S-PMA from the urine of 
benzene exposed workers. The performance of the imrnunoaffinity 
column has been validated by comparison with data obtained from 
GC/NS analysis of urine from benzene exposed workers (range 12-
168ug/l. corr. coeff. 0.98, n=23). Furthermore immunoaffinity 
chromatography facilitates the quantitative determination of urinary 
S-PMA by HPLIC. Bioconcentration of S-PHA from the urine of benzene 
exposed workers has permitted the quantification of S-PNA by HPLC at 
8 hour Time Weighted Average exposures of around lppm. 
Monoclonal antibodies to low molecular weight mercapturic acids (eg. 
S-(2-hydroxyethyl)mercapturic acid) were generally of too low 
affinity for practical application. As an alternative approach 
antibodies to adducted protein were investigated. Antibody 4D3 binds 
the adducted N-terminal heptapeptide released from the alpha-chain 
of haemoglobin by trypsin hydrolysis. Initial studies suggest 
antibody 4D3 can bind the adducted heptapeptide in whole 
haemoglobin- This may facilitate the determination of adducted 
haemoglobin in hiomonitoring studies. 
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CHAPTER ONE 
THE DEVELOPMENT OF COMPOUND AND CHEMICAL CLASS-SPECIFIC 
ANTIBODIES FOR THE DETECTION, IDENTIFICATION AND 
EXPOSURE MONITORING OF GENOTOXIC CARCINOGENS 
INTRODUCTION 
1.1 GENOTOXICITY 
There is little doubt that chemists have contributed to the improved 
quality of human life by the synthesis of a whole host of 
industrial, agricultural and medicinal compounds. However, human 
exposure to certain chemicals remains hazardous. A correlation 
between chemical exposure and cancer incidence in humans was first 
recognised some 200 years ago in 1775 by Percival Potts. Potts 
observed that the occurrence of scrotal cancer in chimney sweeps 
appeared to he related to their exposure to soot and tar. Today, 522 
agents have been shown to be carcinogenic in animal studies and 55 
compounds are associated with the formation of cancers in humans 
(Ashby and Paton 1992). 
It is now generally accepted that most chemical carcinogens and 
probably all chemicals that induce cancer de novo, ie. cancer 
initiators, operate via a mutational or genotoxic mechanism (Wright, 
1991). DNA is the key (primary and critical) target of the genotoxic 
carcinogens - the essential requirement being the possession of a 
centre(s) of electrophilic reactivity which permits chemical 
reactions with nucleophilic centres in the target molecule. In many 
instances this electrophilic reactivity is conferred on unreactive 
precursor molecules by metabolic activation in exposed organisms 
(Miller 1978, Miller and Miller 1981). The primary products formed 
during the reactions between genotoxic chemicals and DNA are 
generally promutagenic (or lethal), and their occurrence leads to an 
increased risk of mutation and cancer. The detection of these 
products, therefore, signals exposure to a genotoxic carcinogen(s) 
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and their chemical characterisation and measurement provides a basis 
for identifying and estimating the doses of ultimate carcinogens 
delivered, to their critical target (target dose) - essential for 
proper risk assessment. At present it is thought that there is no 
absolutely safe exposure dose and that the initiating actions of 
genotoxic chemicals (cancer initiation, genetic disorders) are 
additive and cumulative with no operational threshold in the low 
dose range (Wright 1990, Britton et al 1991). Among these products, 
DNA adducts have been singled out for special attention, not only 
because of their rautagenic or cancer initiating properties, but also 
because of the high sensitivity, specificity and resolving power of 
the methods available for their analysis. 
The measurement of DNA adducts in tissues probably provides the most 
direct and satisfactory basis for detecting, identifying and 
measuring critical exposures to ultimate genotoxic agents. However, 
tissue DNA is not readily available for such monitoring purposes in 
human populations and a surrogate dose monitor is required In 
addition to reactions undergone with DNA, genotoxic chemicals also 
react with nucleophilic centres in protein molecules giving rise to 
the corresponding range of protein adducts. The reactivity of 
genotoxic chemicals for proteins has led to the use of readily 
accessible blood proteins (eg. the haemoglobin of circulating 
erythrocytes) as surrogates for tissue DNA to monitor human 
exposures to known and previously unknown or undetected hazards. 
(For a review see Ehrenberg, 1991). 
In addition to reactions with informational macromolecules, 
electrophiles also undergo spontaneous and enzyme-catalyzed 
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reactions with the sulphydryl group of glutathione to form adducts 
(or conjugates.)- In the main, such reactions represent an effective 
detoxification step leading ultimately to the excretion of the 
electrophile in the form of the corresponding mercapturic acid 
conjugate in the urine. 
In general, and in quantitative terms, the production of glutathione 
adducts far exceeds reactions with both DNA and proteins. 
Consequently, urinary mercapturic acids provide a valuable source of 
material for the detection, identification and monitoring of 
exposures to genotoxic chemicals. However, the analysis of 
mercapturic acids, particularly the initial preparative work prior 
to assay, are complex and lack the desired sensitivity. Monoclonal 
antibodies can he used in an immunoaffinity column to isolate small 
quantities of specific chemicals from complex matrices as an aid to 
quantification of these chemicals by physico-chemical methods. 
Immunoaffinity chromatography is a form of adsorption chromatography 
in which the molecule to be purified is specifically and reversibly 
adsorbed by an antibody molecule (ligand) covalently attached to an 
insoluble support (matrix). The compound to be purified is applied 
in a solution to the column bed and is selectively adsorbed by the 
immobilised antibody. After washing away unbound material, the 
affinity complex is dissociated and the purified compound eluted. 
A major aim of this project was to develop single step 
iminunoextraction procedues to facilitate and improve the qualitative 
and quantitative analysis of both known and currently unknown 
mercapturic acids. 
1.2 GLUTATHIONE 
The tripeptide glutathione, -L-glutamyl-L-cysteinylglycine, (Fig. 1 
1) discovered in the 1920Th by Sir F. G. Hopkins, has been a subject 
of intensive study. It is the commonest intracellular thiol and is 
present in bacterial, plant and animal cells in high concentrations. 
In mammalian cells, for example, the intracellular level of 
glutathione is in the range of 0.5-10mN. Glutathione functions 
though its glutamyl bond and SH group in many biological processes 
including metabolism, transport and cellular protection (Larsson 
1983, Meister and Anderson 1983). 
Glutathione is synthesized in the liver in two stages (Figure l2) 
First, the formation of a glutamyl linkage between L-glutamate and 
L-cysteine is catalyzed by glutamyl-cysteine synthetase. This is 
followed by the addition of glycine to the glutamyl-cysteine 
molecule catalyzed by glutathione synthetase. Over 99% of the 
intracellular glutathione is in the reduced form GSH, and it is GSH 
which is actively transported from the liver to other organs 
(Griffith and tliester 1979 and Meister 1983). 
Breakdown of GSH also occurs intracellularly (Figure 1.2). Glutamyl 
transpeptidase initiates GSH degradation either by transpeptidation, 
in which glutamyl is transferred to a peptide acceptor, auto-
transpeptidation or hydrolysis. Synthesis, transport and catabolism 
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Figure 1.2 The Glutamyl Cycle 
n. 
The glutamyl cycle plays an important role in the cellular uptake of 
glutasnyl amino acids, and GSH appears to be the storage and 
transport form of the amino acid cysteine. 
GSH itself plays a major role in cellular oxidation-reduction 
reactions. Under conditions of oxidative stress GSH can be 
reversibly oxidized, either enzymatically or non-enzymatically, 
leading to an increase in the disulfide (GSSG). 
Cells are continuously exposed to a range of oxidative insults - 
both hydrogen peroxide and free oxygen radicals are the products of 
many normal cellular reactions. Free radicals also result from 
exposure to ionizing radiation, or from the administration of 
certain drugs. 
GSH functions in other reductive processes essential for cellular 
metabolism including protein synthesis, protein degradation, and in 
alternative pathways of ribonucleotide reduction. 
GSH is known to function as a cofactor in several enzyme systems. 
It is a cofactor in the glyoxalase system which eliminates cellular 
keto-aldehydes. Keto-aldehydes inhibit cell proliferation and this 
may explain how cellular thiols play a role in the control of cell 
proliferation. 
GSH levels decrease with age and falling levels may play a part in 
cell ageing. GSH may also be involved in autoirnmune disease, the 
incidence of which increases with age. GSH levels are known to vary 
in patients with diabetes, and some forms of diabetes are considered 
to be autoimmune diseases. 
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1.3 GLUTATHIONE TRANSFERASES 
The excretion of foreign compounds as N-acetylcysteine derivatives, 
the mercapturic acids, was first noted in 1879 (Baumann et al) but 
it took many years before glutathione was shown to be the source of 
cysteine. Nakashima et al (1934) reported naphthalene depleted GSH 
in the liver cells and eye lenses of rabbits, and Yamamoto et al 
(1944) demonstrated that a fall in liver GSH when rabbits were dosed 
with bromobenzene was related to an increase in mercapturic acid 
excretion. Barnes et al (1959) observed the same in rats for a 
number of different mercapturic acid precursors, and showed that the 
rate of GSH turnover in the liver was sufficient to sustain 
mercapturic biosynthesis. 
It was Booth (1961) who confirmed the presence of a liver enzyme 
which could catalyze the conjugation of foreign compounds with 
glutathione. Investigations soon demonstrated many different GSH-S 
transferases. These enzymes were shown to catalyze more than one 
reaction and were initially classified according to the type of 
substrate involved (eg. GSH S-aryltransferase, GSH S-
epoxidetransferase, GSH S-alkyltransferase, GSH S-alkenetransferase, 
GSH S-aralkyltransferase) (Chasseud 1979). 
It is now known that these enzymes possess a broad and overlapping 
substrate specificity, and a key factor in the reaction of the 
substrates appears to be the electrophilicity of the carbon atom 
which the GSH attacks. By contrast, GSH S-transferases have an 
almost absolute specificity for GSH as the thiol substrate. The GSH 
S-transferases appear to act by bringing the electrophilic substrate 
into close proximity with GSH thereby stopping its reaction with 
other cellular nucleophiles. GS is the reacting nucleophile and GSH 
S-transf erases may promote ionization of the GSH sulfhydryl group, 
thereby increasing its nucleophilicity (Keen et al 1976). Many of 
the reactions catalyzed by the GSH S-transferases can also proceed 
non-enzymatically, and in some cases non-enzymatic reactions occur 
so rapidly under physiological conditions that enzyme catalysis is 
difficult to demonstrate. 
The most studied GSH S-transferases are soluble forms found in the 
cytosol, mitochondria and nucleoplasm, but membrane bound forms 
exist in the mitochondria and endoplasmic reticulum (Kraus and Gross 
1979). The highest concentrations can be found in the hepatic 
tissues and other tissues that come into contact with high 
concentrations of xenobiotics or their metabolic products. In the 
liver (rat and human) 2-10% of the extractable proteins are GSH S-
transferases. 
1.4 MERCAPTURIC ACIDS 
Glutathione S-conjugates are converted to mercapturic acids (Fig. 
1.3) by three enzyme catalyzed reactions (Jakoby 1980): 
The removal of the glutamyl moiety catalysed by glutamyl 
transpept idase. 
Removal of the glycine moiety from the glycine-cysteine 
molecule by a number of potential aminopeptidases and 
dipeptidases - 
N-acetylation of the cysteine conjugate, a reaction catalyzed 
by N-acetyltransferase, to yield a mercapturic acid- 
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GLUTATHIQ NE-S-CO NJ UGATE 
(GLUTAMYL-CYSTE INYL-G LYC IN E) 
GLUTAMYLTRANSFERASE 
CONJUGATE-S-CYSTEINE-GLYCINE + GLUTAMATE 
TRANS PEPTIDASE 
CONJUGATE-S-CYSTEINE + GLYCINE 
N-AC ETYLTRANSFERASE 
N-ACETYLCYSTEINE-S-CO NJUGATE 
(A MERCAPTURIC ACID) 
Figure 1.3 Metabolism of glutathione conjugates to mercapturic 
acids 
10 
In mammalian studies the highest levels of glutamyl transpeptidase, 
amninopeptidase/dipeptidase and N-acetyltransferase activity have 
been found in the kidney. The mercapturic acids are subsequently 
excreted in the urine. 
1.5 EXPOSURE MONITORING 
Methods for monitoring exposure to potential mutagens and 
carcinogens fall into two distinct groups - (1) the measurement of 
the substance, its metabolites, and its reaction products with 
cellular macromolecules, and (2) the quantification of a biological 
endpoint which may be a result of an organisms exposure (Van 
Sittert 1985). The determination of urinary thioethers (eg Van 
Sittert 1987) can be included in the former. Quantification of 
urinary metabolites can give a more accurate measurement of the 
absorption of a substance than can be achieved from the estimation 
of the agent in the environment. Urinary metabolites are a measure 
of the internal dose. It should be noted, however, that measurement 
of urinary thioethers only determines the proportion of the ultimate 
carcinogen/mutagen excreted in the urine after detoxification. It 
does not measure the proportion of the dose which evades 
detoxification and reacts with cellular macromolecules. The 
proportion of the dose reacting with cellular macromolecules is the 
effective dose. A knowledge of compound metabolism is therefore 
needed. 
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1-6 I1ERCAPURIC ACIDS AND BIOtIONITORING 
The assay of urinary thioether detoxification products as a tool in 
detecting human exposure to electrophilic compounds was first 
reviewed in 1981 by Van Doorn et al. Van Doorn demonstrated that 
spectrophotometric analysis of urinary mercapturic acids, after 
extraction and alkaline hydrolysis had an important signalling 
function - that is, an increase in urinary mercapturic acids 
indicated an exposure to one or more electrophilic compounds. 
However, the assay of urinary thioethers is non-selective, the 
compounds causing the raised levels remain unidentified, and Van 
Doorn concluded that more selective methods were to be preferred. 
Onkenhout et al (1986) outlined 3 GC/MS methods for the specific 
detection of N-acetyl-S-(Z or E 3-chloropropenyl-2)(-L-)cysteine 
(Fig. lA) - the mercapturic acid excreted after exposure to Z and 
E 1,3-dichioropropene. Dichioropropene is a major constituent of a 
number of commercial soil fumigants and a known mutagen (Watson et 
al 1987). Applicators in the Dutch flower bulb industry are exposed 
to 1,3-dichioropropene and the respiratory occupational exposure to 
the Z and E isomers of 1,3-dichloropropene has recently been 
assessed (Brower et al 1991). Van Welie et al (1991) have shown that 
the Z and E mercapturic acids of 1,3-dichioropropene can he measured 
in the urine of exposed flower culture workers at levels suitable 
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Figure 1.4 Conjugation of Z and F dichioropropene 
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1.7 BENZENE EXPOSURE 
Benzene is an important industrial chemical. In the past it was used 
as a solvent in the manufacture of paint, plastic and rubber 
products. Today it is the starting material for the synthesis of 
polystyrene and other bulk chemicals. Benzene enriched aromatics are 
added to gasoline as replacements for alkyl lead compounds due to 
their anti-knock properties. Benzene is emitted in engine exhaust 
gases, cigarette smoke, and is ubiquitous in the environment. 
Benzene possesses appreciable vapour pressure and hazardous 
occupational exposure due to inhalation can occur. Petrochemical 
workers, petrol station attendants and cigarette smokers are at risk 
as chronically exposed populations (Yardley-Jones et al. 1991). A 
person with respiratory rate of 16/minute and a tidal volume of 0.51 
will absorb 7.5ul of benzene per one hour through the lungs in an 
environment of 10 ppm (Nelson 1992). 
The major effect of chronic benzene exposure is its haemopoietic 
toxicity, unique to benzene among the simple aromatic hydrocarbons. 
The hallmark of benzene exposure is pancytopenia, a decrease in the 
number of circulating erythrocytes, leukocytes and thrombocytes. 
Continued exposure may lead to aplastic anaemia and leukemia (Snyder 
et al. 1985). The occupational exposure limit in the United Kingdom 
(Maximum Exposure Limit, MEL) and the United States (Permissible 
Exposure Limit, PEL) have recently been lowered to Sppm and lppm, 8 
hour TWA (Time Weighted Average) respectively, reflecting a concern 
for the risk of neoplasia. Benzene is a Group 1 carcinogen. 
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1-8 BENZENE METABOLISM 
Studies indicate that one or more metabolites of benzene mediate 
haemopoietic toxicity. Early studies identified phenol, trans,trans-
muconic acid, phenylmercapturic acid, ethereal sulfate and 
glucuronide conjugates of catechol, hydroquinone and 
trihydroxybenzene as metabolites of benzene (Snyder et al. 1985). 
Following the synthesis of pure C14 benzene Parke and Williams 
(1952) were able to account for all of an oral dose of benzene in 
rabbits. Over a 2 day period 43% of the administered benzene was 
exhaled unchanged, 1.5% was exhaled as carbon dioxide and 35% was 
excreted in the urine, mainly as conjugated phenols. Acid hydrolysis 
of the conjugates showed phenol (23%) was the major component, the 
minor components were hydroquinone (4.8%), pyrocatechol (2.2%), 
trans,trans-muconic acid (1.3%), phenylmercapturic acid (0.5%) and 
hydroxyhydroquinone (0.3%). The rest of the benzene remained in the 
body to be eliminated more slowly in the urine or as carbon dioxide 
in expired air. The metabolism of benzene appears to be similar in 
humans and rabbits. 
Benzene metabolism takes place predominantly in the liver but also 
in the bone marrow (Fig. 1.5). Benzene is first metabolised to 
benzene epoxide by mixed function oxidases. Benzene epoxide is 
converted non-enzymatically to phenol, or enzymatically to either a 
premercapturic acid derivative or benzene dihydrodiol. Phenol and 
dihydrodiol can be further metabolised to hydroquinone and 
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1.9 BIOtIONITORING BENZENE EXPOSURE 
Benzene in blood and exhaled air has been used as a specific and 
sensitive biomarker for measuring occupational and non-occupational 
exposure to benzene (Perhellini et al. 1988). For occupational 
exposure monitoring non-invasive sampling methods are preferred. 
Several urinary metabolites of benzene have been examined as 
potential biomarkers of occupational exposure. 
Urinary phenol is suitable for monitoring exposures, 8 hours NA, of 
lOppm or greater (Van Haaften and Sic 1965). At exposures of less 
than 6ppm it is not reliable due to a lack of specificity. There is 
a linear relationship between benzene exposure and urinary phenol 
concentration. Haaften compared gas chromotography procedures with 
two colorimetric methods for determining phenol concentrations, and 
found the former procedure to be superior in terms of sensitivity. 
Recently, urinary trans, trans-muconic acid as been proposed as a 
biomarker of benzene exposure (Inoue et al. 1989). Trans, trans-
muconic acid can be directly determined in a urine sample after 
precipitates have been removed by centrifugation. There is a linear 
correlation between concentration of urinary trans, trans-muconic 
acid and TWA benzene exposure measured in the breath zone of 
workers. It is possible to separate groups of workers exposed to 6 
ppm of benzene from non-exposed populations. The increased 
sensitivity of muconic acid over phenol determinations is due 
primarily to the low background levels of muconic acid. Trans, 
trans-muconic acid allows the determination of exposures down to 
lppm 8 hours TWA (Boogaard and Van Sittert 1995). Trans,trans- 
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muconic acid levels in non-exposed populations are below the 
detection limit of the assay (less than 0.1 mg/ml). Trans, trans-
muconic acid is not suitable for individual exposure monitoring 
because 95% confidence limits on individual values fall between 25-
50ppm. An additional drawback is that coexposure to toluene lowers 
urinary trans, trans-muconic acid concentrations. Benzene is often 
combined with toluene in solvent preparations. 
1.10 S-PFjENYUIERCAPrURIC ACID 
S-phenyimercapturic acid is a highly specific marker of benzene 
exposure (Stommel et al 1989). Boogaard and Van Sittert (1995) have 
demonstrated that S-phenylmercapturic acid could be used as an 
indicator of benzene exposures of 0.3 ppm at the group level. It may 
also possibly be used at the individual level. Stommel found a 
linear correlation between benzene exposures of 1-100 ppm and 
urinary S-phenylmercapturic acid in the rat. Above lOOppm excretion 
is proportionately less. 
To determine the most appropiate sampling time, Van Sittert et al 
(1993) studied the pattern of S-PMA excretion, and found that 
mercapturic acid was excreted in a single phase in most workers, the 
highest concentrations being detected at the end of a shift (average 
half-life of elimination 9 +/- 4.5 hours). In some workers, the 
highest levels were found at the beginning of the next shift. This 
delayed excretion could be due to skin exposure to benzene or to 
individual differences in toxicokinetics. In some workers a 
tentative second phase of elimination was found with a half-life of 
18 
45 +/- 4 hours. The average S-phenylmercapturic acid concentration 
in end of shift samples from workers exposed to 1 ppm of benzene for 
8 hours is 46ug/g creatinine (approximately 100ug/1). 
1_11 S-(2-HYDROXYETHYL)ACETYL--L-CYSTEINE 
Gerin and Tardif (1986) measured urinary S-(2-hydroxyethyl)acetyl-L-
cysteine in rats after exposure to ethylene oxide, and indicated a 
possible biological monitoring role for this mercapturic acid in 
man. S-(2-hydroxyethyl)mercapturic acid (2-HENA) has also been shown 
to be a urinary metabolite of several other important industrial 
chemicals including vinyl chloride (Watenahe et al 1976), 1,2-
dibromoethane (Van Bladeren et al 1980), 2-bromoethanol (Jones and 
Wells 1981) and acrylonitrile (Van Bladeren et al 1981). A critical 
evaluation of the possibilities and limitations of 2-HEMA as a 
potential tool in biological monitoring studies has been promoted by 
Vermeulen et al (1989). 
1.12 BIOTRANSFORMATION REACTIONS LEADING TO 
5- ( 2-HYDROXYETHYL)ACETYL-L-CYSTEINE 
A number of possible biotransformation reactions may lead to the 
excretion of 2-RENA (Vermeulen et al 1989). 
The halohydrins are widely used industrial chemicals which have no 
known carcinogenic potential but possess high acute toxicity. 
Urinary excretion of 2-HENA has been reported for the halohydrins 2-
bromo and 2-iodoethanol. Three possible biotransformation reactions 
may lead to the excretion of 2-HENA. These are 1) the direct 
conjugation of the compound with GSH, 2) its metabolism to ethylene 
19 
oxide and its subsequent conjugation to GSH, and 3) conversion of 
the halohydrin to a haloacetaldehyde by the enzyme ethanol 
dehydrogenase, conjugation of the haloacetaldehyde with glutathione 
followed by reduction of the aldehyde group to the alcohol (Fig. 
L7). 
The 1,2-dihaloethanes are also widely used industrial chemicals 
(solvents, pesticides, fumigants, and gasolene additives) which have 
been associated with carcinogenic effects in animal studies. 2-HEtIA 
has been identified as a urinary metabolite of rats treated with 
1,2-dibromomethane. Three metabolic pathways which, in principle, 
may lead to the excretion of 2-HEMA have been derived for the 1,2-
dihaloethanes. These metabolic pathways proceed through the 
formation of haloethanol and/or haloacetaldehyde, episuiphoniurn ion 
or halonium ion intermediates (Fig- 1.8). 
Apart from the halogen substituted ethanes, other disubstituted 
ethanes may give rise to 2-HEMA via GSH dependent metabolic 
pathways. For example, the alkylating ester ethylene dimethane 
sulphonate (Fig. 1-9) and chloroethylamine derived compounds (such 
as the anti-neoplastic agents ribopyranosyl-1-nitrosourea, RPCNU, 
and cyclophosphamide, Fig. 1_10). The later appear to be metabolized 
via an oxidative N-dealkylation reaction to chloroacetaldehyde 
and/or chioroethanol. Chioroacetaldehyde and chioroethanol are 
compounds which may directly, or via an intermediate 
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Ethylene is an important industrial chemical. It is used in the 
manufacture of plastics, as a plant growth regulator and is a 
component of diesel exhaust and tobacco smoke. Ethylene itself is 
relatively non-toxic but can be metabolized by cytochrome P450 in 
the liver to ethylene oxide. Ethylene oxide is a known mutagen and 
carcinogen. Conjugation of ethlene oxide with glutathione can lead 
to the excretion of 2-HEMA (Fig. 1.12). 
Ethylene derived compounds may also give rise to 2-HEMA. The mono-
substituted ethylene vinyl chloride is a known carcinogen widely 
used in the polymer industry. Vinyl chloride is metabolized via a 
primary epoxidation to an oxirane. This can rearrange to form an 
haloacetaldehyde which, as seen above, can be conjugated by GSH and 
subsquently excreted as 2-HENA (Fig 1.13). 
The monomer acrylonitrile (vinyl cyanide) is used in the manufacture 
of rubber, plastics and adhesives. It is a carcinogen, teratogen and 
a potent toxin of the central nervous system. It is highly reactive 
and may act as a direct alkylating reagent. There are two major 
routes of biotransformation. A direct non-enzymatic conjugation with 
GSH leads to the excretion of the mercapturic acid N-acetyl-S-(2-
cyanoethyl)-L-cysteine. Indirectly, vinyl cyanide can be oxidised to 
an epoxide which may be conjugated by GSH and excreted as 2-HEMA. In 
rats, both mercapturic acids are excreted as urinary metabolites 
(Fig. 1.14)- 
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1.13 BIOACTIVATION AND GLUTATHIONE TOXICITY 
Until recently glutathione conjugation was recognised as a universal 
detoxification mechanism. Bedford et al (1975) was the first to 
deduce that reaction with glutathione can, in certain circumstances, 
give rise to intermediates which are very reactive towards 
nucleophilic attack. Bedford proposed that 2-HEMA could be produced 
from ethylene bromide via a reactive episulphonium ion - this has 
subsequently been confirmed. It is now accepted that glutathione 
conjugation is an important bioactivation mechanism with 
implications for organ-selective toxicity and carcinogenicity.  
Glutathione-dependent toxicity has been recently reviewed by Anders 
et al (1992). 
The vicinal dihaloethane 1,2-dibromoethane is a widely used 
industrial chemical with known mutagenic and carcinogenic 
properties. The major urinary metabolite of 1,2-dibromoethane in 
rats is 2-HENA. Up to 50% of a single oral dose (SOOumol/kg body 
weight) is excreted as 2-HEMA (Van Bladeren et al 1980). Two 
possible biotransformations may lead to 2-HEMA excretion - 1) the 
direct conjugation of 1,2-dibromoethane with glutathione which gives 
rise to a thiiranium ion, and 2) oxidation of 1,2-dibromoethane to 
bromoacetaldehyde, conjugation of bromoacetaldehyde and glutathione 
followed by the reduction of the aldehyde group to yield a 2-
hydroxyethyl-glutathiOfle conjugate. 2-hydroxyethyl-glutathione is 
metabolised to 2-HENA. In rats the direct conjugation and oxidative 
routes occur in the ratio 1:4 (Van Bladeren et al 1981b). The 
thiiranium ion is able to bind covalently to DNA to give (2-(N-7-
guanyl)ethyl)glutathione. In rats exposed to 1,2-dibromoethane 95% 
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of the DNA adducts formed were S_(2_(N_7_guanyl)ethyl)glutathiOfle. 
This adduct is excreted in the urine as N-acetyl-S-(2-(N-7-
guanyl)ethyl)-L-cysteine (2-GEHA). The urinary excretion of 2-HEMA, 
2-GEtIA, and the formation of DNA adducts in the liver and kidney 
were dose dependent. 2-GEtIA may be considered to be the first 
mercapturic acid acting as a biomarker of effective dose. However, 
to be applicable in exposure monitoring the sensitivity of 2-GEMA 
analysis must he increased considerably (Van Welie et al 1992). 
Some haloalkenes (eg. hexachiorohutadiene, tetrachloroethene and 
chiorofluoroethene) are known nephrotoxins, nephrocarcinogens, or 
both. The selective nephrotoxicity of these compounds appears to he 
due to a multistep pathway involving hepatic glutathione S-conjugate 
formation. The glutathione conjugates are transported to the kidney 
where they are metabolised to the corresponding mercapturic acid. 
The mercapturic acids are converted to reactive thiol conjugates by 
cysteine conjugate beta-lyases. The thiol conjugates may be further 
transformed to a number of generally unknown reactive sulphur 
intermediates (Fig. 1.15). 
1.14 REACTIVE INTERMEDIATES LEADING TO S- ( 2-HYDROXYETHYL)ACETYLL 
-CYSTEINE 
The biotransformation reactions leading to 2-HEMA may proceed by 
five reactive intermediates (thiiranium ion, activated double bonds, 
(halo)ethylcarbonium ions, (halo)oxiranes and (halo)acetyaldehydes). 
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reactive intermediates into a potential type or intensity of 
toxicity (Vermeulen et al 1989). Since toxicity also depends upon 
the rates of formation and degradation of the intermediate, 
intermoleculer interactions and any organ or tissue selective 
features. 
Reactive intermediates have been classified according to the 'hard" 
and soft' acid-base properties of electrophiles and nucleophiles 
(Coles 1985). "Hard" electrophiles and nucleophiles possess ionic 
character, they have isolated charges, small atomic radii, low 
polarizability and a low ease of oxidation. "Soft" electrophiles and 
nucleophiles have covalent character, a low positive charge, a large 
size, filled outer orbitals and a high polarizability. Comparing 
electrophiles and nucleophiles, as a general rule 'hard" reacts with 
"hard" and "soft" reacts with "soft". Nucleophilic sites in proteins 
(cysteinyl and lysinyl amino groups) are "soft", and the 
nucleophilic sites in DNA (ring and exocyclic nitrogen and oxygen 
atoms) tend to be "hard". "Soft" electrophiles such as cyano-
containing compounds and haloacetaldehydes have been shown to form 
covalent adducts with cysteinyl residues in proteins, and "harder" 
electrophiles such as the thiiranium ion have been shown to form 
adducts with "harder" nucleophiles present in DNA (Vermeulen et al 
1989). 
Intermediatary compounds such as ethylene oxide and some 
halooxiranes give rise both to protein and DNA adducts (Fig. 1.16). 
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Figure 1.16 Intermediates in the formation of 2-HENA 
29 
Measurement of mercapturic acids is therefore important for two 
reasons - in the hioinactivation of electrophilic compounds and in 
the bioactivation of electrophilic intermediates. 
1.15 ANALYTICAL PROCEDURES FOR I1ERCAPIURIC ACIDS 
Several techniques have been described for the qualitative and 
quantitative analysis of the mercapturic acids. These include thin-
layer chromatography, spectrophotometry, amino acid analysis, HPLC 
and GC. In general the assay of the mercapturic acids can he divided 
into three steps - isolation, derivatisation and analysis. 
Plercapturic acids can he extracted from acidified urine (pH 2 or 
less) using organic solvents such as ethyl acetate Because of the 
high polarity of mercapturic acids such as 2-HEHA, solid-liquid 
extraction (ic. freeze drying followed by redissolution of the 
residue in a methanol-ether mixture) may yield higher recoveries. 
For application at low urinary concentrations the latter procedure 
has to be preferred (Vermeulen et al 1989). 
The most selective and sensitive analytical procedures for the 
quantitative analysis of urinary mercapturic acids employ HPLC and 
GC separation techniques. Separation of mercapturic acids can be 
achieved by reverse phase chromatography on C8-18 silica, cation and 
anion exchange columns. 
Due to the low volatility and high polarity of mercapturic acids, S 
PtIA and 2-HENA must be derivitized prior to GC analysis. Separation 
can be achieved on apolar or medium polar columns. Flame-ionization, 
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nitrogen-phosphorus, sulfur-selective detection and mass 
spectrometry have all been used to detect mercapturic acids after 
GC 	GC/11S is the most sensitive procedure for the detection of 
mercapturic acids- 
At present only GC/MS possesses the required sensitivity for 
biomonitoring occupational exposure to benzene (0.1ug/1). Assays for 
2-HEHA lack sensitivity for biomonitoring. Background levels of 2-
HEMA cannot be identified in human urine. A naturally occurring 
background is expected because of the presence of endogenous 
hydroxyethylating agents, such as as ethylene. For application in 
occupational monitoring assay sensitivity should be at least 
0.1mg/mi (van Welie et al 1992). 
1.16 PROJECT AIMS - THE COMPOUND AND CLASS-SPECIFIC 
IMMUNOPURIFICATION OF NERCAFI'URIC ACIDS 
A limitation of GC/NS analysis, for both biomarkers, is a complex 
work-up prior to assay. The sensitivity of the procedures is also 
limited by the purity of the samples. The development of single step 
extraction procedures may both facilitate and improve the 
sensitivity of the quantitative MS analysis of S-PNA and 2-HEMA. In 
addition, GO/MS analysis restricts this method to use in 
sophisticated laboratories. The use of an immunoaffinity column to 
enrich S-PNA and 2--HEMA may permit the analysis of mercapturic acids 
by HPLC which at present lacks the sensitivity for application in 
biomonitoring programmes. The major aim of this project was to 
develop immunoenrichment systems for S-PMA and 2-HEMA. 
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Current immunopurification systems are generally compound specific, 
i.e. each designed to isolate one specific analyte. However, a 
broader specificity, which would permit isolation to he based on 
membership of a particular group or class of chemicals, could he 
even more useful. In biomedical monitoring studies a class-specific 
antibody which recognises mercapturic acids would greatly facilitate 
the identification of unknowns and permit simultaneous monitoring of 
mixed exposures. 
The principle of class-specific immunopurification has been 
demonstrated in this laboratory. An immunoaffinity chromatography 
column has been prepared using a monoclonal antibody raised to 6-
(2,4-dinitroanilino)hexanoic acid which selectively binds the 2,4-
DNP moiety when the substituent at Cl of the aromatic ring is linked 
through an oxygen or a methylene carbon. This column has been used 
to selectively abstract chemicals containing the 2,4-dinitrophenyl 
group from an aqueous cocktail containing low concentrations of 
related chemicals variously substituted in the aromatic ring with 
one or two amino groups. Noerever, the immunopurification system has 
also proved effective in the selective and quantitative abstraction 
of these chemicals from the complex matrix urine. 
A second aim of this project was to develop class specific 
antibodies for application in the detection and identification of 
mercapturic acids to facilitate the monitoring of exposures to 
genotoxic carcinogens. 
CHAPTER TWO 
SYNTHESIS AND CHARACTERISATION OF IIERCAPTURIC ACIDS, 
NERCAPTURIC ACID-PROTEIN CONJUGATES AND THE INDUCTION OF ANTIBODIES 
WHICH BIND MERCAPTURIC ACIDS IN NICE 
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INTRODUCTION 
2.1 THE IMMUNE RESPONSE 
The invasion of a vertebrates body by a foreign substance elicits 
an immune response. Part of this response is the secretion of 
antibodies by plasma cells. Antibodies contain binding sites which 
recognise the shapes of determinants (epitopes) on the foreign 
substance- Antibody-epitope binding induces a number of processes 
which eventually lead to the neutralistion and elimination of the 
foreign substance from the host. A typical response is highly 
heterogenous. Many different antibodies are produced which recognise 
different determinants or the same determinant with varying 
affinities- Each antibody is secreted by a different lymphocyte- If 
a lymphocyte could be grown in culture then a large quantity of 
identical antibody could be produced. Unfortunately lymphocytes 
cannot be maintained in culture. 
A myeloma is a tumour of antibody secreting cells which is derived 
from a single cell and secretes a single type of antibody. Myeloma 
cells can be grown indefinitely in culture medium, but against which 
determinant they are directed remains unknown. Attempts to induce 
myelomas of known specificity have failed. 
In 1975 Kohler and Milstein fused mouse lymphocytes from the spleen 
of an animal immunised with a known immunogen with myeloma cells. 
The resulting hybrid-myelomas, or hybridomas, had two important 
properties. They secreted antibody of known specificity and 
possessed immortal character. The hybridoma cells were cloned and 
single clones were grown in culture. The culture medium contained 
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antibodies of one type, all identical in structure and function. 
Kohler and Milstein had developed a powerful technique for 
dissecting out a polyclonal immune response into its monoclonal 
components. They were awarded a Nobel Prize for Medicine and 
Physiology in 1975 for this work. 
2.2 HAPTEN IMMUNOCHEMISTRY 
Compounds of low molecular weight (<1000) are not normally 
antigenic. S-PMA and 2-HEMA, the mercapturic acids of interest in 
this project, have molecular weights of 239 and 220 respectively. 
However, low molecular weight substances (haptens) can be rendered 
immunogenic by coupling to larger carrier proteins. Hapten 
immunochemistry was first investigated by Landsteiner in 1917. 
Landsteiner held an almost dogmatic belief that a special chemical 
constitution peculiar to proteins was required for antibody 
production. We now know this is not true but Landsteiners work lay 
the foundation of modern immunochemistry. 
Landsteiner prepared his hapten-protein conjugates either by the 
acylation of amino groups with acid chlorides and anhydrides, or by 
the diazotisation of the histidine, tyrosine and tryptophan amino 
acids. With these conjugates Landsteiner established that the 
original specificity of the protein carrier was altered and 
antibodies were produced by compounds which themselves were not 
antigenic. He also noted that antibodies were produced to the 
protein carrier and, to be certain that the antibodies were against 
the determinant group, it was necessary to test the sera against 
conjugates made with an unrelated protein. 
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A number of protein carriers have been used to stimulate antibody 
production. These include globulin fractions, the serum albumin of 
various species, haemocyanin, ovalbumin, thyroglobulin and 
fibrinogin. Whether choice of carrier significantly influences the 
antihapten response is a controversial subject. KLH is the preferred 
carrier in this laboratory and is known to induce a large immune 
response in immunised mice. 
In his early experiments Landsteiner sought to determine the number 
of haptens coupled to protein which gave the optimal response. He 
concluded that too much or too little led to a poor response, and 
for serum albumin carriers ten haptenic groups appeared optimal. 
tTiswender and llidgley (1970) studied steroid-protein conjugates and 
suggested a minimum of twenty molecules of hapten should be coupled 
to BSA, any less giving an inferior antigen. Klaus and Cross (1974), 
in studies on BSA-DNP conjugates, obtained a good response with five 
to nineteen DNP groups per BSA. However, fifty to sixty DNPTh per 
BSA elicited an Igtl response only. The nature of the hapten probably 
exerts a very strong influence on the response, but good antibody 
titres can usually be obtained with epitope densities between eight 
and twenty five. 
Landsteiner also established in his work that antibody specificity 
is directed primarily at that part of the hapten molecule furthest 
from the functional group that is linked to the protein. Many other 
similar studies exist in the literature. This specificity can be 
further improved by the use of conjugates in which the hapten is 
attached via a spacer arm to the protein. 
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Regardless of the protein carrier used, the same functional groups 
are available for attachment to the hapten - the carboxyl group of 
the C-terminal and of the aspartic and glutamic acid residues; the 
amino groups of the N-terminal and the lysine residues; the 
imidazole and phenolic functions of the histidine and tyrosine 
residues; and the sulfhydryl group of cysteine. All have been used 
for the preparation of immunogenic hapten protein conjugates. 
2.3 IIERGAPTURIC ACID SYNTHESIS 
S-PNA is commercially available, 2-HEMA is not commercially 
available and must be synthesized. Mercapturic acids have been 
successfully synthesised using three different strategies. These 
are: - 
The reaction of the nucleophilic thiolate anion of N-acetyl-L-
cysteine with the appropriate electrophile under 
alkali conditions (Van Bladeren et al, 1980) (Figure 2.1a). 
The reaction of electrophilic sulfur in the sulfenylhalogenides 
and thiolsulfinites with an appropriate nucleophile (Buijs et al, 
1986) (Figure 2..1b). 
The reaction of a thiol with 2-acetamidoacrylic acid in a 
Michael type addition (Van Bladeren et al, 1980 and Buijs et al, 
1986)(Figure 2.1c). 
2-(hydroxyethyl)mercapturic acid has been synthesised by procedures 
1 and 2 with yields of up to 82% (Van Bladeren et al, 1980). 
Purification of 2-(hydroxyethyl)mercapturic acid from the reaction 
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FIGURE 2.1 Synthesis of mercapturic acids a) by the reaction of the 
thiolate anion with an electrophile: b) by the reaction 
of electrophilic sulphur with a nucleophile: 
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and c) by a Michael type addition. 
In his systematic study of mercapturic acid preparation, Van 
Bladeren found dry methanol to he suitable for the synthesis of 2-
(hydroxyethyl)mercapturic acid. with sodium methoxide as the base ( 9-
equivalents), 
2
ivalents), N-acetyl-L-cysteine (dianion) was reacted with 
hydroxyethyl bromide (Figure 2.2). When the reaction was complete 
the solvent was either evaporated, the products taken up in acetone 
and neutralised with a minimum amount of concentrated HC1, or the 
solvent was neutralised with dry methonalic hydrogen chloride, 
evaporated and the residue resuspended in acetone. The salt was 
removed by filtration and, after evaporation of the solvent at 
reduced pressure, 2-(hydroxyethyl)acetylcysteine was obtained as a 
colourless oil which was recrystallised from chloroform/ether or 
ethylacetate/petroleum ether. The procedure avoids losses due to 
difficult extraction steps, and the presence of 2-
(hydroxyethyl)rnercapturic acids was confirmed by NMR and MS. Proper 
NIIR and MS spectra however do not guarantee a pure reference 
standard, and similarly titration of the carboxylic acid groups 
with sodium hydroxide may give erroneously high yields due to 
interferences with N-acetyl-L-cysteine or alkali salts (Vermeulen et 
al, 1989). 
Not all mercapturic acids can be synthesised by taking advantage of 
the nucleophilic properties of N-acetyl--L-cysteine in basic solution 
(Buijs et al 1986). An alternative synthetic route was devised by 
Buijs who employed the electrophilic properties of sulfur in 
sulfenyihalides. This strategy has been successfully employed to 
synthesise a number of mercapturic acids, and is particularly useful 
in the synthesis of mercapturic acids derived from the conjugation 
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Figure 2.2 Synthesis of 2-HENA by the method of 
Van Bladeren et al (1980). 
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Figure 2.3 Synthesis of 2-RENA by the method of Buijs et al (1986) 
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of glutathione with vicinal dihalogenoalkanes and dihalogenoalkenes 
which are difficult by other methods. 
Buijs recommends the use of sulfenyl chlorides and bromides because 
sulfenyl fluorides and iodides are difficult to handle (N-
chlorosuccinimide is the preferred chlorinating agent as no side 
reactions take place). 2-(hydroxyethyl)mercapturic acid may he 
synthesised by this route. First 2-) chioroethyl) and 2-( bromoethyl 
acetylcysteine are synthesised by reacting the corresponding N-
acetyl-L-cysteine derivative with ethene (yields of 79% and 86% 
repectively have been reported). These reactive B-halogeno 
thioesters are easily converted to 2-(hydroxyethyl) mercapturic acid 
by the addition of water (Figure 2.3). 
The mechanism of addition of sulfenyl halides to alkenes is biphilic 
and can lead to both Narkovnikov and anti-Markovnikov products. 
Aliphatic sulfenyl halides predominantly give Markovnikov products 
(ie. sulfur containing residue at the least substituted carbon), and 
anti-Markovnikov products tend to he observed only with sterically 
hindered alkenes. This is an important consideration since N-acetyl--
L-cysteine is optically active and reactions with chiral or pro-
chiral substrates only give mixtures of distereo isomers which may 
have different chemical or biological properties figure 2.1b.)- 
2.4 HAPTEN - PROTEIN CONJUGATION 
A) CONJUGATION WITH CARBODIINIDES 
Sheehan and Hess (1955) introduced carbodiimides for the synthesis 
of peptide bonds from amines and carboxylic acids The preparation 
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procedure is simple and easy to perform and it has become an 
important coupling method. The reaction may he represented as a 
dehydration whose mechanism is not fully understood but is thought 
to occur via an 0-acylisourea intermediate (Figure 2.4). The 
formation of 0-acylisourea is rapid and may lead to a peptide either 
by immediate aminolysis (i) or via a symmetrical anhydride (ii) with 
the production of urea. Urea is sparingly soluble in most solvents 
and can be easily removed by filtration. The intermediates are 
highly reactive and side reactions can occur. One such side reaction 
is the collapse of the 0-acylisourea by intermolecular acyltransfer 
which competes with the desired attack by external nucleophiles, and 
leads to the formation of the less reactive N-acylurea (Figure 2.4). 
Acylureas are the main side products at elevated temperatures and, 
in order to shift the reaction toward peptide bond formation, 
temperatures around 0°C should be used. Dicyclohexylcarbodiimide is 
the most commonly used carbodiimide. It is soluble only in organic 
solvents. Dicyclohexylurea formed in coupling reactions with 
dicyclohexylcarbodijmide is insoluble in most solvents. It 
precipitates out during coupling reactions and can be easily removed 
by filtration. l-ethyl--3-(dimethylamino)carbodiimide is a popular 
water soluble carbodiimide. The urea formed during coupling with 
this reagent is water soluble and is removed by dialysis when the 
conjugation of hapten to protein is complete. 
Problems can occur when using carbodiimides as the coupling reagent, 
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FIGURE 2.4 Synthesis of peptide bonds with carbodiimide (side 
reactions lead to the less reactive N-acylurea) 
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poor coupling efficiencies. In addition, the coupling procedures are 
normally carried out at pH 4-5 pHs which may adversely effect the 
carrier protein. Problems associated with the use of carbodiimide 
can he overcome by coupling in the presence of a nucleophile which 
is able to react rapidly with the 0-acylurea before any side 
reactions can occur to form an acylating agent of lower potency. The 
resultant carboxylic acid derivative is still reactive with respect 
to aminolysis but is more discriminating and does not lead to 
racemisation and other side reactions. Several alternatives have 
been investigated and the use N-hydroxysuccinimide to generate an 
active ester (Anderson et al 1963) became popular in the 1970s. 
Esters of N-hydroxysuccinimide are not only more resistant to 
hydrolysis than 0-acylureas but also allow coupling reactions to be 
carried out at a physiological pH. 
B) CONJUGATION WITH N-HYDROXYSUCCINIIIIDE ESTERS 
Primary amines are the principal targets of NHS-esters. The amines 
at the protein N-terminus are seldom available for hapten 
conjugation and therefore the coupling reactions with amino acid 
side chains are very important. Cautrecasus and Parikh (1972) 
compared the reactivity of NHS-esters towards the side chains of 
various N-acetylated amino acids and free alanine which contains a 
primary amine. Only lysine is able to react significantly with the 
NHS-esters through its epsilon amino group. The cysteine thiol group 
shows some reactivity with the NHS-esters, due to the nucleophilic 
character of the sulphydryl group, but the reaction is more 
efficient with a primary amine. 
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Hydrolysis of the NHS-ester is a major competing reaction of the 
NHS-ester acylation reaction. Hydrolysis is a more significant side 
reaction in dilute solutions. The rate of hydrolysis increases with 
pH, the half-life of 4-5 hours at pH 7, 0°C decreases to 1 hour at 
pH 8, 250C. The rate of hydrolysis of NHS-esters is decreased in dry 
organic solvents (Carlsson et al. 1978). 
Water insoluble and soluble NHS-esters exist. The water soluble 
forms are characterised by the presence of a sulfonate group on the 
N-hydroxysuccinimide ring (Figure 2.5a). N-hydroxysulfosuccinimide 
esters are hydrophilic active esters which hydrolyse slowly compared 
with their rates of reaction with primary amines (Staros et al, 
1986). Staros et al demonstrated that water soluble carbodiimide 
mediated couplings could be enhanced using N-
hydroxysulfosuccinimide, presumably by the formation of the 
HOSu(S03) active ester in situ (Figure 2.5b). 
Recent progress in the preparation of homogenous hapten protein 
conjugates mainly results from the use of heterobifunctional cross-
linkers. Fujiewara et al (1990) investigated N-(aminobenzoyloxy) 
succinimide as a heterobiftmctional agent for the preparation 
hapten-protein conjugates (Figure 2.6). The succinimidyl ester 
reacts immediately with the amino group and an aminobenzoyloxy group 
is incorporated into the hapten. The aminobenzoyloxy group is 
activated by diazotization to a diazobenzoyl group which can couple 
with the tyrosine and histidine residues of the carrier protein. The 
reactions are easy to perform, the reagents being added sequentially 
to a single tube with a change in pH. Acylation of the hapten is 
time dependent, the longer the incubation the greater the 
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Figure 2..5a The water soluble NHS-ester 
bis ( sulfosuccinimidyl )suberate (BS3) 









Figure 2..5b Coupling S-PNA to protein with the NHS-ester BS3. 
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Figure 26 Conjugation of 2-HENA to protein with m-aminobenzoy1oxT 
succ inimide 
incorporation. In addition self-coupling between the aromatic amino 
group and the succinimidyl ester does not occur during the first 
acylation at near neutral pH. The azo linkage formed during hapten-
protein coupling gives a bright orange-yellow colour Fujiwara 
investigated the use of ortho, meta and para-isomers of N- 
(aininohenzoyioxy succinimide 	and found the best 	coupling 
efficiencies were achieved, with the meta isomer- 
2.5 CONJUGATE CHARACTERISATION 
Before characterizing the conjugate, non-covalently bound hapten 
must he removed from the protein carrier. This can be achieved by 
dialysis or gel filtration. Hapten incorporation can be determined 
directly by the incorporation of a radioactive tracer into the 
conjugation procedure. Alternatively if the hapten contains a 
chromophore which allows it to be differentiated from the protein, 
the degree of hapten incorporation can be calculated from 
spectroscopic measurements. If there is overlap in the two spectra, 
hapten incorporation can he determined from difference spectroscopy. 
Sanger (1949) measured hapten incorporation by determining the 
number of free amino groups on the protein before and after 
coupling. Substituted and unsubstituted proteins were reacted with 
dinitrofluorobenzene and the number of dinitrophenyl lysines were 
determined by spectroscopy after their extraction from an acid 
hydrolysate. Habeeh (1966) determined the number of free amino 
groups in protein by reaction with trinitrobenzenesulfonic acid. 
Primary amines react with TNBS to give trinitrophenyl derivatives. 
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Figure 2..7 The reaction of TNBS with a primary amine gives a yellow 
trinitrophenyl derivative 
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maximum at 335nm. Trinitrohenzenesulfonic acid reacts under mild 
conditions. At pH 8.5-9. Complete reaction with lysine occurs, and 
there is a linear relationship between absorbance and protein 
concentration (upto 1mg/mi ) - 
Protein concentrations can be calculated from spectrophotometric 
readings at 280nm At which wavelength the absorbance is due 
primarily to the phenylL groups of the aromatic amino acids. Many of 
the 	alternative 	methods 	available, 	(eg 	ninhydrin, 
tririitrobenzenesuttonc acid) depend upon the reaction of the 
reagent with protein amino groups and are therefore unsuitable for 
the determination of hapten protein conjugates where the hapten is 
coupled through this functional group. 
When a protein solution is treated with OuZ+ in a moderately 
alkaline solution, a coloured chelate of unknown composition is 
formed between the C112+  and carbonyl and imine groups of the peptide 
bond. The reaction of protein is similar to the reaction of the 
organic compound biuret and is referred to as the biuret reaction. 
C112 is linked by co-ordinate bonds to 4-6 nearby peptide linkages. 
There must be at least 2 peptide bonds in the peptide for the 
reaction to occur. The colour intensity is proportional to the 
number of peptide bonds available and the biuret reaction forms the 
basis of several simple colorimetic methods for protein 
determination 
Lowry et al (1951) studied the use of folin-phenol to enhance the 
sensitivity of the biuret reaction. This reagent appears to have 
several advantages - it is 10-20 times more sensitive than UV 





absorption at 280nin, is several times more sensitive than ninhydrin 
reagent and 100 times more sensitive than the biuret reaction. Two 
distinct steps lead to the final colour: 1) the reaction with copper 
in alkaline conditions; 2) the reduction of folins reagent at pH 10. 
At this pH the reagent is only reactive for a short time which makes 
this an exacting technique with respect to reagent addition and 
mixing - 
The sodium salt of bicinchoninic acid is a water soluble compound 
which is highly specific and sensitive for Cu-, forming a stable 
coloured complex. Smith et al (1985) replaced Folins reagent with 
bicinchoninic acid in the method of Lowry to give a more simple 
technique. In addition, Smith found the bicinchoninic acid method 
was more sensitive than the Lowry assay, was more tolerant towards 
interfering substances, and possesed greater working reagent 
stability. 
In general, methods for determining protein concentration using dyes 
are insensitive. Bradford et al (1975) described a sensitive method 
(4x Lowry assay) for determining protein concentration using the dye 
Coomassie Brillant Blue. The binding of Coomassie Brillant Blue to 
protein causes a shift in the absorption maximum of the dye from 465 
to 595nm. The increase at 595nm is measured. Bradford's assay is 
rapid (2 mm), reproduceable and relatively free from interferences. 
Coomassie Brillant Blue was used to determine protein concentrations 
and the results were compared to the values obtained with 
bicinchoninic acid. 
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2.6 IN-VIVO INNUNISATION 
At present mice are the animals of choice for immunisation, and a 
number of different species are available. There is considerable 
variation between species in the response to antigen and the best 
responders vary according to the antigen. Balb/c mice however are 
the simplest and preferred choice for immunisation. If the spleen 
cells are not of Balb/c origin and the hybridomas are to be grown as 
tumours in mice to produce antibody, the hybridomas will only grow 
in a Balb/c Fl hybrid. Several mouse myelomas are available. 
Although these possess different properties they are all of Balb/c 
origin. 
Immunisation causes the B cells to divide and differentiate. 
Expanding the number of relevent spleen cells increases the chance 
of obtaining the desired hybrid. In addition, activated B cells 
appear to fuse preferentially. 
Soluble proteins are often weakly immi.mogenic. Their immunogenicity 
can be increased by the use of adjuvents (Oi et al 1978). The usual 
practice is to emulsify aqueous antigen with Complete Freunds 
Adjuvent (containing heat killed N. tuberculosis in an oily 
suspension) for the primary immunisation, and with Incomplete 
Freurids Adjuvant for subsequent boosts. The stable water in oil 
emulsion probably acts as a depot allowing a slow and steady release 
of antigen from the site of injection. The adjuvent may also 
stimulate local inflammatory reactions (Goding 1986). 
Various immunisation protocols have been successfully used. In 
general the initial immunisation is given either subcutanaeously or 
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interperitoneally in Complete Freurids Adjuvent. One or more 
subsequent boosts in Incomplete Freunds Adjuvant are normally 
administrated by the same route 21 days later. The final boosts in 
saline are given either interperitoneally or intervenously 3-4 days 
before a fusion. 
Purity of the antigen is usually irrelevent unless the impure 
material gives a weaker response, or the screening assay does not 
distinguish between the component of interest and the impurity. 
The chances of obtaining a monoclonal antibody with particular 
properties is directly related to the concentration of corresponding 
antibody in the serum of the spleen donor. The magnitude of the 
response reflects the proportion of spleen cells secreting the 
desired antibody in the total population. The maximum yield of 
positive hybrids is obtained 3-4 days after the final boost. The 
maximum antibody titre occurs about 14 days after the second 
immunisation. The optimum screening time is therefore after the 
penultimate boost. 
S-PNA and 2-HEIIA are low molecular weight compounds (MW 239 and 220 
respectively). To generate compound specific antibodies to S-PMA 
mice were immunised with S-PMA and S-phenylcysteine protein 
conjugates. This chapter describes the preparation of S-PMA protein 
conjugates using either carbodiimide or N-hydroxysuccinimide 
chemistry. 
The synthesis of 2-HENA, S-(2-hydroxyethyl)cysteine and 2-HEMA 
protein conjugates is described. 2-HEMA and S-(2- 
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hydroxyethyl)cysteine were prepared by reacting the nucleophilic 
anion of acetylcysteine with ethylene oxide. 2-HENA protein 
conjugates were prepared with both homohifunctional 
(bis(sulfo)succinimidyl suherate) and heterobifunctjonal (m-
aminohenzoyloxysuccinimide) crosslinkers. 2-HEMA appears to a weakly 
immunogenic and in order to improve antibody induction the role of 
the carrier protein was investigated. Coupling 2-HENA to gelatin and 
homologous proteins was investigated. 
To generate class-specific antibodies mice were immunised with 
acetylcysteine coupled through the sulfhydryl group to the carrier 
protein. Acetylcysteine was coupled with lodoacetic acid N-
hydroxysuccjnimjde. 
Protein conjugates were fully characterised, hapten-protein ratios 
were determined either spectrophotometrically or by amino acid 
analysis. Balb/c mice were immunisied. Sera were screened by ELISA 
and RIA for antibodies which bind free mercapturic acids. The 
difficulties of generating antibodies to small MW compounds and the 
results of the screening strategies are discussed. 
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METHODS AND MATERIALS 
MATERIALS 
REAGENTS 
The following reagents were purchased from Aldrich Chemical Co. 
Ltd., 	Gillingham, Dorset. UK.:- N,N-Hydroxysuccinimde and N,N- 
dicyclohexylcarbodilmide, 
The following reagents were purchased from BDH Merck, Merck Ltd., 
Dagenham, Essex. UK.:- Acetic acid (chromatography grade), acetic 
anhydride (AnalaR), ammonia (0888), butanol (GPR), chloroform 
(AnalaR),citric acid (AnalaR), dimethylformamide (DMF, GPR), 
dimethylsulfoxide (SO, GPR), di-sodium hydrogen phosphate 
(AnalaR), formic acid (HPLC grade), hydrochloric acid (GPR), Kiesal 
gel 60, methyl chloride (AnalaR), potassium dihydrogen phosphate 
(AnlaR), potassium hydroxide (AnalaR), sodium bicarbonate (AnalaR), 
sodium carbonate (AnalaR), sodium chloride (AnalaR), sodium 
dihydrogen orthophosphate (AnalaR), sodium dodecyl sulphate (SDS), 
sodium hydroxide (AnalaR), sodium nitrite (GPR), toluene (GPR) urea 
(AnalaR) and kieselgel 60 F254 TLC plates. 
2,2-azino-di-[3 ethylbenz-thiozaline sulphonic acid] was purchased 
from Boehringer Mannheim, Lewes, E. Sussex. UK. 
Second antibody, peroxidase-conjugated rabbit immunoglobulins to 
mouse immunoglobulins, was purchased from Dakopatts a/s, High 
Wycombe, Bucks. UK. 
-Alanine and ethylenediamine were obtained from Fluka Biochemika, 
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Gillingham, Dorset. UK. Ethyl acetate (AnalaR), charcoal and sodium 
acetate (GPR) were supplied by Hopkins and Williams Ltd., Chadwell 
Heath, Essex. UK 
S-PtIA was obtained from Janssen Chimica, Hyde, Cheshire. UK. 
G100-Sephadex was supplied by Pharmacia Ltd., Milton Keynes, Bucks. 
UK- 
-3),  (55.  bichinchonic acid and coomasie 
blue protein assay kits were purchased from Pierce Chemicals Ltd., 
Luton. UK. 
Acetonitrile (HPLC grade), methanol (HPLC grade), and 
tetrahydrofuran (THF) were purchased from Rathburns Ltd., Wakerburn, 
Scotland. UK. 
The following reagents were purchased from Sigma Chemical Co. Ltd., 
Poole Dorset UK.:- acetylcysteine, m-aminobenzoic acid, bovine serum 
albumin (catalogue no. A7030), cysteine, cystine, dextran (clinical 
grade), diaminopentane, p_dimethylaminobeflZaldehYde, dithiothreitol, 
ethylene oxide, 	N_ethyl_N_(3_dimethYlamifl0_proPYl)a0dm) de 
(EDU, protein sequencing grade), EllmanTh reagent, N-ethylmaleimide, 
Freunds complete and incomplete adjuvent, gelatin (Type A 60 
bloom), glutathione (GSH), human serum albumin (catalogue no. 
A1887), hydrogen peroxide, iodoacetic acid-N-hydroxysucciflimide, 
Keyhole Limpet hemocyanin tlegathura Crenulata,(catalogue no. 
H2133), mouse serum albumin (catalogue no. A1056), suberic acid di-
tT-hydroxysuccinimide, trinitrobenzeneSulfOflic acid (TNBS), Trizma 
base (reagent grade), Tween-20. 
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PBS buffer tablets (Oxoid) were from Unipath, Basingstoke. UK. 
ANIMALS 
Balb/C mice were supplied by Charles River, Margate, Kent. UK. 
PLASTICS 
Nunc Immunoplates F96 cert and Covalink microtitre plates were 
purhased from Gibco Ltd-, Paisley, Scotland. UK. 
BUFFERS 
ABTS substrate consisted of 2,2 azino-di-[3 ethylbenz-thiozaline 
suiphonic acid] (0.63mg/ml) in citrate phosphate buffer (0.114, pH 
4.3) containing 0.0036% hydrogen peroxide. 
0.111 Citrate buffer pH 4.3 consists of 0.114 citric acid and 0.1M 
disodium hydrogen orthophosphate. 
10mM Acetate buffer pH 6.2 consisted of 10mM sodium acetate adjusted 
to pH 6.2 by the addition of 10mM acetic acid. 
0.111 Carbonate buffer pH 8 consisted of 0.1M sodium carbonate and 
0.111 sodium bicarbonate. 
Coating buffer (pH 9.8) consisted of sodium carbonate (0.015M) and 
sodium bicarbonate (0.03M). 
0.111 Phosphate buffer pH 4.5 consisted of 0.111 sodium dihydrogen 
orthophosphate adjusted to pH 4.5 by the addition of 0.111 sodium 
hydrogen orthophosphate. 
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0.111 Phosphate buffers pH 7.5, 7.6 and 8 consisted of 0.111 disodium 
hydrogen phosphate adjusted to pH by the addition of 0.111 sodium 
dihydrogen phosphate. 
0.111 Phosphate buffer pH 7.0 containing 311 urea consisted of 0.111 
potassium dihydrogen phosphate (390m1), 0.111 sodium hydrogen 
phosphate (610m1) and 311 Urea 
0.0111 Phosphate buffer pH 72 containing 0.1411 sodium chloride 
consisted of 0.1411 sodium chloride in 0.0111 sodium hydrogen 
phosphate, adjusted to pH 7.2 by the addition of 00111 potassium 
dihydrogen phosphate. 
0.0511 Phosphate buffers pH 7.4 and 8 consisted of 0.0511 sodium 
hydrogen phosphate adjusted to pH 7.4 and pH 8 by the addition of 
0.0511 potassium dihydrogen phosphate. 
Phosphate buffered saline (PBS) pH 7.4 was prepared from tablets 
(Oxoid), 1 tablet/lOOmi distilled water. 
PBS/Tween consisted of 0.05% w/v Tween-20 in PBS pH 7.4. 
Saline/Tween wash solution consisted of 0.9% w/v saline, 0.05% w/v 
Tween-20 in distilled water. 
0.111 Tris/HC1 pH 9.0 consisted of 0.111 Trizma base adjusted to pH 
9.0 by the addition of 0.111 HC1. 
METHODS 
S-PHENYL-N-ACETYLCYSTE INE 
2.7 CONJUGATION OF S-PHENYL-N-ACETYLCYSTEINE TO BSA AND KLH BY 
MEANS OF 3_(3_DIMETHYLAMINOPROPYL)CARBODIIMIDE WITH 
DIAMINOPENTANE AS A SPACER ARM. 
S-PMA was coupled to BSA and KLH as follows. BSA (60mg, 10mg/mi) and 
KLH (60mg, 5mg/mi) in OlM phosphate buffer pH 8 was added to an 
excess of disminopentane (1.03m1 and 70u1 respectively) with 
stirring. EDC (1.66 and 0.115g) was added with stirring to the 
mixture and the solution was reacted with continous stirring at room 
temperature for 2 hours. The solution was dialysed extensively first 
against distilled water then against 0.1M phosphate buffer pH 8. 
Dianiinopentane in the dialysate was monitored with the colourimatic 
reagent p-dimethylaminoheflzaldehYde (amines condense with p-
dimethylaminobenzaldehyde to yield a yellow schiff base). 
Briefly, a drop of a saturated solution of p-
dimethylaminohenzaldehyde in toluene was dropped onto a filter 
paper, spotted with dialysate and heated in an oven at 1000C for 4 
minutes. After removal of the diaminopentane the protein 
concentrations were determined from spectrophotometric readings at 
270nm. 
S-PtIA (10mg/mi in 10% v/v methanol water) was reacted 
stoichometrically with EDC at 40C for 30 minutes with stirring. An 
excess (xlOO moles) of activated 5-PHA (0.724ml) was added to the 
protein-diaminopentafle spacer solutions (20mg BSA 2.45 mg/ml, 20mg 
KLH 1.6 mg/ml respectively) with stirring. The mixtures were reacted 
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overnight at room temperature with continous stirring then 
extensively dialysed against distilled water and PBS. Protein 
concentrations were determined using coomasie blue (2.8.1) and 
bicinchoninc acid (2.8.2) protein assay reagents. After dialysis the 
concentration of the BSA and KLH conjugates were 1.07 and 0.81 mg/ml 
respectively. Similar protein conjugate concentrations were obtained 
with coomasie blue and hicinchoninic acid. 
Hapten incorporation ratios were calculated from absorbance readings 
at 270nm Hapten incorporation ratios were determined 
spectrophotometrically. The average hapten incorporation ratio for 
BSA was approximately 16:1. 
2.8 DETERMINATION OF PROTEIN CONCENTRATION 
2.8.1 DETERMINATION OF PROTEIN CONCENTRATIONS WITH COOIIASIE BLUE. 
Coomasie brillant blue G-250 protein assay reagent was bought ready 
for use from Pierce Chemicals. BSA and KLH standards (0.125-2mg/mi) 
were prepared in distilled water. To O.lml of standard, blank and 
sample respectively was added 5ml of coomasie blue assay reagent. 
The solutions were mixed and the absorbance read at 595nm. The blank 
absorbance was subtracted from the standard and sample OD readings. 
The protein concentration in the samples was determined from the 
calibration plot protein concentration v absorbance. 
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2.8.2 DETERMINATION OF PROTEIN CONCENTRATION WITH BICINCHONIC ACID 
Protein concentration was determined using a Pierce Chemicals 
bicinchonic acid assay reagent kit. The assay was carried out 
according to Pierces instructions. Briefly, BSA and KLH standards 
(0125-20ug/ml) were prepared in distilled water. To 0.1ml of 
standard, blank and sample was added lml of freshly prepared 
reagent, 2 parts sodium carbonate, sodium bicarbonate and sodium 
tartrate in 0.2N NaOH (solution C) plus 48 parts 4% hicinchonic acid 
in water (solution B) plus 50 parts 4% cupric sulfate pentahydrate 
in water (solution A). The solutions were mixed and reacted in a 
water bath at 600C for 60 minutes. After incubating the solutions 
were allowed to stand for 60 minutes and cool to room temperature 
The absorbances were read at 562nrn. The blank absorbance was 
subtracted from standard and sample OD values. The protein 
concentrations in the samples was determined from the calibration 
plot of standard concentration v absorbance. 
2.9 CONJUGATION OF S-PHENYL-N-ACETYLCYSTEINE TO BSA, HSA AND KLH BY 
MEANS OF THE HONOBIFUNCTIONAL CROSS-LINKER BIS(SULFOSUCCININIDYL) 
SUBERATE (BS3). 
S-PMA (225mg) was deacetylated by heating with 6N HC1 (20ml) at 900C 
for 3 hours. The acetic acid, a product of the acid hydrolysis, was 
removed by rotary evaporation at 350C. The reaction was monitored by 
TLC using the solvent mixture butanol, acetic acid and water 3:1:1, 
TLC plates were developed with both iodine vapour and ninhydrin. A 
single spot, which gave a positive reaction with ninhydrin, was 
observed after TLC of the reaction mixture. The Rf values of S-1A 
and S-phenylcysteine were 077 and 0.64 respectively. 
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The loss of the acetyl group was confirmed by NMR. 	NNR was 
performed on a GE QE300 operating at 300MHz, referenced to ThA at 
Otpm. PMA: shift (ppm) 7.18-7.42 (m, SF!, 06H5), 4.52 (dd. J60 and 
8.1Hz, IH, CH), 3.10-3.50 (m, 2H, SCH), 1.85-1.90 (s, 3H, CH3). 
Phenylcysteine: shift (ppm) 7.18-7.42 (m, 5H, (,6H5), 4.52 (dd, J=6.0 
and 8.1Hz, 10, OH). 3.10-3.50 tm, 2H, SCH9)]. 0D400 was used as 
solvent. 
The S-phenylcyst.eine was dissolved in di-sodium hydrogen phosphate 
(60ml) and the pH of the solution (pH 8.5) was adjusted to pH 8 by 
the addition of iti sodium dihydrogen phosphate (12ml). 50mg of BSA, 
HSA and KLH were dissolved in 0.05F1 phosphate buffer pH 8.0 (5m1, 
5m1 and 8.33ml respectively). To each protein solution was added 9mg 
(3.6m1) of 5-phenylcysteine with mixing. The homobifunctional 
crosslinker BS (70mg) was dissolved in distilled water (lml) and 
immediately added to the protein solutions (21.35mg, 152.5u1) with 
rapid mixing. The mixtures were reacted overnight with continous 
stirring then dialysed extensively first against distilled water 
then against PBS. The protein concentration was determined using 
coomasie blue protein assay reagent and the hapten incorporation 
ratio was measured spectrophotometrically (270nm) Phenylcysteine 
was coupled to BSA with an average hapten incorporation of 25:1. 
2.10 IMMUNISATION SCHEDULE 
Primary immunisations (day 1) and secondary immunisations (day 21) 
were given subcutaneously. Each mouse received lOOug of hapten in 
200ul of a 50:50 v/v hapten adjuvant emulsion. Primary immunisations 
were prepared in Freunds complete adjuvant, secondary immunisations 
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were prepared using Freund-- incomplete adjuvant. Mice were bled 
(approx. 200u1) from the retro-orbital plexus on day 30. 
Serum was separated from whole blood by centrifugation (2200rpm for 
5 mm), and stored frozen at _700 C. 
2.11 SCREENING MOUSE SERA BY ENZYME LINKED INMUNOSORBENT ASSAY 
(ELISA) 
2.11.1 COATING PLATES 
NUNC NAXISORB 
Haptens conjugated to Bovine Serum Albumin (BSA) were used for plate 
coating. A solution of conjugate in coating buffer (lug/'ml,) was 
added (iQOul) to the central 60 wells of a microtitre assay plate. 
The plate was sealed with a plastic cover and incubated for 3 hours 
at room temperature. The wells were emptied and washed 5 times with 
saline/Tween solution, shaken dry and stored in the dry at 40  C. 
until use. 
NUNC COVALINK 
To a solution (lml) containing 1.87mg/mi of NHS and 3.12mg/ml of EEC 
in distilled water was added 39..9ugs of S-PMA (3.99ul of lOmg/ml in 
DMSO). The mixture was reacted for 30 minutes at room temperature 
with continous stirring then diluted 1:100 with cold (40C) 01N 
carbonate buffer pH 8.6 The dilute activated S-PHA was dispensed 
(lOOul/well) into the 96 wells of a covalink NH9 microtitre plate 
The plate was sealed with a plastic film and maintained at 40C for 
30 minutes. The wells were emptied and washed 4 times with 
PBS/Tween. Plates were shaken dry and stored as above until 
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required. 
2.11.2 SCREENING ASSAY 
Sera were diluted with PBS/Tween to give antibody titration curves 
in the range 1:10 to 1:25,600. Aliquots (iQOul) were transferred to 
the antigen coated wells of a microtitre plate, which was sealed 
with a plastic film and incubated overnight at room temperature- The 
wells were emptied, washed 5 times with saline/Tween and shaken dry 
Excess wash solution was removed by aspiration lOOul of anti-mouse 
IgO peroxidase conjugated antibody diluted 1:1000 in PBS/Tween was 
added to each well. The plate was covered and incubated for a 
further 2 hours at room temperature The plate was washed again and 
dried, as above, and 100u1 of ABTS substrate added. In the presence 
of peroxidase this substrate turns from a colourless solution to 
green. Optical density was measured at 405nm using a microtitre 
plate reader (spectrophotometer). 
The ability of an antibody to recognise free hapten was examined in 
binding inhibition studies. Sera were diluted in PES/Tween to give a 
limiting dilution and transferred to the wells of a conjugate coated 
plate (SOul/well). The sera are incubated in the presence of either 
S-PMA (50u1/well of 200ug/ml standard), or standard diluent 
(50ul/well). The assay was performed as described above 
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S-(2-HYDROXYETHYL)-N-ACETYLCYSTEINE 
2.12 SYNTHESIS OF S-(2-FWDROXYETHYL)CYSTEINE 
Cysteine (1.2g. O.Olmol) was dissolved in distilled water (lOml) and 
cooled to oc using an ice water cooling mixture. Potassium 
hydroxide (1.1g, 0.02mol) was also dissolved in distilled water 
(3ml) and cooled to 000.  The potassium hydroxide solution was slowly 
added to the cysteine with stirring, maintaining the temperature at 
000. 
A 25ml bottle of ethylene oxide (boiling point 1000)  was cooled to - 
7000 with dry ice. A calibrated pasteur pipette (14drops = 0.176g, 
4mmol. of ethylene oxide) was cooled by pumping with the cold 
ethylene oxide. Using the cold pipette 6 drops of ethylene oxide was 
transferred to the stirred cysteine solution. The ethylene oxide 
bottle was stoppered to prevent moisture from entering. After 
approximately two minutes a further six drops of ethylene oxide was 
transferred, this was repeated until 36 drops (0.48g, 0.01mol) of 
ethylene oxide had been added to the cysteine solution. The solution 
was reacted at 400 for 16 hours, The mixture was then acidified with 
20% concentrated HC1 in water to pH 6 with ice water cooling and the 
solution rotary evaporated at 3000 until dry. 
The reaction was monitored and the fractions checked by TLC, using 
silica gel 254F plates (0.2mm thick, 20cm x 5cm) and either 
methanol:chloroform 60:40 containing 0.880 ammonia (5 drops in 
20mls), or propanol water 1:1 as solvent. Plates were developed 
using iodine vapour. The best separation was achieved using 
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propano1: water  as the mobile phase, the Rf value of the product was 
0.6 and the Rf of cysteine was 0.35. Using rnethanol:ch]oroform 
(60:40) as the mobile phase, the Rf values were 0.25 and 0.5 
respectively. 
The S-hydroxyethylcystejje was purified by crystallisation from 
methanol water 80:20. The S-hydroxyethylcystejne was dissolved in a 
minimum amount of solvent at room temperature and cooled in a fridge 
overnight. Crystals were removed by filtration, washed quickly with 
a small amount of methanol water (95:5) and dried in a desiccator 
with molecular sieve. The remaining filtrate was rotary evaporated 
and recrysta.lised as above. Rotary evaporation and crystallisation 
produced a white solid NHR [shift (ppm) 3.88 (dd, J=6.0 and 8.1Hz, 
1H, CH). 3.69 (t, J6.6Hz, 2H, CH-,,OH), 3.1 and 2.98 (dAB. J=15.0, 
8.1 and 6.0Hz, 2H, SCH2CH), 2.70 (t, J6.6Hz, 2H. SCH9)] (solvent 
D20) and MS analysis (+ve CI: N+H 166 (40%), 149(100%) confirm 
product was S-(2-hydroxyethyl)cystejne. Optical rotation 
measurements with L-valine and S-(2-hydroxyethyl)cysteine indicate 
racemisation in the presence of KOH did not occur. 
2.13 SYNTHESIS OF S-(2HYDROXYETHYL)-N-ACETYLCYSTEINE 
The preparation of this compound was as for S-hydroxyethyl cysteine, 
using 1.6g of N-acetylcysteine. 
Hydroxyethylation of acetylcysteine gave a single product when the 
reaction mixture was monitored by TLC. TLC was performed using 
silica gel 254F plates (0.2 mm thick, 5cm x 20cm) and 
methanol:chloroform solvent (60:40 or 40:60) containing 0.880 
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ammonia (5 drops i 	Plates were developed with iodine 
Vapour. The Rf of acetylcysteine was 060 and 0.30 and the Rf of S-
(2-hydroxyethyl)-N-acetyl cysteine was 0.40 and 0.215 respectively. 
Rotary evaporation of the solvent, after HPLC purification, left a 
clear, oily product. NMR [shift (ppm) 8.42 (s, 1H, NH), 4.45 (dd, 
3=6.0 and 8.1Hz, 1H, OH), 3.68 (t, 36.61iz, 2H, CH70H), 3.08 and 
2.88 (dAB, J=15.0, 6.1 and 6.0 Hz, 2H, S012CH), 2.72 (t, 3=6.6Hz, 
2H, SCH2), 2.02 (s. 3H, ,H' , 	solvent) and MS analysis (+ve Cl: 
P1-i-H 207 (67%), 190 (45%), 166 (15%), 162 (59%), 130 (100%)) 
confirmed this was S-hydroxyethyl-N-acetyl cysteine (Van Bladeren et 
al 1980). 
The sample was purified using HPLjC with the following conditions: 
Column: 	 Spherisorb ODS-2, 5 micron, 25cm x 20mm ID 
Detector: LJV, wavelength 210am; Mass Evaporative 
Detector 650C 30psi Nçi nebuliser flow. 
Mobile phase: 	10% acetronitrile in water containing 0.03% 
formic acid 
Flow rate: 	12m1/min 
After HPIJC solvent was removed from the S-hydroxyethyl-N-
acetylcysteine by rotary evaporation with a water bath at 300C, 
traces of formic acid were removed by adding small amounts of water 
and re-rotary evaporating. Characterisation was as above. 
2.14 CONJUGATION OF S-(2-HYDROXYETHYL)CYSTEINE TO PROTEINS 
2.14.1 CONJUGATION WITH THE HETEROBIFUNCTIONAL CROSS-LINKING AGENT 
N- (ANINOBENZOYWXY ) SUCCIN TNT DE 
A modification of the procedure used by Fujiwara et al (1990) was 
used to prepare the heterobifunctional crosslinking agent N- 
68 
(arniriobenzoyloxy)succinimide and hapten-protein conjugates. 
A) PREPARATION OF N-(ANINOBENZOYWXY)SUCCININIDE 
N-( aminohenzoyloxy)succinimide (ABS.) was synthesized as follows. 
Meta-aminohenzoic acid (1.37g, lOmmol) and dicyclohexylcarbodiimide 
(247g, 12rnmol) were dissolved in distilled tetrahydrofuran (THF) 
(30ml) and cooled, on ice, to 40 C. N-hydroxysuccinimide (1.15g, 
lOmmol) was added slowly to the mixture with rapid stirring. The 
mixture was reacted overnight at 40  C. followed by 2 hours at room 
temperature with continuous stirring. The precipitate (N,N-
dicyclohexylurea) was removed by filtration and the filtrate was 
concentrated by evaporation under a stream of N2 gas. 
The reaction products were separated by column chromatography. The 
reaction residue was dissolved in a mobile phase (lOml) of mixed 
solvent (3:1 by volume methyl chloride and ethyl acetate) and loaded 
on to a Kiesel gel 60 column (2 x 22cm containing lBg dry gel)The 
order of elution and the position of the reaction products in the 
column eluent were determined by TLC using Kiesel gel 60 plates 
(Merck). 
Evaporation of the fractions which appeared to contain only rn-ABS 
gave 79mg of a pale brown solid with a melting point of 152-1540 C. 
Mass spectrometry indicated the solid was a mixture of 2 main 
components and a number of minor components. One of the main 
components had a molecular weight of 218, as expected. Additional 
fragments rn/z 120 and m/z 136 were consistent with NH9.Bz.CO and the 
free amide NH2.Bz.CONH2 respectively. NMR studies confirm the 
presence of rn-ABS and other reaction products [Shift (ppm) 7.10-7.20 
(t, 1H, C4)1  6.88-6.92 (d, 1H,C5), 6.82 - 6.88 (s, 1H, Cl), 6.72 - 
6.78 (d, 1H, C3). 1-98 - 2.12 (q, 4H, 08 and C9)1(solvent CD3CN). 
Undefined peaks at 1.15-1.60 and 1.70-1.85 are probably due to 
traces of dicyciohexylurea and N-hydroxysuccinimide - 
B) CONJUGATION OF S_(2_HYDROXYETHYL)CYSTEINE TO PROTEIN USING ABS 
AS A CROSS-LINKING AGENT 
Incorporation of the rn-ABS into the hapten, activation of the 
aiainobenzoyl group by diazotization and its subsequent azocoupling 
to Bovine serum albumin (BSA) and Keyhole Limpet hemocyanin (KLH) 
JgthLzra Crenizlata was carried out as follows. 
To imi of hydroxyethylcysteine (10mg/mi) in acetate buffer (10mM p1-I 
6.2) was added rn-ABS (4.12mg, 17.52umol) in 206u1 of THF. The 
mixture was reacted at room temperature for 3 hours with continuous 
stirring, then acidified by the addition of 57.9ul of iN HC1. 
Diazotization was carried out by the addition of sodium nitrite 
(368mg, 52.57umoi in 36..8u1 of distilled water), and reaction for 
15 minutes at 40 C. with stirring. Activated hapten was added 
(555.5u1) to either BSA (5m1 of 1.075mg/mi) or KLH (5m1 of 
0.85mg/mi) dissolved in Tris/HC1 (0.1M, pH 9.0) and reacted for 2 
hours at room temperature with continuous stirring. The mixture was 
then applied to a column of Sephadex 0-100 (approx. 2 x 20cm 
containing 3.6g of dry gel, and a void volume determined with 
methylene blue) and eluted with phosphate buffer (0..1N, pH 7.0) 
containing 3M Urea. 
The protein-ABS-hydroxyethylcysteine conjugate eluted in the void 
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volume of the column (azo-coupling S-(2-hydroxyethyl)cysteine to 
either ESA or KLH gave a bright orange/yellow conjugate). lml 
fractions were collected and absorbance readings were monitored at 
280nm. Fractions with the highest protein concentrations were 
pooled). Protein recoveries (pooled fractions) of 59% and 61% were 
obtained for the BSA (0.79mg/ml) and KU-I (0.86mg/ml) conjugates 
respectively. Spectrophotometric analysis demonstrated the 
qualitative binding of hapten to protein, but it was not possible to 
calculate spectrophotometrically a quantitative hapten-protein 
incorporation ratio 
The hapten-protein ratio was determined by amino acid analysis 
(2.15.2). 	Pooled conjugates were used to immunize Balb/c mice and 
for coating ELISA assay plates (2.18). 
2.14.2 PREPARATION OF S-(2-HYDROXYETHYL)CYSTEINE - GELATIN CONJUGATES 
The preparation of acetylated gelatin, the coupling of the spacer 
arm B-alanine to the acetylated gelatin and the subsequent 
conjugation of hapten was based on the method of Marini et al (1989). 
A) PREPARATION OF ACETYLATED GELATIN 
Acetylated gelatin (Ac-Gel) was prepared as follows. Gelatin was 
dissolved at lOmg/ml in 6m1 of O.IM phosphate buffer, pH 45 
(coupling buffer), with gentle heating and stirring. Acetic 
anhydride (1.2ml) was added slowly, dropwise, with stirring to the 
gelatin solution. The mixture was reacted for 24 hours with 
continuous stirring at room temperature then dialyzed extensively 
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first against distilled water, then against coupling buffer. 
After dialysis the Ac-Gel was diluted to lmg/ml in coupling buffer. 
Ac-Gel was stored at _700  (". for future use. 
CONJUGATION OF CHEMICAL SPACER TO ACETYLATED GELATIN 
The spacer arm B-aianine was conjugated to Ac-Gel as follows 
B-alanine (6mg) was added to Ac-Gel solution 30m1, lmg/ml in 
coupling buffer). The pH of the clarified solution was adjusted to 
4.5 with 11 HC1. N-ethyl-N-(3 dimethylarninopropyl)-carhodjjmide 
([ELX] 1.5g) was added in 4 equal aliquots, with stirring, while 
maintaining the pH at 4.5 with HCl. The mixture was reacted for 20 
hours with continuous stirring at room temperature and dialyzed 
extensively first against distilled water, then against coupling 
buffer. Solutions (0.9mg/mi) B-alanine-Ac-Gel were stored at -700 C. 
until use 
CONJUGATION OF S-HYDROXYETHYLCYSTEINE TO SPACER MODIFIED GELATIN 
Hydroxyethlcysteine (4J31mg) was dissolved in 5ml of coupling buffer 
containing B-alanine-Ac-Gel. The pH of the mixture was maintained at 
45 with HCl. EDC (250mg) was added in 4 equal aliquots as described 
previously. The mixture was reacted for 24 hours with continuous 
stirring at room temperature then dialyzed extensively first against 
distilled water, then against PBS. The concentration of and 
gelatin-B-aianine-S-(2-hydroxyethyl)cysteine was 0.69mg/mi after 
dialysis. 
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2.14.3 CONJUGATION OF S-(2-HYDROXYETHYL)CYSTEINE WITH 
DI-N--HYDROXYSUCCININIDE SUBERIC ACID 
A) SYNTHESIS OF N-SUBERYL-S-HYDROXYETHYLYSTEINE HYDROXYSUCCINIMIDE 
ESTER (Figure 2.8) 
S-hydroxyethylcysteine (165mg) was dissolved in 25ml of DHSO 
containing 1 to 5% water. Suberic acid di-N-hydroxysuccinimide ester 
(0.37g) was also dissolved in DNS0 containing 1-5% water (5m1). 
Aliquots (imi) of S-hydroxyethylcysteine were added every 15 minutes 
with stirring to the suberic acid di-N-hydroxysuccinimide and the 
mixture was reacted at room temperature with continous stirring. The 
reaction was monitored by HPLC with the following conditions: 
Column: 	Spherisorb 0DS-2 5 micron 10cm x 4.6mm ID 
Wavelength: 210nm 
Flow rate: 	1.5ml per minute 
Gradient: 10% acetonitrile in water containing 0.03% formic 
acid to 30% acetonitrile in water containing 0.03% 
formic acid over 10 minutes, then to 100% 
acetonitrile over 5 minutes. Hold at 100% 
acetonitrile. Equilibrate with starting solvent for 
10 minutes before injecting the next sample. 
S-hydroxyethylcysteine was added (110-123mg) until the amount of 
mono-substituted product appeared optimal. The monosubstituted 
product was purified from the disubstituted product and the 
unreacted suberic acid di-N-hydroxysuccinimde ester by HPLC using 
the following conditions: 
Column: 	Spherisorb ODS-2 5 micron 25cm x 20mm ID 
Detector: ACS Evaporative Mass Detector 
Flow rate: 	12ml per minute 
Gradient: As for analytical runs 
The retention times of the S-hydroxyethylcysteine, disubstituted 
product, monosubst ituted product and di-N-hydroxysucc inimide suberic 
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acid were 2, 10 7 12 and 14 minutes respectively (figure 2.9). 
Solvent was removed from the collected fractions by rotary 
evaporation. Traces of formic acid were removed by re--evaporation 
with water. The structure of the N--suheryl-S--hydroxyethyl cysteine 
hydroxysuccinimide was confirmed by NtIR [shift (ppm) 7.10-7.20 (d, 
10, 	UONH ) , 4M-4.60 (q, 10, OH). 3,60-3.68 K, 20, CH20H ) , 2.80- 
305 	(m, 2H, SCHo) , 2.75 ( s, 40, ring), 2.62-2.70 (t, 2H, SCH7) 
2.52-2.62 (t, 20, 0C()0H2), 2.15-2.25 (t. ZH, NCOCH2)1 1.50-1.70 (m, 
40, 002, chain), 1.25-1.45 (m, 40, 002, chain)](CD3CN solvent). 
B) COUPLING N-SUBERYL-S-HYDROXYETHYLCYSTEINE F-IYDROXYSUCCININIDE 
ESTER TO BSA, KLH AND GELATIN 
CONJUGATION 1 (KLH, BSA AND GELATIN) 
N-Suheryl-S-hydroxyethylcysteine hydroxysuccinimide ester was 
conjugated to BSA, KU-I and acetylated gelatin incorporating an 
ethylenediamine spacer arm. The preparation of the acetylated 
gelatin is described above. Ethylenediamine was conjugated to 
acetylated gelatin as for B-alanine (described above) substituting 
B-alanine with :3.6m1 of ethylenediamine. 
Coupling was carried as follows. 64mg of BSA (51.9mg/11) and KLH 
(30mg/ml) in 0.111 phosphate buffer pH 7.5, and 2nd of 
ethylenediamine spacer acetylated gelatin (0.55mg/mi) in 0.111 
phosphate buffer pH 4.5 were cooled on ice. To each solution was 
added 21.6mg of N-suberyl-S-hydroxyethylcysteine hydroxysuccinimide 
ester in LF (65mg/mi) dropwise with rapid stirring on ice. The 
mixture was allowed to react for 1.5 hours at room temperature with 
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Figure 2.8 Synthesis of N-suberyl-S-hydroxyethylcysteine 
hydroxysuccinimide ester 






Figure 2.9 Chromatogram showing the separation of N-suberyl-S-
hydroxyethylcysteine from other reaction products. 
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continous, gentle stirring and was then extensively dialysed aganist 
PBS. Protein concentrations were determined from OD readings at 
280nm. After coupling, the concentration of the BSA, KLH and gelatin 
conjugates was 24.5, 18.6 and 0.18mg/ml respectively (recoveries of 
74%, 76% and 46%). The hapten protein incorporation ratios were 
determined using TNBS and by amino analysis (215). 
CONJUGATION 2 (NSA AND BSA) 
Solutions (20mg/mi) of NSA and BSA were prepared in 01N phosphate 
buffer pH 7.6. N-suberyl-S-hydroxyethylcysteifle hydroxysuccinimide 
ester was dissolved in methanol (100mg/mi) and immediately added 
(61.4u1 and 307u1) to the NSA and BSA solutions, imi and 5m1, with 
stirring. The solutions were reacted at room temperature with 
continous stirring for 3 hours. To the NSA conjugate was added imi 
of phosphare buffer and both solutions were extensively dialysed, 
first against water then against PBS. Protein concentrations were 
determined from OD readings at 280nm. After conjugation the 
concentration of the BSA and NSA conjugates was 14.3 and 8mg/mi 
respectively. The incorporation ratios are given below (2.15). 
2.15 DETERMINATION OF HAPTEN INCORPORATION RATIOS 
2.15.1 DETERMINATION OF THE FREE AMINO GROUPS USING 
TRINITROBENZENESULFONIC ACID 
The number of free amino groups in proteins can be determined using 
2,4,6-trinitrobenzenesulfonic acid (TNBS) (Habeeb, 1966). Using the 
method of Habeeb the number of free amino groups in BSA, KLH and 
spacer modified gelatin was determined before and after conjugation. 
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Briefly, to lmi of protein solution, or water blank, was added imi 
of 4% NaH03 pH 8.5 (adjusted by the addition of HC1) and imi of 
0.1% TNBS. The solution was mixed and reacted for 2 hours at 400C. 
imi of 10% sodium lauryl sulfate (SDS) was added to soluhilize the 
protein and prevents its precipitation on addition of 05ml of iN 
HCL The absorbance of the solution was read at 335nm. 
A linear increase in absorbance was obtained when BSA, KLH and 
gelatin (0-1mg/mi) were reacted with TNBS. Assuming the molar 
extinction coefficient of one free amino group is 0.995x104, then 1 
mole of BSA contains 51 moles of free amino groups. 
In coupling 1 it was estimated that 49% of the free lysines in BSA 
were conjugated and that the hapten incorporation ratio was 25 moles 
of 2-HENA to 1 mole of BSA. Similar percentage conjugations, 50% and 
44%, were achieved with the KLH and gelatin conjugates. 
In coupling 2 57% of the BSA lysines were conjugated and the 
incorporation was 29:1. For NSA, after reaction with TNBS, it was 
calculated that 1 mole NSA contains 43 moles of free amino 
functions (assuming the NW is the same as BSA, 66000). Reacting the 
MSA-2-HENA with TNBS revealed that 45% of the available amino groups 
were conjugated, and the hapten incorporation ratio was calculated 
as 19 moles of hapten to 1 mole of NSA. 
2.15.2 AMINO ACID ANALYSIS 
BSA, KLH and spacer modified gelatin can be degraded to their 
constituent amino acids by acid hydrolysis. Acid hydrolysis was 
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performed with 5.711 HC1 (constant boiling fraction) in a sealed tube 
containing N9 at 1100C for 90 hours. After hydrolysis the acid was 
removed by lyophilisation and the sample dried using NaOH. Samples, 
diluted in loading buffer, were injected onto the amino acid 
analyser - a cation exchange column from which the eluting amino 
acids were detected with Ninhydrin reagent (fig. 2.10). By 
comparison of the retention times of the eluting amino acids with 
those of a standard solution, containing the common amino acids and 
S-(2-hydroxyethyl)cysteine, protein amino acid composition can be 
derived. A calibration run was performed before each sample. 
One mole of BSA contained 52 moles of lysine, the hapten-BSA 
conjugation ratio was 14:1. For the KLH conjugate 37% of the lysines 
were coupled during the reaction with N-suberyl-S-
hydroxyethylcysteine suberate. No 2-(hydroxyethyl)cysteine was 
observed in the gelatin conjugated sample. An additional peak was 
observed in the conjugated sample when compared to the gelatin 
sample which may have been cysteine. However, it was difficult to 
be certain if this peak (retention time of 28.86) was valine or 
cysteine due to a slight displacement in the retention times of the 
sample compared to the standard. In addition, a number of amino 
acids detected in the gelatin conjugate were not detected in gelatin 
alone. 
2.16 CONJUGATION OF N-ACETYLCYSTEINE TO lISA AND BSA WITH IODOACETIC 
ACID N-HYDROXYSUCCINIMIDE AS THE CROSSLINKER (Figure 2.11) 
lISA (45mg) and ESA (100mg) were dissolved in 0.0511 phosphate buffer 







Figure 2.10 Chromatogram showing the separation of S-(2-
hydroxyethyl)cysteine and protein amino acids 
acheived during amino acid analysis. 
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Figure 211 Conjugation of N-acetylcysteine to protein with 
lodoacetic acid N-hydroxysuccinimide. 
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BSA was added 26.5 and 60mg of lodoacetic acid N-hydroxysuccinimide 
dissolved in DNS0 (194 mg/ml). The mixture was reacted overnight at 
room temperature with continuous stirring, then dialysed extensively 
aganist 0.05N phosphate buffer pH 7.25. The reaction was monitored 
with the colourimetric reagent TNBS and 90% of the availahe protein 
amines were conjugated. After dialysis the NSA and ESA spacer 
concentrations were 10.5 and 102 mg/ml respectively. 
N-Acetyicysteine was linked through its sulfhydryl group to the 
halogen activated proteins as follows. To 40mg of activated NSA and 
90mg of activated BSA was added 24u1 and 55ui respectively of 
100mg/mi N-acetyicysteine dissolved in distilled water. The mixtures 
were reacted overnight at room temperature with continous stirring, 
then dialysed extensively aganist PBS. The reaction of N-
acetylcysteine with protein was monitored by measuring the fall in 
the number of free sulfhydryl groups with Ellmans reagent. 
Ellman s reagent 	(5,5 -dithio-bis-(2-nitrohenzoic acid) 	was 
dissolved (4mg/mi) in 0.1M disodium hydrogen phosphate and adjusted 
to pH 8 by the addition of 0.1N sodium dihydrogen phosphate. To 
lOOul of sample was added 100ul of ElimanTh reagent and Sml of 0.1I1 
phosphate buffer pH 8 The solution was mixed and reacted at room 
temperature for 20 minutes. The absorbance was read at 412nm - at 
this wavelength the extinction coefficient (E412) equals 1.36 x 
cmN'. The average hapten incorporation ratios were r:l, 
determined from the number of free suithydryl measured rercre -tu 
after coupling. The protein concentration atter irtiy 
lOmg/ml. 
dl 
2.17 SYNTHESIS 	OF 	RAUIOLAI3ELLEU S- 2-HUROX(THL -ft- 
ACETYL(YS1E INE 
LW L Id 	vtin 	U2 m(.i/rnmole ) was obtained from NEN 
adicic)emicals 'Ihe cystine was labelled on all the carbon atoms. To 
JOuCi of cystine in 0.5m1 2% ethanol in water (as supplied) was 
added 10mg of N-hydroxysuccinimide acetate (in lOOul of UHF), and 
25u1 of a 1% solution of sodium carbonate in water. The mixture was 
reacted at room temperature for two hours and monitored by TLC. 
Samples were spotted onto F254 silica coated plates (0.2mm thick, S 
X 20 cm), and developed using either propanol:water (1:1), 
hutanol:acetic acid:water (3:1:1) or chloroform:methanol (6:4) 
containing 5 drops of 0,222 ammonia in 20ml of solvent. The 
components were detected by radioscanning. The best chromatography 
was achieved using propanol-water as the solvent. The reaction was 
complete after 2 hours giving a single spot in the N,N-
diacetylcystine position, 
Dithiothreitol (3mg) was added directly to the reaction and the 
mixture was heated at 6000 for 5 hours under a nitrogen atmosphere. 
The mixture was examined by PLC using the above conditions. In 
addition, a sample of the reaction was co-chromatographed with cold 
acetylcysteine. After PLC the products were visualised with iodine 
vapour. The labelled product had the same Rf value as cold 
acetylcysteine whilst the cold acetylcysteine doped with labelled 
product coeluted. 
Confirmation of the result was obtained by HPLC. The retention time 
of the radio peak was compared to the retention time of cold 
acetycysteine in a sample of cold acetylcysteine spiked with the hot 
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reaction product. The conditions were as follows- 
Column: 	spherisorh SAX 5 micron 15cm x 4.6mm ID 
Mobile phase: 	30% methanol in water containing 0.1% formic acid 
Flow rate: 1 ml/minute 
Detector 1: 	DV detector wavelength 220nm 
Detector 2: Ramona Raytest detector. 
The retention time of the radio peak in line radiochemical 
detection) was coincident with cold acetylcysteine (UV detection). 
Potassium hydroxide solution (0.1% in water) was added to the 
reaction mixture until the pH was 14. The mixture was cooled in ice-
water and imi of ethylene oxide was added. The reaction was 
monitored by HPLC using the conditions described above. when the 
reaction was complete the pH was adjusted to 6 by the addition of 
30% hydrochloric acid in water. The sample was stored overnight at - 
300C (16 hours). When the mixture was thawed and checked by HPLC it 
was found to contain another component close to the solvent front. 
The sample was isolated by HPLC, using the conditions described 
above, and reinjected to confirm the retention time with cold S-(2-
hydroxyethyl)-N -acetylcysteine. The result was checked by radio TLC 
with confirmation by doping with cold S-(2-hydroxyethyl)---N-
acetylcysteine and detection with iodine. 
Isolated fractions were radiocounted and freeze dried. Samples of 
freeze dried material were also counted and the activity of the 
prepared S_(2_hydroxyethyl)_N_acetylCySteifle was calculated. The 
total activity of the labelled 2-HEIIA prepared was lSOmCi/mmole 
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2.18 IMNUNISATION AND SCREENING 
Nice were immunised with the 2-HENA KLH, NSA and gelatin conjugates 
using the protocol described above (2.10). The sera were screened by 
ELISA aganist BSA 2-HEMA conjugates. In addition sera were screened 
for antibodies by RIA. 
2.18.1 RADIOINMUNOASSAY OF 2-(HYDROXYETHYL)ACETYLCYSTEINE. 
Labelled 2-HEMA was diluted in PBS on the day of use so lOOul 
contained 10 000 dpm. To lOOul of serum diluted 1:10 in PBS and a 
control blank serum (serum from a mouse immunised with a different 
conjugate) was added lOOul of labelled 2-HEMA Totals containing 
lOOul of label only were also prepared. All the samples were capped 
and reacted overnight, at room temperature. 
SEPARATION OF BOUND AND FREE LABEL. 
Preparation of 5% dextran coated charcoal:- 
Charcoal (50g) and dextran (05g) was first mixed to a smooth paste 
with a few drops of PBS and the volume made upto a lOOml by the slow 
addition of PBS with continous stirring. The mixture was stirred at 
40C for 90 minutes before use. 
Separation:-
To all the samples and the blank was added lOOul of 5% dextran 
coated charcoal (at 40C). After incubation at room temperature for 5 
minutes, the charcoal was separated by centrifugation (2400rpm for 
20 minutes) and the radioactivity in the supernatent counted. The 
radioactivity in the supernatent is directly proportional to the 
amount of labelled analyte bound by the antibody. 
RESULTS 
S-PHENYL-N-ACETYLCYSTE INE 
2.19 BINDING STUDIES WITH MOUSE SERA 
Mice were bled 14 days after the second immunisation yielding 50-
150u1 of serum per mouse. Sera were sreened for the presence of 
antibody by ELISA. All the screened sera contained antibody which 
bound to the conjugate coated plates. The antibody titre (sera 
concentration giving half the maximim OD) varied between mice 
immunised with the same conjugate. Mice (x2) immunised with KLH-S-
PMA had the following titres :- 
MOUSE 	 PLATE 
COVALINK 	 BSA-PMA 
1 	 1:1500 	 1:2000 
2 1:2000 1:3000 
When substrate was added at the end of the screening assay, higher 
optical densities were observed in the wells of the covalirik plates. 
None of the antibodies hound free S-PtIA (200ug/ml) in the inhibition 
studies. 
Antibody titres of 1:20 000-1:25 000 were obtained with 
phenylcysteine conjugates (figure 2.12). Competitive inhibition 
using 200ug/ml of free S-PMA resulted in a reduction of binding of 
3-26% in the ELISA. 
85 
	
IMMUNOGEN 	HOUSE 	TITRE 	%INHIBITION 
HSA-PHA 	1 	1:20 000 	8 
2 1:25 000 9 
3 	1:20 000 	33 
KLH-PMA 	1 	1:25 000 	22 
2 1:20 000 3 
3 	1:25 000 	26 
Figure 212 Titre and relative affinity of antisera from mice 
immunised with S-Phenylcysteine conjugates. 
5- ( 2-HYDROXYETHYL )ACETYLCYSTE I NE 
2.20 BINDING STUDIES WITH HOUSE SERA. 
Sera were screened for the presence of antibodies which recognise 2-
HEMA by ELISA. All the sera contained antibody which hound 
conjugated hapten. The highest titres (1:4000-1:20000) were obtained 
with the KLH-conjugate immunised mice (Figure 2.13). Titres obtained 
with 2-HENA gelatin and NSA conjugate-immunised mice were similar, 
1:15-1:150 (Figure 2.13). MSA-acetycysteine-immunised mice had 
titres of 1:600-1:2500. The inhibition of colour development (1-57%) 
showed the bleeds from 18 out of 19 mice contained some antibodies 
which recognised free 2-HEtIA (Figure 2.13 and 2.14). Mice immunised 
with the gelatin and MSA conjugates gave the largest percentage 
inhibition values (Figure 2.13 and 2.14). 
Nice immunised with HSA-acetylcysteine conjugates were screened 
against acetylcysteine, 2-HEHA and S-PNA. As the molecular weight of 
the hapten increased the percentage inhibition in the binding study 
also increased. The percentage inhibition observed with 5-PHA was 
also increased. The percentage inhibition observed with S-PNA was 
1.6 to 3.8 times greater than that observed with 2-HEMA (Figure 
2.14). 
Figure 2.13 RESULTS OF 2-HEMA MOUSE SCREENING ASSAYS 
IMMUNOGEN MOUSE PLATE COATING TITRE % INHIBITION 
KLH-ABS-HEMA 1 BSA-ABS-HEMA 1:2000 11% 
2 1:4000 4% 
3 1:5000 10% 
GEL-BALA-HEMA 1 BSA-ABS-HEMA 1:300 21% 
2 1:200 16% 
3 1:300 5% 
KLH-7C-HENA 1 BSA-7C--HEMA 1:20000 13% 
2 1:9000 3% 
3 1:20000 11% 
GEL-7C-HEMA 1 BSA-7C--HENA 1:150 3% 
2 1:15 57% 
3 1:100 1% 
MSA-7C-HEMA 1 BSA-7C-HEMA 1:150 28% 
2 1:100 15% 
3 1:50 0% 
4 1:150 13% 
Figure 2.14 RESULTS OF MSA-ACETYCYSTEINE SCREENING ASSAY 
MOUSE TITRE % INHIBITION 
AcCy 2-HEMA 	S-Pt4A 
1 1:2500 9 22 84 
2 1:600 31 35 81 
3 1:600 39 41 69 
FW4 
2.21 RADIOINNUNOASSY OF 2-HEtIA 
Separation of bound and free 2-RENA was achieved with 5% dextran 
coated charcoal. Ten percent of the added label was non-specifically 
bound (NSB). Specific binding was low in all the screened sera. 
Mouse 2, immunised with gel-7C-HENA bound 16% of the added label. 
The other sera bound 10 to 14 percent of the added label. 
DISCUSSION 
Small molecules (<1000 daltons) are not usually antigenic but can he 
rendered immunogenic by coupling to large carrier molecules such as 
KLH and BSA. S-PMA was successfully coupled to KLH and BSA using 
carbodimide and diaminopentane as a spacer. Conjugation was 
demonstrated spectrophotometrically, and the average BSA hapten 
incorporation ratio was 16:1. The molecular weight of KLH is less 
precisely known and KLH hapten incorporation ratio was not 
calculated. 
Conjugate concentrations were determined using Coomassie Brillant 
Blue and Bicinchonic acid Comparable results were obtained with the 
two methods. Lower protein concentrations can he measured with 
Bicinchonic acid. Both methods are sensitive enough for determining 
protein conjugate concentrations. Coomassie blue is quick and easy 
when compared with Bicinchonic acid, and was therefore the method of 
choice in future work. 
Mice were immunised with lOOug of KLH-PMA conjugate. It is important 
that the immunisation protocol does not expose mice to too much 
immunogen as this may give rise to low affinity antibodies. High 
exposures can also cause a failure in the class switching mechanism, 
and IgG antibodies will not be secreted by the lymphocytes after the 
second immunisation. The immunisation protocol proved successful as 
all the sera contained antibodies which bound conjugated hapten. 
Sera were screened against BSA-PtIA conjugate coated microtitre 
plates and against S-PMA, covalently coupled to covalink microtitre 
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plates. S-PI1A is covalently coupled through its carboxylic acid to a 
secondary amino group attached to the end of an 11 carbon spacer. 
The spacer is hydrophilic and should therefore be fully extended in 
an aqueous environment to give optimal presentation of hapten to 
antibody- In addition the method is specific and excludes detection 
of antibodies which recognise other common epitopes in the coating 
and irnmunogen carrier proteins. 
Activation of S-PMA (via the carboxylic acid) was performed with 
high concentrations of NHS and EDC in a short time period (30 
minutes) to prevent hydrolysis of the hydroxysuccinimidyl ester 
formed It has been reported that coupling high concentrations of 
activated hapten to covalink microtitre plates gives rise to high 
assay backgrounds (Sondergard-Anderson et al, 1990). Activated 
hapten was therefore diluted in carbonate buffer before use. 
Conjugation of S-PNA to covalink microtitre plates was based on the 
method of Sondergaard-Anderson (1990). 
Titres obtained with the covalink plates were lower than those 
obtained with the BSA-PMA coated plates. The optical density 
determined at the end of the screening assay was also higher 
(approximately 50%) with the covalink plates. These observations can 
be explained if the coated hapten concentration is greatest in the 
covalink plates, as a limiting dilution is obtained at a higher 
antibody concentration. None of the antibodies bound free S-PIIA. It 
was postulated that the antibodies bound either the hapten plus 
spacer with a greater affinity than hapten alone, or, the COOH group 
in free S-PIIA inhibited antibody binding. To test the latter, S-PtIA 
was deacetylated and coupled to protein through the amino group. 
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Deacetylation of 2-HEHA using the enzyme acylase 1 has been reported 
(Gerin and Tardif, 1986). However, efforts to deacetylate S-PtIA 
using acylase 1 in the described conditions were unsuccessful. 
When acylase was added to S-PMA, enzymic deacetylation started, but 
soon as phenyl cysteine formed further conversion was inhibited S-
PHA could he deacetylated by hydrolysis using 6M HC1. 
Phenylcysteine was successfully coupled to KU-I, HSA and BSA using 
the homohifunctional crosslinker bis(sulfosuccinimidyl)suberate 
(Figure 25a). This cross linker forms an amide bond with the free 
amino group and the conjugate appears as S-PNA linked through the 
acetyls methyl group. The cysteinyl carboxylic acid is left intact 
(Figure 25h). Hapten incorporation could he demonstrated 
spectrophotometrically for all three conjugates. The hapten to ESA 
ratio was 25:1. 
A large immune response was induced when mice were immunised with 
KLH and HSA conjugates. Inhibition studies with free S-PNA showed 
that some of these antibodies recognised free mercapturic acid 
(Figure 2.12). Mice whose sera showed the greatest inhibition were 
selected for fusion. The production of a monoclonal cell line which 
secretes antibody specific for S-PHA is described in chapter three. 
A second aim of this project was to generate antibodies which 
recognise 2-HENA. This has proved extremely difficult. To generate 
antibodies which recognise 2-HEA, the role of the protein carrier 
was investigated. With a novel, carefully designed and fully 
characterised hapten-protein conjugate antibodies which recognise 
conjugated 2-HEHA have been generated. With a judicious screening 
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strategy it has been shown that these antibodies have a very low 
affinity for free 2-HEMA, and do not bind hapten free in solution. 
2-HEHA standard and S-hydroxyethylcysteine for coupling were 
synthesized by using the nucleophilic properties of the thiolate 
anion under alkaline conditions (Figure 2.1a). Acetylcysteine and 
cysteine were reacted with ethylene oxide in the presence of the 
base KOH. It was observed that ethylene oxide reacts preferentially 
with the cysteinyl sulfhydryl moiety and an excess needs to be 
present before substitution at the amino group of cysteine takes 
place. It was estimated that recoveries were in excess of 80%. This 
compares with 82% achieved by Van Bladeren at al (1980) reacting 
acetylcysteine with hydroxyethyl bromide (Figure 2.2). 
For immunisation, 2-hydroxyethylcysteine was initially coupled to 
KLH using the heterobifunctional cross-linker rn-ABS (Figure 2.6). 
The cross-linker was successfully synthesized by the method of 
Fujiwara et al (1990), the product indicated by melting point, NHR 
and mass spectroscopy studies. One advantage of coupling with rn-ABS 
is the colour change when an azo-linkage is formed between an 
activated hapten and protein. The bright colour indicates a 
successful conjugation. A hapten incorporation ratio was not 
determined for the hydroxyethylcysteine rn-ABS conjugations. When the 
same reaction was carried with hydroxyethylglutathione and BSA, 
however, amino acid analysis showed that 75% of the available 
tyrosines and histidines were conjugated and the hapten 
incorporation ratio was 30:1. 
A large immune response was induced (1:2000-1:5000) in all the mice 
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immunised with the KLH conjugate (Figure 2.13). The antibody titre 
however, is lower than the titres observed in the S-PtIA KLH 
conjugate immunised mice (Figure 2.12). All the sera contained 
antibodies which recognised free S-HEMA in competitive inhibition 
studies. The percentage inhibition values (4-11%) were low for all 
the sera, and therefore only a relatively few hybridoma clones might 
be expected to secrete antibody specific for 2-HE1,1A after fusing. 
This is borne out in fusion results to date (chapter 3). KLH is a 
highly immunogenic protein whilst 2-HEHA is a small molecule lacking 
structural features, and the immune response of the mice may he 
directed towards immunodominant epitopes in the carrier molecule. 
Gelatin is a well known non-immunogenic carrier protein. Marini et 
al (1989) conjugated haptens to spacer modified gelatin and induced 
a strong antigenic response in mice. In an attempt to increase the 
relative antigenicity of 2-HEMA, hapten was coupled to spacer 
modified gelatin. 
The preparation of spacer modified gelatin and the conjugation of 2-
hydroxyethy1cysteine was based on the method of Marini. Successful 
reactions were qualitatively demonstrated by spectrophotometric 
analysis. The hapten hydroxyethylcysteine absorbed strongly at 190-
200nm, although a quantitative estimation of the molar incorporation 
ratios proved difficult technically. Accurate determinations could 
not be made for the following reasons: 
The stacking of absorbance peaks from buffer components. 
The large dilutions of conjugate needed to bring the absorbance 
values on to scale. 
The possible absorbance of any trace impurities at this 
wavelength. 
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Marini et al (1989) conjugated haptens containing a chromophore, and 
were able to determine that 10-12 molecules of hapten were coupled 
per 100 residues of polypeptide of gelatin. 
2-HE1A was also conjugated to protein via a seven carbon spacer arm 
bis(sulfosuccinimidyl)suherate. This spacer arm should be poorly 
immunogenic when compared to rn-ABS - It would he expected that 
antibodies which recognise the spacer wi] 1 bind it with low 
affinity. Acetyc-ysteine was coupled via the intermediate N-suheryi-
S-hydroxyethy].cysteine hydroxysuccinimide (Figure 2.E). Synthesis of 
this compound allowed easy control of the coupling ratio. in 
addition, it was possible to easily determine the incorporation 
ratio by detecting the number of free amines in the carrier protein 
before and after conjugation. The method should he generally 
applicable to other mercapturic acids. 
N-suheryl-S-hydroxyethylcysteine hydroxysuccinimide was prepared 
with DNSO containing 1-5% water as the solvent. The 1-5% water is 
added to prevent excessive di-substitution of the suheric acid di N-
hydroxysuccinirnide by S-hydroxyethylcysteine. The disubstituted 
product becomes the predominant and often only product isolable if 
dry DMSO is used. 
Before it was realised that water was effective as a deactivation 
catalyst other catalysts were added in order to inhibit the 
reactivity of the amino group of S-hydroxyethylcysteine. Traces of 
hydrochloric acid prevented the reaction completely. Formic acid 
gave both mono and disubstituted suberic acid N-hydroxysuccinimide 
and a large proportion of another unrequired product. N-suberyl-S- 
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hydroxyethylcysteine hydroxysuccinimide was isolated by HPLC and 
stored dry at -200C to prevent hydrolysis of the ester. 
N--suberyl-S---hydrox,rethylcysteine hydroxysuccinimide was successfully 
coupled to ESA, KLH gelatin and NSA. The incorporation ratios were 
determined using TNBS. TNBS reacts with amines to give a yellow 
trinitrophenyl derivative (Figure 2.7) The reaction of TNBS with 
GSA, Kid-I and gelatin is linear over the range 0-1 mg/ml. It was 
calculated that one mole of GSA contains 52 moles of free lysine. 
This compares with the ratio obtained by Haheeb (1966) of 60:1. 
Incorporation ratios were also calculated by amino acid analysis. 
With amino acid analysis it was calculated that one mole of GSA 
contains 51 moles of lysine. This value is in reasonable agreement 
with that obtained with TNBS above. Incorporation ratios calculated 
by amino acid analysis were lower than those obtained with TNBS. The 
small differences may be explained by rounding up the ratios in the 
chemical formula to whole numbers. 
Nice immunised with gelatin conjugates all produced antibodies which 
recognised conjugated hapten. The antibody titres were lower than 
those observed with the KLH conjugates. Gelatin is non-immunogenic, 
or poorly immunogenic, and may not be able to stimulate the 
production of antibodies which recognise common protein epitopes in 
the coating material. 
Sera from mice immunised with the gelatin conjugates had the highest 
inhibition values. Inhibition values of up to 57% were obtained 
although in general the percentage inhibition was low (Figure 2.13). 
Antibodies may he generated which bind a hapten-spacer-protein 
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complex. Low inhibition values may he explained if the antibodies 
have a high affinity for the complex and a low affinity for free 2- 
HENA 	inhibition studies were carried out with high concentrations 
of 2-HENA (iOOug/ml). None of the sera were inhibited by non-
conjugated BSA. 
Sera from mice immunised with the gelatin B-alanine 2-HENA 
conjugates were screened against the BSA-ABS-HENA conjugate. These 
conjugates differ in carrier protein, spacer and linking chemistry, 
which involves different protein amino acid residues Highest 
inhibition values were obtained when the screening conjugate 
differed from the immunisation conjugate with respect to carrier 
protein, spacer and chemical linkage. The importance of screening 
with conjugates which differ from immunogen in respect to carrier 
protein and chemical linkage for small haptens has been recently 
confirmed by Danilova (1994). 
In a novel approach to antibody production, NSA was selected as a 
carrier protein. Using homologous mouse protein all the immune 
response should be directed towards the hapten. 2-HENA was coupled 
to NSA using the intermediate N-suberyl--S-hydroxyethylcysteifle 
hydroxysuccinimide (Figure 2.8). In addition, acetylcysteine was 
successfully conjugated to NSA using Iodoacetic acid N-
hydroxysuccinimide. The N-hydroxysuccinimidyl ester was first 
reacted with the protein, incorporating an active halogen in to the 
NSA. Acetylcysteine reacts with the active halogen via its 
sulfhydryl group, linking the hapten by a short (2 carbon) spacer to 
the protein (Figure 2.11). Using a short spacer it was hoped the 
role of bridge in antibody affinity would be lessened without 
compromising hapten presentation. In addition antibodies produced to 
this conjugate should he class-specific - recognising 
acetylcysteine, they should hind mercapturic acids per se. 
An immune response was induced in all the mice immunised with the 
NSA conjugates. Mice immunised with the. NSA acetyicysteine 
conjugates had the greatest titres (1:600-1:2500) when compared to 
the NSA 2-HENA conjugates (1:50-150). Reducing the length of the 
spacer arm does not appear to have affected antibody presentation. 
In addition, larger percentage values were obtained with sera from 
mice immunised with the MSA-acetylcysteine conjugates (22-41%) when 
compared to sera from NSA 2-HEMA immunised mice (0-287.) in the 
inhibition studies. Using a non or weakly immunogenic carrier 
molecule with a short protein-hapten bridge it has been possible to 
focus the immune response and induce antibodies which recognise free 
2-HENA. Inhibition studies were performed with a high concentration 
of standard (lOOug/ml), and from the percentage inhibition it 
appears that the sera has a low affinity for free hapten. 
Sera from mice immunised with the NSA-acetylcysteine conjugate were 
also screened against acetylcysteine and phenylmercapturic acid 
(Figure 2.14). As the molecular weight of the inhibitor increased 
the percentage inhibition in the binding study also increased, 
confirming that affinity is limited by hapten size. One of the 
limitations of the EUISA screen is that antibodies which recognise 
free hapten but bind conjugated hapten with a greater affinity may 
not be detected in the assay. In order to overcome the limitations 
of the EUISA a non-competitive RIA was developed. 
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Hapten iodination, commonly used to prepare radiolabelled antigens, 
would significantly increase the size of the hapten and may gave 
rise to false positives in the screening assay It was therefore 
decided to prepare a 014 labelled hapten with the 014 incorporated 
into the cysteine molecule. 
Using the 014 labelled 2-HEtIA a RIA was developed for screening the 
mouse sera. Dextran coated charcoal was selected to separate free 
hapten from bound after the reaction of antibody with 014 2-HENA. In 
the initial screening assay high levels of non-specific binding (30-
35%) were observed. The high NSB appears to be caused by sticking of 
hapten to Tween 20, since the background can be reduced by the 
removal of Tween from the assay buffers. After optimisation the non-
specific binding was reduced to 10%. Only one sera, from mouse 2 
immunised with the gel-7C-HENA conjugate, showed an appreciable 
increase over background. This sera also demonstrated the greatest 
inhibition in the ELISA (57%). In general, antibodies which bound 
conjugated hapten in the ELISA did not bind to free hapten in the 
RIA. This appears to confirm that antibodies which recognise 
derivitised 2-HEIIA show low affinity for 2-HEUA. This low affinity 
is due to the low NW of 2-HENA. 
The relationship between hapten molecular weight and antibody 
affinity has been reviewed in a recent paper by 0. Chappey et al 
(1994). 0.(happey et al found that for haptens of low molecular 
weight (NW K 300-325 da) the influence of the linkage arm appears 
critical, and high affinity antibodies (10 12N 1) can only be 
produced when using a chemical entity resembling an immunogenic 
conjugate. A NW of approximately 350 appears optimal for maximum 
interaction with the antibody binding site. X-ray crystallographic 
studies have shown that the antigen binding site is a pocket with an 
area of about 7rim2 (Amit et al, 1990). Antibodies to 2-
phenyloxazolane possess an interacting area of about 4nrn2 and all 
have a low affinity constant never exceeding 105H (AIzari et al, 
1990). 
The interaction of antibodies with proteins has recently been 
reviewed by Davies and Cohen (1996) Antibody-antigen crystal 
structures demonstrate good shape complementarity between the 
interacting surfaces and the juxtaposition of polar residues 
permiting hydrogen bonding between antibody, antigen and water 
molecules in the binding site. 
Recent studies of antibody amino acid composition show a clustering 
of aromatic residues at the antibody binding site (Jones and Wells 
1996). Non-polar interactions may help explain why antibodies were 




MONOCLONAL ANTIBODY PRODUCTION 
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INTRODUCTION 
3.1 MONOCLONAL ANTIBODY PRODUCTION 
The production of specific lymphocyte-myeloma cells has proved to he 
an effective means of generating antibodies to a wide range of 
antigens. As a result, hybridoma technology has become routine in 
many laboratories. Monoclonal antibody production involves many 
steps (figure 3.1) which have been performed in many different ways, 
and a number of extensive reviews exist (Goding, 1980 and 1986; 
Fazekas De St. Groth and Scheideggar, 1980; Galfre and Milstein 
1981; Edwards 1981; Siddle 1985;). A critical step is the ability to 
achieve a high efficiency of hyhridoma production upon fusion of 
sensitised lymphocytes with myeloma cells. This involves several 
distinct stages: 1) choice of myeloma cell line; 2) fusion of 
immunogen primed lymphocytes with myeloma cells; 3) culture and 
growth in selective medium; and 4) cloning and mass production of 
antibody in vivo or in vitro. 
3.2 CHOICE OF IIYELOMA CELL LINE 
In general, the fusion of cells from different species does not give 
stable hybrids and the choice of myeloma cell depends upon the 
choice of animal used for immunisation. Immunisations (chapter 2) 
are usually carried out using Balb/c mice and the chosen myeloma 
cell line is therefore of Balb/c origin. The chain composition of 
the myeloma cell is also an important consideration in the choice of 
myeloma cell line Kohler and Milstein (1975) used a mouse myeloma 
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P3-X63/Ag8 secretes IgG whose heavy and light chains are generally 
designated G(gamma) and K(kappa). When P3-X63/Ag8 fuses wth a 
lymphocyte (whose light and heavy chains are designated L and H) a 
hybrid of composition HLGK is formed. Hybridoma cells co-dominantly 
express the immunoglohulin chains of both parental cells. The 
association of the chains is a random event and only a small number 
of immunoglohulins will express the heavy and light chains of the 
spleen cell (1. in 16). The majority of antibodies will therefore he 
Inactive. In addition HLGK hybrids have a tendency to lose 
chromosomes- This loss is not random and the heavy chains are 
usually lost first. 
A number of cell lines have been derived from P3-X63/Ag8. The 
variant P3-NS1-Ag4/1 synthesises Kappa light chains but does not 
secrete them. As a result, 25% of the immunoglobulins will he of 
spleen origin. Two myeloma cell lines X63-Ag8.653 (X63s) and Sp2/0. 
Ag8 (Sp2s) completely lack the ability to make their own IgG 
(Shulman et al 1978) and all the immunoglobulins secreted will 
therefore be of spleen origin. Thus the Sp2 myeloma cell line was 
selected for use. 
3.3 FUSION 
The spontaneous fusion of cells in nature is a rare event. However, 
almost any two cells can be made to fuse by the addition of a 
fusogen. Kohler and Milstein used inactivated Sendai virus as the 
fusogen in their original work. Polyethylene glycol MW 500-4000 
(PEG) is now the agent of choice and is used in nearly all hybridoma 
work. The use of PEG increases the number of hybridoma cells when 
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compared with fusions performed with Sendai virus (Gefter et al 
1977). Surprisingly, the concentration of PEG needed for a 
successful fusion is close to its toxic concentration 00-50%). 
However, even with the use of PEG, cell fusion is still a rare 
event, and fusion efficiency has been estimated by Siddle (1985) to 
he 1 in 10,000 cells. 
After much investigation the fusion mechanism is still poorly 
understood. PEG appears to promote the close apposition of cell 
membranes while additives (antioxidant and/or polymerisation agents) 
in the commercial preparations may stimulate the fusion process. 
Variations in the additives and impurities may explain the 
differences in the fusion efficiencies achieved with different 
brands, lots and molecular weights of PEG. Although PEG encourages 
membrane and protein aggregration, transfer of the cytoplasmic 
contents appears to take place when the PEG is diluted (Wojcieszyn 
et al 1983). The transfer of the cytoplasmic contents of one cell to 
another results in the formation of a heterokaryon, a cell which 
possesses two or more nuclei. At the next division the nuclei of the 
heterokaryon fuse and a hybrid cell results. 
Fusion protocols vary widely The spleen to myeloma cell ratio does 
not appear to be critical within the ratios of 1:1-1:10 (spleen 
myelomas) However the condition of the myeloma cells is critical to 
the success of the fusion. For the best fusion results the myeloma 
cells should be maintained in the logarithmic phase of growth for 
one week prior to fusion (Galfre and Milstein 1981). At fusion the 
myeloma cells should be in the rapid exponential phase of growth for 
optimum results. Spleen cells should be stimulated 3-4 days before 
104 
fusion when antigen induced proliferation is strongest. 
The lymphocytes and myeloma cells are mixed and brought into close 
contact by centrifugation. PEG is added to the pelleted cells then 
slowly diluted by the addition of medium. PEG of Ns 500-4000 
daltons at a concentration of 30-50% w/v are typically used and the 
variation does not appear to he critical. The use of PEG below 30% 
results in a low fusion efficiency whilst above 50% toxicity is a 
problem (Goding 1980, Lane 1985). The fusion procedure described in 
the work below is a modification of the method of Gefter et al 
(1977). Alterations in the original protocol are due in part to 
Fazekas De StGroth and Scheidegger (1980) and Lane (1985). 
3.4 CULTURE AND GROWTH IN SELECTIVE MEDIUM 
After fusing, the hybrid cells are vastly outnumbered by the unfused 
myeloma and spleen cells. The spleen cells cannot grow indefinitely 
in culture and die within about five days. The myeloma cells, 
however, can grow indefinitely in culture and it is necessary to 
isolate a relatively small number of hybridoma cells from the large 
excess of myeloma cells. This can be achieved with the use of a 
selective medium which inhibits the growth and causes the death of 
the myeloma cells. The most popular strategy is that of Littlefield 
(1966). 
The biosynthetic pathway for purines and pyrimidines can be blocked 
by the folic acid antoganist aniinopterin. If this pathway is blocked 
in normal cells the DNA precursors are synthesied by an alternative 
route - the salvage pathway - in which preformed nucleotides are 
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recycled. The salvage pathway depends upon the enzymes thymidine 
kinase (TK) and hypoxanthine guanine phosphorihosyltransferase 
(HGPRT). If one of these enzymes is absent DNA synthesis ceases 
(Figure 3.2). 
Mutant myelomas lacking the enzymes TK or HGPRT have been produced 
by the use of toxic drugs. TK mutants are difficult to induce since 
two simultaneous mutations, a rare event, are needed. HGPRT mutants 
are relatively easy to induce since the enzyme is coded on the X-
chromosome. Mammalian cells possess only one active X-chromosome and 
only a single mutation is needed for total loss of the enzyme. 
Using the strategy of Littlefield, mutant myeloma cells are chosen 
which are deficient in the enzyme HPGRT. The HPGRT myelomas are 
unable to grow in HAT selective medium, which contains the 
nucleotides hypoxanthine and thymidine and the antogonist 
aminopterin. The spleen cells are HPGRT. The fusion of a HPGRT 
spleen cell with a HPGRT myeloma cell results in the formation of a 
HPGRT hybridoma cell. The hybridoma cell is able to grow in the HAT 
selective medium (Figure 3.3). 
3.5 CLONING AND MASS PRODUCTION OF ANTIBODY 
Following fusion, initial cell growth takes place in HAT selective 
medium. In general, antibody secreting cells grow slower than non-
secreting hybrids and the non-secretors soon dominate the culture. 
Cloning, or the isolation of single desired hybridoma cells, should 
therefore be carried out as early as possible. The early detection 
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The screening assay needs to be sensitive, detecting antibody at 
concentations of lug/ml or less in supernatant. The assay should 
also be simple, giving rapid answers on many samples, but need not 
be precisely quantitative or totally specific at this stage. 
Kohler and Milstein (1975) cloned by low dilution in semi-solid 
agar The agar physically separates the cells until they form 
colonies large enough to be individually transferred to culture 
wells. Cloning by limiting dilution is now the usual method of 
choice. 
Failure to obtain positive clones from strongly positive cultures 
may reflect the low proportion of positive cells or, the inherently 
poor cloning effiency of some cells which will not grow well at low 
concentrations. To support the growth of single cells during 
cloning, feeder cells are routinely used in hybridoma technology. 
Peritoneal macrophages, splenocytes and thymocytes have all been 
used to support the growth of hybrids. 
Having confirmed monoclonality, cell numbers are expanded by culture 
in stationary flasks. The harvested supernatant usually contains 10-
100ug of antibody per millilitre of culture supernatant. 
3.6 CHARACTERISATION OF ANTIBODY CONTAINING SUPERNATANT 
Antibody titre is determined by serial dilution of the supernatant. 
The titre is the dilution of the supernatant which gives half the 
maximal binding activity. Titre is therefore a function of antibody 
concentration and avidity. 
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Antibody affinity can be determined by scatchard analysis. Here, 
antigen binding to a limiting concentration of antibody is expressed 
as a function of antigen concentration- It is often stated that 
monoclonal antibodies are of low affinity (108-109N 1) compared to 
the best available polyclonal antisera (1011-l012M). The isolation 
of low affinity antibodies reflects their preponderance in-vivo. 
Although high affinity antibodies are a minority, the production of 
antibodies with dissociation constants of l0'°-1011N 1 should be 
possible. Relative antibody affinity can he determined by the 
preparation of calibration plots. 
Antibodies are divided into five major classes of immunoglobulin - 
1gM, IgG, IgA, IgE and IgD (Goding, 1986). Antigenic analysis of IgG 
myelomas has shown that they can he further grouped into four sub-
classes (eg. IgGs1-4). The differences all lie in the heavy chain 
of the immurioglobulin molecule and these are termed isotypic 
variants. Variations exist in the biological and physical properties 
of the antibodies in each class or isotype. 
3.7 IN-VITRO IMIIUNISATION 
Although the production of monoclonal antibodies in-vi.vQ has become 
a routine technique it does not always lead to the production of 
specific antibody secreting hybridomas. For example, 2-HE11A is a 
small, weakly immunogenic molecule (chapter 2) and a poor antigen 
ifl-VIVQ- To improve the efficiency of specific hybridoma production, 
in-vitro immunisation with 2-HEMA has been examined. 
A primary antigen specific stimulation of dissociated mouse spleen 
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cells in-vitro was first demonstrated by Hishell and Dutton in 1966. 
Using sheep red blood cells (SRBCs) as the immunogen an in-vitro 
response comparable to that in-vivo —vi 	was obtained. Twelve years 
later, again using SRBCs as the immunogen, Hengartner et al (1978) 
combined in-vitro immunisation with hybridoma technology for the 
production of monoclonal antibodies. Luhen and Mohler (1980) 
combined, in-vitro immunisation with hyhridoma methodology to produce 
antibodies to a soluble protein antigen (Lymphokine Osteociast. 
Activating factor) and found in-vitro immunisation to he three times 
more effective at producing hybridomas of the required specificity 
thanin-vivo immunisation. However in-vitro immunisation has not yet 
become a widely used procedure and the theoretical advantages of jn~_-
Yj—vQ immunisation are being realised only slowly in practice. 
In-vitro immunisation requires smaller quantities of antigen (0.1-
200ug) and labile antigens may be sufficiently stable in-vitro to 
allow sensitisations which would be impossible in-vitro. Responses 
to weakly immunogenic antigens in-vitro, conserved epitopes and 
self-antigens may also be possible (Borrebaeck and Muller 1986), due 
to an absence of imrnunosuppression mechanisms in-vivo (Miner et al 
1981). Each step of the procedure can be monitored and the time (3-5 
days) is much shorter than the time taken for an in-vivo 
immunisation (typically 28 days). The number of antibody producing 
cells per 106 spleen cells is significantly higher in-vitro due to 
the preferential survival of in-vitro activated cells. Borrebaeck 
1986) has reviewed the progress of in-vitro immunisation and 
monoclonal antibody production. Several in-vitro immunisation 
procedures have been described for the production of antigen 
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specific hybridomas (Reading 1986, Boss 1986). 
B-cell activation appears to consist of three separate stages- 1) 
induction/activation, 2) proliferation and 3) differentiation, 
requiring the co-operation of T-helper cells, accessory cells (eg. 
macrophages, monocytes) and B-cells. Their interactions are 
regulated by membrane bound proteins (MHC, class 11 molecules) and 
by soluble antigen non-specific growth and differentiation factors 
(the lymphokines). The cell-cell interactions which characterise the 
in-vivo immune response are absent in laboratory cultures but the 
soluble growth and differentiation factors must be added in the form 
of conditioned media. The conditioned media used in jnvitro 
immunisation appear remarkable in their heterogenity Thymocyte 
conditioned media (Luben and Mohler 1980, Van Ness et al 1984 and 
Ossendorp et al 1986), mixed lymphocyte culture media (Miner et al 
1981 and Pardue et al 1983) and the supernatant from phorbal ester 
activated thymoma cells EL-4 (Borraboeck and Holler 1986 and De Boer 
et al 1988) have all been used to stimulate the development of 
antigen specific hybridomas. 
An additional consideration when setting up an in-vitro immunisation 
is the source of serum. Rathjan and Underwood (1985) found batch to 
batch variation in calf serum critically influenced the hybridoma 
yield, possibly due to variations in the levels of endotoxins or 
hormones. Calf serum also gives high levels of non-specific 
hybridomas due to the activation of B cells by serum proteins. A 
number of authors including Mu.11bacher et al (1985) have reported 
the use of rabbit serum at 1-3% which will reduce the effect of 
serum proteins when compared to 15% calf serum. The effect of serum 
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proteins could he avoided by carrying out the entire procedure under 
protein free conditions, and several authors have described 
conditions for protein freein-vitro immunisations (Ossendorp et al 
1986, Dc Boer et al 1989). 
Antibodies secreted by hybridomas derived from in-vitro immunised 
spleen cells are predominantly of the 1gM isotype, and this is 
thought to represent the primary response of activated naive B 
cells. IgG antibodies, however, are the result of the activation of 
antigen specific memory B cells formed after a first exposure to 
antigen. 	Takakashi et al (1987.) increased the number of hybrids 
secreting IgG to 60% by prolonging the stimulation period from 5 to 
8 days. Generally the increasing cell death beyond 5 days in culture 
has resulted in very poor fusion efficiencies. Dc Boer et al (1987) 
reported jnyj.ç priming followed by in-vitro boosting increased the 
number of IgG secreting hybridomas from 10% to 85%, successfully 
combining the advantages of both procedures. 
This chapter describes the production of monoclonal antibodies which 
recognise S-PNA and 2-HEtIA Antibodies which bind S-PMA were derived 
from lymphocytes sensitized in-vivo. High affinity antibodies to 2--
}-JEMA were difficult to induce in-vivo (Chapter 2), and in-vitro 
immunisation was therefore examined. The relative affinity and 
specificity of the antibodies produced were determined in 
characterisation studies. The results of the fusions and the 
characterisation studies will be discussed. 
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METHODS AND MATERIALS 
MATERIALS 
PLASTIC WARE 
24 and 96 well tissue culture plates, and Immunoplates Maxisorb f96 
cert were purchased from Nunc (Gibco Ltd. Paisley, Scotland.) 
25cm2 and 75cm4 sterile 0.2urn filter vented culture flasks and 
Transtar 96 well transfer cartridges were purchased from Costar 
(High Wycombe, Oxfordshire). 
1, 10 and 20m1 sterile syringes (Becton Dickenson), sterile blind 
hubs (Sabre), sterile Kwills (Avon Medicals), 30m1 sterile universal 
container (Sterilin), sterile petri dish (Greiner), 60 and 200m1 
sterile square media bottles (Nalgene), sterile disposable scalpels 
(Swann-Morton). 0.6 x 16mm and 0.8 x 16mm MonojectTM hypodermic 
needles (Sherwood Nedicals). 
CULTURE MEDIA 
The following media constituents were purchased from Flow 
Laboratories Ltd. (Rickmansworth, Herts.):- 
lx RPMI 1640 Medium containing 2.0g/l sodium bicarbonate. Sodium 
Pyruvate (100mM, 11.0mg/ml), L-glutamine (200mM, 29.23mg/ml). 50x 
HAT solution containing 5000u11 hypoxanthine, 201-iN aminopterin and 
BOOuM thymidine. 50x HT solution containing 5000uM hypoxanthine, 
800uN thymidine and xlOO amino acids for basal medium (modified). 
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Antibiotics:- Pencillin (50001u/m1) Streptomycin (5000ug/ml), 
Amphotericin B Deoxycholate (Fungizone [250ug/ml]), and Gentamicin 
Sulphate (SOng/mi ) - 
Myoclone Plus Foetal Calf Serum and Protein Free Serum Free Medium 
(Gibco Ltd.), DM50 (tissue culture grade), mercaptoethanol and 
tryptan blue (Sigma Chemical Co. Ltd), Polyethylene glycol (PEG 
1500; Sera-Lab, Crawley Down, Sussex) 
RPMI 1640 was stored at 40 C. All other media additives were stored 
in aliquots at _200 C All media were stored at 40  C. and used 
within 2-3 days of preparation. 
STANDARD SERUM FREE MEDIUM:- 
Standard serum free medium consisted of RPMI 1640, penicillin 
(lOOm/mi) and streptomycin (lOOug/rni). 
COMPLETE MEDIUM:- 
Consisted of serum free medium with L-glutamine (251), sodium 
pyruvate (1mM), 10-15% v/v myoclone foetal calf serum and Fungizone 
(25ug/ml). 
SELECTION MEDIA:- 
HAT medium consisted of complete medium with a 1/50 dilution of 
stock HAT solution. The final concentrations were hypoxanthine 
lOOum, antinopterin 04um and thymidine 16um. 
HT medium consisted of complete medium with a i/SO dilution of 
stock HT solution. Final concentrations were hypoxanthine lOOum and 
thymidine 16uni. 
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4 FREEZING MEDIUM:- 
Freezing medium consisted of 90% v/v foetal calf serum 10% DMSO. 
5..10VITR0 INMUNISATION MEDIUM:- 
In-vitro immunisation medium consisted of 50ml of protein free serum 
free medium containing 2ml glutamine, imi sodium pyruvate, lml of 
HT, lml of non-essential amino acids, 2ml of sodium bicarbonate, 
35ul of mercaptoethanol, 05ml of fungizone and 25ml of myoclorie 
plus FCS (5%). 
MYELOMA CELL LINES 
Balb,/c myeloma cell line Sp 2/0. Ag 1-4, which secretes no 
immunoglobulin chain, was purchased from Flow Laboratories. Myeloma 
cells were cultured in complete medium. Aliquots of cultured cells 
(106 cells in 500u1 of freezing medium) were stored frozen at _1700 
C. in liquid nitrogen. 
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METHODS 
All cell culture procedures were carried out under sterile 
conditions using aseptic technique. All cells were cultured in a 370 
C humidified incubator in the presence of 5% (09 in air. 
3.8 PREPARATION OF MYEWMA CELLS 
Thawing Cells 
Nyeloma cells (106 cells in 500u1 freezing medium) were stored in 
cryotubes frozen at _1800 C in liquid nitrogen. DM50 is toxic to 
thawed myeloma cells therefore the following operations were carried 
out rapidly. A cryotube containing a frozen solution of myeloma 
cells was thawed in a water bath at 370C, sprayed with 70% 
alcohol:water and dried. The cells were transferred to a 30 ml 
plastic pot (Sterilin) and diluted with 20 mis of cold serum free 
medium inside a laminar flow hood. Diluted cells were centrifuged 
(1500rpm.,5min.) and the supernatant discarded. The remaining pellet 
was gently resuspended in 10mls of warm complete medium. Resuspended 
cells were cultured in a 25cm2 2u.m vented culture flask. 
Culture of Nyeloma cells. 
Myeloma cells were grown in stationary culture and maintained in a 
logarithmic phase of growth. Cells were cultured initially in 25cm2, 
02um vented culture flasks and, as the single layer of cells 
approached confluency, expanded to 75cm2 vented culture flasks. 
Cell medium (complete) was changed at regular intervals 
(approximately every 2-3 days). 2-5 x 107  cells were required per 
117 
fusion, approximately three 75cm2 culture flasks. Viability was 
determined by Trypan Blue staining and cells were counted using a 
Neubauer haernocytometer. 
Immediately prior to fusion, myeloma cells were resuspended, by 
gently scraping the bottem of the culture flask, and the suspension 
sedirnented by centrifugation (1500rpm., 5mm.). The pellet was 
resuspended in lOml of 370  C. serum free medium. 
3.9 PREPARATION OF SPLEEN CELLS. 
On two consecutive days prior to fusion the mouse was immunised 
intra-peritoneally with 100ug of conjugate in lOOul of PBS. Two days 
after the final pre-fusion immunisation the mouse was sacrificed by 
asphyxiation in diethyl-ether. The mouse was placed on its right 
hand side and soaked with 70% alchol:water. The spleen was carefully 
removed using a sterile pair of scissors and forceps and placed in a 
sterile container containing 20mls of cold serum free medium. 
The spleen was transferred to a petri dish and any remaining 
connective 	or fatty tissues cut away. A superficial cut was made 
along the length of the dorsal ridge of the splenic capsule with a 
scalpel. Two lOml syringes fitted with 0.6 x 16mm gauge needles and 
filled with serum free medium at 37k)  C, were used to anchor the ends 
of the spleen and flush the splenocytes out of the capsule. This 
yielded a high population (108)  of single cells in suspension. The 
cell suspension was centrifuged, the medium discarded, and the 
pellet resuspended in lOml of 370  C. serum free medium. 
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3.10 FUSION PROTOCOL. 
The fusion procedure employed was based on a modification of a 
method described by Lane (1985). The splenocytes and myeloma cells 
prepared above were mixed, centrifuged and the pellet resuspended in 
20ml 370  C. serum free medium. The mixed cell suspension was divided 
equally between six 30ml universal containers, and the cells 
pelleteci by centrifugation. The supernatants were discarded and 
excess fluid carefully drained so as not to dilute the polyethylene 
glycol (PEG 1500) to be added in the next stage. Each pellet was 
then gently disrupted, using the needles (0.6 x 16mm) fitted to lml 
syringes. PEG-1500 (0.3ml/trniversal, 370  C.) was added evenly, with 
gentle agitation, over 30 seconds. The PEG was immediately diluted 
by the addition of lOul of warm serum free medium added gradually 
over 1 minute. The cells were centrifuged, resuspended in 6ml of 
complete culture medium (370 C.) and distributed evenly (lO(:ul/well 
using a lOml syringe fitted with a 0.8 x 16mm needle) between the 
central 60 wells of a 96 well tissue culture plate. Finally, double 
strengh HAT medium (lOOul/well) was added and the culture plates 
incubated as described. 
Every two days lOOul of medium was removed from the wells and 
replaced with lOOul fresh HAT medium. After twelve days, HAT medium 
was replaced with HT medium. The appearance of hybridoma clones 
observed microscopically and indicated macroscopically by a change 
in medium colour, from pink to yellow, usually occurred between days 
5-12. 
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3.11 SCREENING CULTURE SUPERNATANTS 
3.11.1 BY ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
Coating Plates 
Haptens conjugated to Bovine Serum Albumin (BSA) were used for plate 
coating. A solution of conjugate in coating buffer was added lOOul) 
to the central 60 wells of a microtitre assay plate. The plate was 
sealed with a plastic cover and incubated for 3 hours at room 
temperature. The wells were emptied and washed 5 times with 
saline/Tween solution, shaken dry and stored at 40  C until use. 
Screening Assay 
Supernatants were transferred to the antigen coated wells of a 
microtitre plate using a 96 well transfer cartridge. The plate was 
sealed with a plastic film and incubated overnight at room 
temperature. The wells were emptied, washed 5 times with 
saline/Tween and shaken dry. Excess wash solution was removed by 
aspiration. To each well was then added lOOul of anti-mouse IgG 
peroxidase conjugated antibody diluted 1:1000 in PBS/Tween. The 
plate was covered and incubated for a further 2 hours at room 
temperature. The plate was washed again and dried, as above, and 
lOOul of ABTS substrate added. In the presence of peroxidase this 
substrate turns from a colourless to a green solution. Optical 
density was measured at 405nm using a microtitre plate reader 
(spectrophotometer). 
The capacity of an antibody to recognise free hapten was tested in 
competitive inhibition studies. Supernatant was diluted to give a 
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limiting dilution in PBS/Tween and transferred (50ul) to the wells 
of a conjugate coated plate. The supernatant was incubated in the 
presence of either standard or PBS/Tween (SOul). The assay was 
performed as described above. 
3.11.2 BY RADIOIMIIUNOASSAY (RIA) 
Wells from the 2-HEMA fusions which gave a positive result in the 
initial ELISA screening assay were also tested by RIA RIA 
conditions have been previously described (chapter 2). Separation of 
bound and free label was achieved with 5% dextran coated charcoal 
(which has been described) and saturated ammonium sulphate solution. 
Separation of Bound and Free Label with Saturated Ammonium Sulphate 
To the samples and the blanks was added 50ul of normal rabbit serum 
and 450ul of saturated ammonium sulphate solution. The tubes were 
mixed, incubated at room temperature for 20 minutes and centrifuged 
(2400rpm, 40C for 20 minutes). The supernatant was removed by 
aspiration and discarded The pellet was resuspended in 200u1 of PBS 
and transferred to a scintillation vial. Scintillant was added (Sml) 
and the radioactivity assessed using a beta radiation counter. The 
counts are directly proportional to the amount of labelled analyte 
bound by the antibodies. 
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3.12 CELL CLONING BY LIMITING DILUTION 
Preparation of thymocyte feeder cells 
A young (4-6 weeks old) Balh/c mice was sacrificed by ether 
anaesthesia, placed on its back and soaked with 707 alcohol:water. 
An incision was made in the mid-line of the thorax below the rib 
cage and extended longitudinally to the neck region using a sterile 
pair of scissors. The thoracic cavity was opened using sterile 
scissors and forceps The thymus, a two lobed whitish-cream coloured 
organ anterior to the heart, was carefully removed and transferred 
to 25m1s of cold serum free medium in a sterile container. The 
thymus was then transferred to a petri dish containing lOmls of 
serum free medium and teased with a pair of blunt forceps. The 
resulting cell suspension was transferred to a 30m1 sterilin, 
discarding the connective tissue, and centrifuged at 1500rpm for 5 
minutes. The medium was discarded and the pellet resuspended in 20m1 
of warm complete medium. This method releases 2-3 x 108 thymocytes, 
in general, from a thymus. 
Cloning by limiting dilution 
It is most likely that positive wells in the post fusion screening 
assay will contain clones originating from more than 1 parent cell. 
The aim of this dilution procedure is to achieve 1 hybridoma cell 
per well which develops to form a single hybrid clone. 
Hybridoma cells were diluted (50 cells per ml) in 4mls of thymocyte 
containing medium. 2.4ml of this suspension were equally distributed 
over the first 2 rows (24 wells) of a 96 well microtitre plate. 
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Theoretically, this gives 5 cells/well. To the remaining LSrnl was 
added 2.4m1 of thymocyte containing media, and 24ml of this were 
equally distributed over the next two rows of the microtitre plate 
(2 cells/well). The above step was repeated a second time to give, 
theoretically, 1 cell per well. Finally, to the remaining 1.6m1 was 
added 08m1 of thymocytes and the 2.4m1 was distributed over the 
last 2 rows of the microtitre plate, to dispense 1 cell in every 2 
wells. Warm complete medium (lSOul) was added to all the wells. 
Plates were screened approximately 10-15 days later. 
3.13 FREEZING CELLS 
Freezing 96 cell plates 
Medium was carefully removed from the wells of a tissue culture 
plate, leaving the remaining cells adhered to the well surface. 
Cold freezing medium (kept on ice prior to use) was added to the 
wells (lOOul/well) and the plates sealed. Sealed plates were 
immediately placed in a jiffy bag and transferred to a -70° C. 
freezer. 
Freezing larger numbers of cells 
Cells in 2m1 wells and tissue culture flasks were resuspended in the 
culture medium, transferred to a 30m1 universal container and the 
numbers determined by counting a sample using a neubauer 
haemocytometer. The cells were sedimented by centrifugation 
(1500rpm., 5mm.), the medium discarded and the cells resuspended in 
cold freezing medium (stored on ice prior to use) at a density of 
123 
10b cell--,,'l ml medium. Aliquots (500u1/cryotube) were frozen to 
-1700C. in liquid nitrogen using a programmable ramp freezer The 
temperature was reduced in 2 stages, stage 1 at -1 C./min down to 
--70° C and stage 2 at 10 0./mm. down to -1400 C. Frozen cells 
were transferred to 	liquid nitrogen cell store and kept at _1700 C.  
3.14 IN-VITRO IMMUISATI0N 
The donor mouse was sacrificed by asphyxiation in diethyl--ether and 
the spleen carefully removed as described above. A suspension of 
single spleen cells was obtained by perfusion with 20ml of protein 
free serum free medium. Perfusion of the spleen is described in 
detail above. The cell suspension was centrifuged, the medium 
discarded and the cells resuspended in lOrd in-vitro immunisation 
medium. The spleen cells were transferred to a 25ml tissue culture 
flask. 
To the flask was added lOml of thymocyte conditioned medium, 200u1 
of BRM and filtered antigen (0.75-1ug/ml). Antigen was diluted in 
protein free serum free medium and filtered through a low protein 
binding filter 0.2um. The flasks were cultured in a 370C. humidified 
incubator in the presence of 5% CO2 in air for five days. 
Immediately prior to fusion the cultured cells were resuspended and 
the suspension sedimented by centrifugation (1500rpm., 5mm.). The 
pellet was resuspended in 10ml of serum free medium. Viability was 
determined by Tryptan Blue staining and cells were counted using a 
Neubauer haemocytometer. Cells were fused, cultured and screened as 
described above. 
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3.15 ANTIBODY CHARACTERISATION 
Relative antibody affinity was determined by the preparation of 
calibration plots. The lower limit of detection was determined for 
each supernatant under optimal assay conditions. Antibody 
specificity was determined in cross-reactivity studies. Calibration 
plots were prepared using compounds containing structurally similar 
features, and the 1050 values (the concentration of standard that 
gives 50% inhibition) determined. 
3.16 FUSIONS 
3.16.1 S-PHENYL-N-ACETYL-L-CYSTEINE 
Fusions 1 and 2 
Mice 3 and 1 immunised with phenylcysteine coupled to KU-I with the 
homobifunctional crosslinker bis(sulfosuccinimidyl)suberate were 
selected for fusion (chapter 2). Mouse 3 was primed (lOOug of 
conjugate in 200u1 PBS) 29 and 30 days after the second challenge. 
Mouse 1 was primed 72 and 73 after the second challenge- Two days 
after priming the spleens were removed and the splenocytes fused 
with the myeloma cell line Sp2/0. Agl-4 (day 0). The fused cells 
were cultured in HAT media (days 0-12), HT media (days 13-19) and 
complete media thereafter. Supernatants were screened by ELISA using 
plates coated with BSA-BS3-1A (lug/ml) on day 9. The number of 
wells containing hybridoma clones were determined by microscropic 
examination on the day of screening. 
Rapidly growing clones which were positive in the screening assay 
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were expanded into 24 well tissue culture plates. All the positive 
wells and the expanded wells were re-screened on day 11. In the 
second screen, competitive inhibition studies using free S-PMA 
(iOOug/ml in PBS/Tween) were included. Cells from wells (96 well 
plates) containing antibody which hound free hapten were cloned by 
limiting dilution. Clone plates were screened 14 days later for the 
presence of antibody activity and inhibition studies were carried 
out. Monoclonal wells were determined on the day of screening by 
microscopic examination. 
3.16.2 S-(2-HYDROXYETHYL)-N-ACETYL-L-CYSTEINE 
Fusions 3-17 (in-vivo immunisations) 
Nice immunised with 2-HENA coupled to either KLH, gelatin or NSA 
were primed 6 to 22 weeks after the second challenge. Two days later 
the spleens were removed and fused. The fused cells were cultured as 
above. The plates were screened by ELISA on day 14. Supernatants 
from the KLH-ABS-HENA and GEL-ALA-HENA immunised mice were screened 
against plates coated with BSA-ABS-HENA conjugate (05ug/ml in 
coating buffer). Supernatants from the KLH, GEL and NSA-7C-HENA 
immunised mice were screened against plates coated with BSA-7C-HENA 
(lug/ml in coating buffer). The number of wells containing viable 
hybridomas were counted on the day of screening. Rapidly growing 
colonies which were positive in the screening assay were expanded 
into 24 well tissue culture plates. Positive and expanded wells were 
rescreened on day 16. In the second screen competitive inhibition 
studies with 2-HENA (lOOug/mi, 4.2x10r7 moles/ml in PBS/Tween,) were 
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-11  included. Positive wells were also screened by MA against 3x10 
(2000dpm/rnin) or 1.5x10' 0 moles/ml (10000dpm/min) of label. 
Separation of bound and free label was achieved using either 5% 
dextran coated charcoal, or saturated ammonium sulphate solution. 
Fusions 18-20 (inil rc immunisations) 
Study 1:- 
Spleen cells from mouse :3 immunised with Gel-7C-HEMA were primed in 
vitrQ 16 weeks after the first challenge. Spleen cells were cultured 
in the presence of lug/ml of Gel-7C-HEHA. The culture was examined 
daily macroscopically. After 5 days the cells were fused as 
described above. After 12 days the wells were screened by ELISA. 
Inhibition studies (lOOug/ml, 4.2x10 7 moles/ml 2-HEHA) were 
performed on the positive wells two days later. Positive wells were 
also screened by RIA (3x10-11 moles/ml of 2-HEMA). Bound and free 
label was separated with saturated ammonium sulphate solution. 
Study 2:- 
In a comparative study a KLH-7C-HEHA immunised mouse was boosted iu-- 
yi-va 	
n  -ii-v 
12 weeks after the second challenge. Spleen cells from a second 
KLH-7C-HEHA immunised mouse were primed in-vitro (12 weeks after the 
second challenge), and a 6 week old naive Balb/c mouse was immunised 
in-vitro. In-vivo immunisations were with 200ui of looug/ml KLH-70-
HEHA in PBS. In-vitro immunised cells were cultured in the presence 
of 0.75ug/ml of KLH-7C-HENA. On the day of fusion the number of 
viable cells was determined. The fusions were cultured and screened 
by ELISA and RIA (3x10 	moles/ml). 
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316.3 NSA-ACETYCYSTEJNE IMMUNISED NICE 
Fusions 21-23 
Mice 1, 2 and 4 immunised with MSA-acetylcystejne were first primed 
for fusion 28, 65 and 66 days after the second challenge. All three 
mice were given the second pre-fusion boost on the following day and 
fused two days later The fused cells were cultured as described 
above. On day 10 the supernatants were screened against plate--
coated 
lates
d. with O.lug/ml of BSA-acetylcysteine conjugate. Positive 
screening wells were rescreened on day 12 in the presence and 
absence of free S-PNA (200ug/ml), 2-HENA (173ug/ml) and 
acetylcysteine (136ug/ml). All three inhibitors contain 84xl0 1  
moles/ml of standard. Positive wells were also screened by RIA 
against 2-HEIIA (15x10 1° moles/ml). Free and bound 2-HENA was 
separated with 5% dextran coated charcoal. 
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RESULTS 
S_PHENYL-N-ACETYLCYSTE I NE 
317 Fusion 1 
Spleen cells from mouse 3 immunised with phenylcysteifle conjugated 
to KLJH were successfully fused with the myeloma cell partner 
Sp2/0s. On the day of screening 60% to 100% of the wells per plate 
contained 1 or more viable hybrid colonies (table 3.1). Supernatants 
were screened against plates coated with BSA hapten conjugate. There 
was considerable variation in the colour intensity of the wells and 
an O.D. of three times background (background = 0.05 units) was 
detected in 20% to 100% of the wells per plate Wells with an O.D. 
greater than 1 were recorded as positive (table 1'. All of the 
positive wells contained viable hybridoma clones. Binding of free 
hapten by these antibodies was detected in 85 supernatant-- (82% of 
the positive wells). Twenty three supernatants (22% of the positive 
wells)) showed more than 40% inhibition with 100ug/ml of S-PHA 
(table 3.1). 
TABLE 3.1 SCREENING RESULTS FOR PMA FUSION 1 PLATES 1-6 
PLATE WELLS PLUS POSITIVE WELLS POSITIVE WELLS 
IN INHIBITION STUDY*.* HYBRIDS (%) IN SCREEN* 
1 100 34 3 
2 90 7 1 
3 100 11 2 
4 60 0 0 
5 100 16 3 
6 100 36 14 
* O.D. greater than 1 in screening assay 
** 40% inhibition or more with lOOug/ml of S-Pt'IA 
These results were confirmed in a repeat assay two days later (Table 
3.2). Well 652 demonstrated the greatest inhibition (79%) with 5-
PMA. The antibody did not recognise 2-HEMA. Well 652 was cloned and 
expanded as described in the methods. Monoclonality was confirmed 
for 6B2H6- 
TABLE 3.2 FUSION 1 - INHIBITION STUDIES WITH bOng/mi 
S-PNA AND 2-HEHA 
POSITIVE % INHIBITION WITH 
WELL PMA 	2-HEMA 
1B2 52 - 
104 49 - 
lD9 42 - 
2E8 61 23 
3011 69 8 
3F8 69 - 
5D10 56 - 
5510 70 - 
SF6 55 - 
6B2 79 - 
6B4 55 15 
6B7 52 18 
658 44 8 
6B11 54 11 
6011 71 21 
6D11 46 - 
658 64 - 
6510 56 6 
6F2 44 11 
6F4 42 - 
5F6 48 - 
6F10 47 7 
6Fll 54 5 
3.18 FUSION 2 
Spleen cells from mouse 1 7  immunised with phenylcysteine conjugated 
to KLH, were successfully fused with the Sp2 myeloma cell line. On 
screening, 90% to 100% of the wells per plate contained 1 or more 
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viable clones (table 3.3). The plates were screened. by ELISA using 
the BSA conjugate as the coating material. Again there was 
considerable variation in the colour intensity of the wells, and 36% 
to 100% of the wells per plate gave 0.]). s greater than three times 
the background. Supernatants with an O.D. of greater than 1 in the 
screening assay were recorded as positive (table 3.3). All the 
positive wells contained viable hybrid colonies. Binding of free 
hapten was detected in 82% of the positive wells, and 22 
supernatants (31% of the positive wells) gave more than 40% 
inhibition with lOOug/ml of S-PNA (table 3.3). 
TABLE 3.3 SCREENING RESULTS FOR S-PNA FUSION 2 PLATES 1-6 
PLATE WELLS PLUS POSITIVE WELLS POSITIVE WELLS 
HYBRIDS (%) IN SCREEN* 	IN INHIBITION STUDY** 
1 90 14 3 
2 90 5 2 
3 95 16 5 
4 95 2 2 
5 100 49 6 
6 90 14 4 
* O.D. greater than 1 in screening assay 
** 40% inhibition or more with lOOug/ml of S-PHA 
These results were confirmed in a repeat assay two days later (Table 
3.4). 
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Supernatants 107, 3F9, 309, 402, 6B2 and 6B8 demonstrated the 
greatest inhibition in binding studies with S-PMA. The relative 
affinities of the supernatants were assessed by comparing 
calibration plots developed using each supernatant. Supernatants 309 
and 6B8 gave the lowest limits of detection. The detection limits 
were less than 0.1 and lug/ml of S-PNA respectively (table 3.51). 
Wells 309 and 6B8 were cloned and expanded. 
Monoclonality was confirmed for wells 3G9F6 and 6B8F9. These wells 
were expanded into tissue culture flasks and the supernatant 
harvested- 
TABLE LE 3.5 INHIBITION WITH 100UG/NL OF S-PMA AND THE LIMIT OF 
DETECTION IN A CALIBRATION PLOT DEVELOPED BY ELISA 















3.19 COMPARATIVE STUDIES WITH MONOCLONAL SUPERNATANTS 6B2, 3G9 AND 
6B8. 
Assay conditions (eg plate coating, antibody concentration) were 
optimised for each supernatant and S-PMA calibration plots prepared. 
The calibration plot developed with antibody 3G9 is shown in figure 
34. The figure shows the mean of six replicate values and 
plus/minus one standard deviation. The lower limit of detection was 
0.04ug/ml of S-PNA. The lower limit of detection corresponds to the 
intersection of the lower 95% confidence limit of the blank with the 
upper 95% confidence limit of the standard plot. The assay range for 
6B2 and 6B8 are given in table 3.6 
TABLE 3.6 COMPARISON OF OPTIMISED ASSAY RANGE FOR SUPERNATANTS 6B2, 
3G9 AND 6B8 
SUPERNATANT 	ASSAY RANGE(ug/ml) 
6B2 	 10-200 
6B8 0.2-10 
3G9 	 0.04-2 
Calibration plots were also prepared in urine. Calibration plots in 
PBS and urine developed with antibody 3G9 are shown in figure 3.5. 
The presence of urine does not appear to affect the performance of 
antibody 3G9. The preparation of calibration plots in urine did 
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Figure 3.4 S-PtA calibration plot developed with antibody 3G9. 
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S-PMA IN PBS 
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Figure 35 S-Pt'iA calibration curves developed with antibody 3G9 in 
PBS and urine 
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TABLE 3.7 1050 VALUES (ug/ml) OBTAINED WITH CALIBRATION PLOTS 
DEVELOPED IN URINE AND PBS 
SUPERNATANT 	 IC50 (ug/mi) 
PBS 	URINE 
6B2 	 60 	<100 
6B8 2.5 100 
3G9 	 0.4 	0.4 
Cross-reactivities of 652, 6B8 and 3G9 with cysteine, acetylcysteine 
and several mercapturic acids were assessed. Supernatant 309 cross-
reacted with S-BMA and S-Pt'IA-methy ester when they were present in 
45 to 88 fold molar excess (Figure 3.6). 1050 values obtained with 
6B2, 3G9 and 658 in cross-reactivity studies are summarised in table 
3.8. 
TABLE 3.8. CROSS REACTIVITY STUDIES WITH 6B2, 3G9 AND 6B8 
INHIBITOR 	 IC50 VALUE (MM) 
652 3G9 658 
S-PNA 	 0.25 0.002 0.01 
CYSTEINE - 	- 	- 
ACETYCYSTEINE 	- - - 
2-HEHA 	 - 	- 	- 
HYDROXYPROPYL-NA - - - 
ALLYL-MA 	 - 	- 	0.34 
S-BMA - 0.14 0.41 
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Figure 3.6 Cross-reactivity studies with antibody 3G9 
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5- (2-HYDROXYETHYL ) -N-ACETYLCYSTE I NE 
320.1 Fusions 3-17 (j.nTvj.yo immunisation) 
All the fusions were performed successfully, and wells which 
contained one or more viable colonies were found on all the fusion 
plates (Table 39) Fusion efficiencies, defined as the number of 
wells containing hybridomas as a percentage of the total number of 
wells, ranged from 38% to 100%. 
TABLE 3.9 FUSION RESULTS FOR NICE IMMUNISED WITH 2-HEMA CONJUGATES 
INHUNOGEN HOUSE WELLS PLUS POSITIVE IN POSITIVE IN 
HYBRIDS SCREEN INHIBITION STUDY 
KLH-ABS-HEMA 1 276 56 0 
2 210 51 C) 
3 288 44 0 
GEL-BAL-HEMA 1 138 4 0 
2 252 9 0 
KLH-7C-HEMA 1 360 110 6 
2 240 3 0 
GEL-7C-HENA 1 324 30 C> 
2 342 114 10 
NSA-7C-HEMA 1 252 12 1 
2 204 10 0 
3 90 0 0 
4 140 0 0 
5 360 6 2 
6 360 55 1 
The number of positive wells varied considerably between fusions. 
Two fusions (NSA-7C-HEMA immunised mice 3 and 4) contained no 
positive supernatants in the screening assay. Up to 33% of the wells 
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which contained clones were positive in the ELISA. There was 
considerable variation in the colour intensity of the positive 
wells. In general the absorbance was low and wells were recorded as 
positive with an 0D. of two times the background- Approximately 2% 
of the positive wells in the ELISA contained no viable hybridoma 
cells. 
Binding of free hapten by antibody was only detected and confirmed 
in a repeat assay for twenty supernatants (4% of the positve wells 
in the screening assay). The percentage inhibition varied between 
the supernatants, but was generally low. With lOOug/ml 2-HE'1A 
standard inhibition ranged from 20% to 740/0/ (Table 3.10). 
TABLE 3.10 INHIBITION WITH 2-HEMA 
INMUNOGEN MOUSE WELL % INHIBITION 
















NSA-7C-HENA 1 5D2 38 
5 1011 21 
2B5 28 
6 lBS 27 
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Positive wells were also screened by RIA. In assays were separation 
of hound and free label was effected with 5% dextran coated charcoal 
total counts were 10 , 000dpm, and the background after separation was 
1414dpm (SD=69.8, n=10) In assays separated by saturated ammonium 
sulphate solution less label was added to the assay. The totals were 
1978dpm and the background was 2b5dpm (5D5.08, ni.b). No positive 
wells were detected by RIA. 
The twenty positive wells were cloned and expanded as described in 
methods Nonoclonality was not achieved despite exhaustive attempts 
to isolate the hybridoma cells - 
3.20.2 Fusions 18-20 (in-vitro immunisations) 
STUDY 1:- 
Spleen cells from the GEL-7C-HENA immunised mouse were successfully 
stimulated in-vitro. Cultured cells were examined daily 
microscopically. On day 2, expanded lymphocytes, or blast cells, 
were observed (Figure 3.7). The blast cells were approximately ten 
times larger than normal lymphocytes. The blast cells divided in 
culture, days 3-4, forming colonies (Figures 38 and 3.9). On day 5 
the cultured cells were fused as described in materials. 
The fusion was performed successfully, and the plating efficiency 
was greater than 90%. On day 12, supernatants were screened against 
plates coated with BSA-7C-HEMA. 60 wells (18% of the wells containg 
clones) contained antibody which hound the coating conjugate. Only 
one supernatant contained antibody which bound free mercapturic acid 
(58% percent inhibition with lOOug/ml 2-HEHA). The antibody was 
140 
- 	0 - 
	






0 	 .- 	C 
- 	!- 	C 	- 	- 
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Figure 3.8 and 8.9 	Blast cells observed after 5 days in 	yitro 
culture in the presence of conjugate. 
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specific for 2-HEMA. The clone plates were frozen at -180C. 
STUDY 2:- 
The number of viable cells on the day of fusion varied considerably 
when lymphocytes were primed in-vitro, in-vivo and immunised in::  
vitro (Table 3.11). 
TABLE 311 A COMPARISON OF IN-VIVO AND IN-VITRO IMNUNISED MOUSE 
FUSIONS 
IMMUNISATION NOS. VIABLE WELLS NOS. POSITIVE NOS. POSITIVE 
PROTOCOL CELLS CONTAINING WELLS IN WELLS IN 
HYBRIDOHAS SCREEN INHIBITION STUDY 
IN-VIVO BOOST 1 X 10 240 (67%) 110 6 
IN-VITRO BOOST 1.2 x 10  70 	(39%) 61 2 
IN-VITRO ll1. 1 x 104  28 	(47%) 18 0 
The results of the in-vivo boosted fusion have been presented 
(3.20.1). Fusions with both in-vitro boosted and primary immunised 
spleen cells were successfull. On screening, the number of wells 
containing one or more clones was determined microscopically. More 
hybridoma clones were observed with the in-vitro boosted spleen cell 
fusion (70 in-vitro to 28 in-vivo). Supernatants from both fusions 
contained antibodies which bound coating conjugate in the screening 
assay. 
The number of positive wells in the screening assay was greater 
after in-vitro boosting (61 compared to 18). Only the in-vitr 
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boosted lymphocytes gave rise to antibodies which hound free hapten. 
Two wells (6D8 and 6F8) demonstrated inhibition (69% and 97% 
respectively) in the inhibition study. Niether were positive in the 
RIA. One well (6B2) gave a positive result in the RIA but did not 
show inhibition in the ELISA. The positive well contained sixteen 
times more label than the background (positive well = 30Udpm, 
background = 26dpm). All three wells contained rapidly dividing 
cells and were cloned immediately. No antibody activity was detected 
in subsequent screening assays. 
3.21 NSA-ACETYCYSTEINE IMMUNISED MICE 
Spleen cells from mice 1, 2 and 4, immunised with acetylcysteine 
conjugated to NSA, were successfully fused with the Sp/2- rnyeloma cell 
line. On the day of screening 90%-100% of the wells per fusion 
contained one or more viable clones. Supernatants were screened 
against plates coated with O.lug/ml of BSA-acetylcysteine conjugate. 
Fourteen, twenty and forty two positive wells were detected in each 
fusion respectively (table 3.12). 
There was considerable variation in the colour intensity of the 
wells. Wells that were recorded as positive in the screening assay 
had an O.D. greater than two times the background. All the positive 
wells contained multiple small and large clones. 
Seventeen supernatants bound free hapten (2-HEHA and S-PHA) in the 
inhibition studies. In the inhibition study for mouse 1 only two of 
the positive supernatants from the screening assay had 0.1). values 
greater than twice the background. The absorhan.ce values were low in 
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general. Results of the inhibition study (supernatants with OD more 
two times background) are shown in table 3.13. 
TABLE 3.12 SCREENING RESULTS FOR NSA-ACETYLCYSTEINE FUSIONS 1-3 
FUSION PLATE NOS. POSITIVE NOS. POSITIVE WELLS 
WELLS IN SCREEN IN INHIBITION STUDY 
MOUSE 1 1 1 1 
2 1 1 
3 8 5 
4 4 2 
5 0 () 
6 0 0 
MOUSE  1 2 2 
2 7 1 
3 2 0 
4 4 1 
5 3 2 
6 2 0 
MOUSE 4 1 0 
2 3 0 
3 6 1 
4 2 1 
5 7 U 
6 15 0 
Eight positive wells (mouse 1: 1D3, 2B10; mouse 2: 1B9, 1G9, 2F7, 
5G11 and mouse 4: 3C5, 4F8) were cloned and expanded as described in 
the methods. On the day of screening, all the plates contained 
viable hybridoma clones. Only 3 clone plates contained wells which 
gave a positive result in the screening assay. For all the positive 
wells the absorbance readings at the end of the assay were 
relatively weak. 
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TABLE 3.13 INHIBITION RESULTS FOR t'ISA-ACETYLCYSTEINE FUSIONS 1-3 
FUSION WELL % INHIBITION 
S-HEHA 	5-PIIA 
HOUSE 1 1D3 75 80 
2810 17 55 
HOUSE 2 189 83 83 
1G9 70 77 
2F7 38 73 
411)3 42 76 
5E7 67 69 
5G11 68 72 
HOUSE 3 3C5 22 23 
4F8 11 66 
Clone plates 189 and 2F7 contained 12 and 5 positive well--
respectively. 
e ls
y. All the positive wells contained several clones when 
examined microscopically. No positive wells were observed after a 
second round of cloning. 
Clone plate 3C5 gave 32 positive wells in the screening assay- Three 
of the positive wells appeared monoclonal when examined 
microscopically- Nonoclonality was confirmed for well 3C5D9. 
Antibody titre was 1:4 for the harvested supernatant. The relative 
affinity of the antibody for 2-HEHA, S-PtIA and acetycysteine was 
determined from calibration plots (Figure 3.10). 1050 values with 2-
HEHA, S-PNA and acetyl cysteine were 0.15, 0.24 and greater than 
0.48 mM respectively. 
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Figure 3.10 2-HEtIA, S-PNA and acetylcysteine calibration plots 
developed antibody 3C5 
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DISCUSSION 
With a carefully designed hapten-protein conjugate and a judicious 
screening strategy, it was possible to generate and detect 
antibodies which hind S-PMA. Using hybridoma technology three 
monoclonal cell lines have been established which secrete antibody 
with relatively high affinity and specificity for S-PMA. The cell 
lines have been cultured in stationary flasks and the media 
harvested. 2-HEMA and acetylcysteine conjugate immunised mice have 
also been fused. Antibodies which recognise free mercapturic acid 
were detected but the affinities were too low for practical 
application. The results of the fusions are discussed below. 
Six mice were immunised with the protein conjugates KLH and HSA-PHA 
Two KLH-conjugate immunised mice (3 and 1) were selected for fusion 
Mice 3 and 1 were selected because these sera gave the highest 
titres (1:25000) and greatest inhibitions (26% and 22% respectively) 
in the screening assays (see chapter 2). 
Both fusions were performed successfully and plating efficiencies 
were high (average 93%, range 60%-100%. tables 3.1 and 3.3). 
Supernatants with a high absorbance in the screening assay were 
selected for competitive inhibition studies. These supernatants 
should contain a greater- proportion of hyhidoma cells secreting 
antibody which binds S-PMA-conjugate, or hybridomas secreting 
antibody of high affinity 
In the inhibition studies 82% of the positive wells hound free 
hapten In fusion 1. well 6B2 demonstrated the greatest inhibition 
(79%, Table 32). in fusion 2, six wells demonstrated almost 
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complete inhibition in the binding assay (Table 3.4). Wells 309 and 
6B8 demonstrated the highest affinity for free S-PNA (Table 3.5). 
Wells 6B2, 309 and 6B8 were therefore selected for further study and 
cloned. Monoc'lonality was confirmed for all three cell lines. 
Cell line 309 had the greatest relative affinity for S-PMA (Table 
3.6). The limit of detection of a calibration plot developed with 
309 was 0.04ug/ml of S-PNA (Figure 3.4). Calibration curves prepared 
with :309 were 250 and 5 fold more sensitive than those prepared with 
6B2 and 6B8 (limit of detection 10 and 0.2ug/ml respectively). 
The aim of this study was to produce an anti-PLIA monoclonal antibody 
and to develop an immunoaffinity column to enrich S-PMA from the 
urine of benzene exposed workers. The performance of the antibodies 
in the presence of urine was therefore assessed. Binding between 
antibody 309 and S-PMA was not affected by the presence of urine 
(Figure 3.5). However, with supernatants 6B2 and 6B8 antibody-
antigen binding was affected by the presence of urine, leading to a 
40 fold loss in assay sensitivity (table 3.7). 
Antibody cross-reactivity was assessed against a number of similar 
analogues (Table 3.8). No cross-reactivity was observed with 6B2. 
However, 6B2 demonstrated a relatively low affinity for S-PMA. 
Supernatants 309 and 6B8 showed no cross-reactivity with cysteine, 
acetylcysteine and 2-RENA. Both supernatants showed some cross-
reactivity with a large excess of S-PNA-methylester and S-BMA. 309 
demonstrated the greatest specificity, and cross-reactivity with 5-
PNA-methyester and S-BHA was only observed when they were present in 
a 120 and 70 fold molar excess respectively. 
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Cross-reactivity studies indicate that both the phenyl and 
carboxylic acid groups of the mercapturic acid appear to he 
important in antibody-antigen binding. Both probably form the 
epitope bound by the antibody's active site. Confirming the 
importance of the carboxylic acid in antibody-antigen interaction 
postulated in the design of the hapten-protein conjugate (chapter 
2). 
Supernatant from cell line 309 demonstrated the greatest relative 
affinity for S-PNA. The antibody was specific for S-PMA and the 
performance was not affected by the presence of urine. Supernatant 
309 was therefore selected for the development of an S-PNA 
iinoaffinity column. (see chapter 4). 
In contrast to S-PMA the production of an antibody which binds 2-
1-lENA with high affinity has proved to he very difficult. in total, 
fifteen mice were boosted in-vitro and the spleen cells fussed 
successfully. In general plating efficiencies were high (up to 
100%), but for three mice the plating efficiencies were less than 
50% (Gel-Pala-HEMA mouse 1, NSA-7C-HENA mice 3 and 4, Table 9). Sera 
from these mice had low antibody titres (less than 1:150, Figure 
2.10) when screened after the second immunisation. Poor stimulation 
of the lymphocytes and a lack of antigen induced proliferation may 
account for the relatively low numbers of hybridoma cells. Two of 
these fusions (NSA-7(-"-HEMA mice 3 and 4) gave no positive wells in 
the screening assay. 
All the remaining fusions contained wells which gave a positive 
result in the screening assay. In general, the number of positive 
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wells was low (l%-33% of the wells containing viable clones) and the 
colour development at the end of the screening assay was weak. This 
contrasted stongly with the results of the S-PMA fusions above. 2% 
of the positive wells did not appear to contain any viable cells 
when examined microscopically. These wells may have contained viable 
cells which subsequently died. Alternatively, absorhace values 
selected as positive in the screening assay (two times background 
because of poor colour development) were to low giving rise to false 
positives. 
In general the number of positive wells per fusion increased as the 
number of wells containing clones increased There was no obvious 
difference between fusions where lymphocytes were stimulated with 
KLH, gelatin and MSA-2--HE1A conjugates. In the EL1SA, mice immunised 
with the Gel-pala-2-HENA conjugate contained relatively few positive 
clones. However, this fusion was screened against a conjugate with a 
different spacer arm to the imraunogen (BSA-ABS-HEHA) and probably 
represents the response that recognises the hapten and not a hapten-
spacer complex. 
Binding studies were performed with a high concentation of 2-HENA 
(lOOug/ml. 4.200-7 moles/ml) but the inhibition was generally low 
(average 42%, range 21070%) indicating that the antibodies were of 
a relatively low affinity. The failure to generate high affinity 
antibodies to low molecular weight compounds has been reported by 
Chappey (1994). 
The limitations of the ELISA for screening low molecular weight 
compounds are discussed in chapter 2 in attempts to overcome these 
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limitations, positive wells were also screened by RIA Supernatants 
were screened against 300 11 or l.5x10 0 moles/ml 2-HENA. No 
positive results were obtained in the RIA, confirming all the 
antibodies which hound hapten in the ELISA were of low affinity. 
To improve the efficiency of specific hybridoma production jny_jtr 
boosting of in-viio primed cells was examined. 	Initially, cells 
were cultured in serum free protein free medium to minimise the non-
specific activation of lymphocytes by serum protiens However it was 
found that low cocentrations of foetal calf serum (5% Mycione Plus) 
were necessary to support cell growth. Under the culture conditions 
employed lymphocytes could he cultured for five days in the presence 
of immunogen. After five days the number of viable cells declined 
rapidly, resulting in poor fusion efficiencies. 
Two mice were boosted in-vitro with two different conjugates 
(gelatin and KLH-7C-HEMA). Similar results were obtained with both 
fusions- In the presence of immtmogen it was observed that a number 
of lymphocytes increased in size (Figure 37). It was presumed that 
these were antigen stimulated cells, or blast cells, described by 
Borrenhoeck 1986). These cells divided to form colonies (Figure 3.8 
and 3.9) which were either anchored to the tissue culture flasks or 
floating free in the culture media. 
Lymphocytes immunised imvitro were fused successfully. Plating 
efficiencies (up to 90%) compared with those obtained using j.yjy 
boosted spleen cells. Antibodies which hound the conjugated hapten 
were detected in the screening assay. The assay results compared 
with the injvQ boosted mice results 
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One supernatant containing antibody which bound free 2-HEHA was 
generated with the gelatin conjugate. This supernatant was only 
sceened by ELISA since there was insufficient supernatant to screen 
by RIA. The plates from this fusion were frozen before cloning and 
were unsuccessfully thawed at a later date. Two supernatants which 
hound free 2-HEHA in the ELISA (Table 3.11) were generated with the 
KLH conjugate. However these antibodies were of low affinity and did 
not bind the labelled hapten in the RIA_ One well (6B2) gave a 
positive result in the RIA but did not show any inhihitioin in the 
ELISA. This can he explained if the antibody had a high affinity for 
free '21-HEM (positive in RIA) but a higher affinity for hapten 
coupled to the carrier protein (negative in ELISA). 
Finally, mice were also immunised with t'ISA--acetycysteine conjugate. 
The results of the fusions (Table 3.12) were comparable to those 
described above. The number of positive wells (approximatly 4%-12% 
of the wells containing clones) compared with results obtained with 
2--FIEMA stimulated spleen cells. However, the number of cells which 
hound free hapten in the ELISA was greater than expected (5/-64% of 
the positive wells). All of these antibodies were of low affinity as 
no binding was observed in the RIA. 
Supernatants were screened against both 2-HEMA and S-PMA by ELISA. 
The inhibitors were of equimolar concentration. However, inhibition 
was generally greater with the S-PHA inhibitor showing that this 
mercapturic acid was recognised by the antibodies with greater 
affinity (Table 3.13)- It was also observed that some antibodies 
recognised non-modified MSA in the sceening assay. That is, some 
antibodies generated to the hapten-HSA complex also cross-reacted 
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with native t'ISA. Autoantibodies were induced. 
It is often difficult to see how such antibodies may arise (Roitt 
1980). In the body mechanisms exist to prevent the recognition of 
1. self components as antigens. However these can break down leading 
to antibodies which recognise self - autoantibodies. 
Autoantibodies lead to a spectrum of autoimmune disease, such as 
organ-specific Hashimatos disease of the thyroid, or the non-organ 
specific disease Systemic Lupus Erythematosus (SLE. 
Serum proteins are exposed to many chemical insults every day. The 
induction of antibodies to modified proteins which cross react with 
native protein has been demonstrated. it is easy to see how 
devastating this could be on the body when the catalytic activity of 
some antibodies are taken into consideration (Schultz 1988). 
Despite exhaustive attempts to clone the cells (from both 2-HEI'IA and 
acetycysteine-conjugate immunised mice) which showed inhibition, 
monoclonality was only obtained with one cell line (HSA-
acetycysteine immunised mouse 3 well 3C5). There are a number of 
possible explanations for this. After fusing, dividing hybrids may 
lose chromosomes to obtain a more stable genotype. There is a 
tendency for chromosome loss to occur after the initial cloning and 
more than 50% of the clones can be lost, at the first, round cloning. 
With successive rounds of cloning cell stability increases (Edwards 
1981). 
Furthermore, due to the low number of positive wells in the 
screening assays many weakly positive wells were cloned, it was 
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observed that all these wells contained a number of large and small 
viable hybrid colonies arid therefore, only a low proportion of cells 
may have been secreting antibody of interest. The few specific 
hybidoma cells could easily he overgrown by a large number of 
rapidly gowing non-secretors. 
Finally, some cell lines have inherently poor cloning effiencies, 
and may not have grown at low dilution even in the presence of a 
layer of thyrnocyte feeder cells. 
From the above it can he seen that the positive selection of hapten 
specific hybridomas would greatly facilitate the cloning process. 
Parkes et al (1979) identified antigen specific hybridomas with 
fluorescent microspheres and cloned using a fluorescent activated 
cell sorter (FAGS). Cloning with a FAGS is expensive and the method 
is unsuitable for routine use. Magnetic beads have been used for the 
positive selection of cell populations by a number of authors, for 
example T and B lymphocytes (Lea et al 1985) and malignant cells 
from bone marrow (Treleaven et al 1984, Kvalhein et al 1987). Cells 
were incubated with magnetic beads coated with antibody to a 
specific surface antigen, rosettes of antigen bearing cells were 
formed which could be separated from the mixture with a powerful 
magnet Horton et al (1989) described an adaption of the method 
selecting antigen specific hybridoma cells using magnetic beads 
coated with hapten. Selected cells were cloned by limiting dilution 
with the heads still bound to their surface. He found a greater 
number (25O% of cell lines could be established in 50% of the 
normal time. The interaction of lymphocytes with magnetic polymer 
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particles has also been studied by Ossendorp et al (1989) and 
Pilling et al (1989). All three authors describe similar optimised 
conditions and their results confirm that coated beads can be used 
for the efficient selection of high affinity B cell hybridomas. 
In order to improve cloning efficiency the use of antigen coated 
magnetic beads to select lymphocytes bearing specific antibody on 
their surface was investigated. The spacer arm B-alanine was coupled 
to tosyl activated magnetic beads (LYynal). 2-hydroxyethylcysteine 
was then coupled via its amino group to the ft-alanine carboxylic 
bead using N-hydroxysuccinimide and carhodiimide. Cells and 2-HEHA 
coupled beads were mixed and incubated. The beads were separated 
using a selaniusrt magnet. After separation cells were counted (during 
counting several heads were observed on the surface of some of the 
cells) and cloned by limiting dilution. When the clone plates were 
screened the number of positive wells was increased 2-3 fold. 
However it appeared cells secreting antibody with a high affinity 
for 2-HEIIA plus spacer were selected since none of the supernatants 
demonstrated inhibition in the binding studies. Horton et al (1989) 
reported that the use of antigen coated beads selected cells that 
secreted antibody of high affinity (<1O 1/mole), and this method 
may he unsuitable for cloning cells bearing low affinity antibody. 
This study demonstrates that the number of B cells secreting high 
affinity antibody form a very small percentage of the total 
response. Cell fusion is inefficient, the genetic information of 
only about 1:1000() lymphocytes is fixed in hybrid cells. in 
addition, it is not always possible to isolate these cells during 
cloning. Molecular biology techniques are been increasingly used to 
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generate monoclonal antibodies (for a review see Owens and Young 
1994). With recombinant antibody technology the entire gene 
reportiore can he saved and expressed. Recombinant technology should 
increase the chances of generating high affinity antibodies to 2-
HEHA In addition, with mutagenesis it may be possible to alter the 
genetic framework of a low affinity 2-HEHA antibody to give an 
antibody with high affinity for 2-HENA. 
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CHAPTER FOUR. 




Benzene is an important industrial chemical, and the current 
occupational exposure limits for benzene (8 hour Time Weighted 
Average or TWA) in the United Kingdom (Maximum Exposure Limit or 
MEL), European Union and United States (Permissible Exposure Limit 
or PEL) are 5, 1, and 1ppm respectively. In order to comply with a 
limit value of lppm, 8 hour rrwp exposures must he well below this 
value most of the time. Methods sensitive enough to measure below 
lppm are therefore needed. 
4.1 ANALYTICAL METHODS FOR THE DETERMINATION OF URINARY S-PtIA 
Urinary S-PMA is a sensitive and specific marker of benzene exposure 
(chapter 11) 	and several techniques have been described for the 
quantitative analysis of S-PMA. These include amino acid analysis 
HPLC and GU (fig. 4.1). At present only GC/MS determination of S-PMA 
possesses the required sensitivity for biomonitoring occupational 
exposure to benzene. 
4.2 GC/MS DETERMINATION OF URINARY S-PNA 
Van Sittert et al (1993) determined S-phenylmercapturi-c acid in 
human urine using a modification of the method described by Stommel 
et al (1989). Briefly, the urine is acidified and the mercapturic 
acid extracted into ethyl acetate- Following centrifugation the 
ethyl acetate is removed and evaporated to dryness under a gentle 
stream of nitrogen in a water bath at 45
0C. The residue is 
resuspended in methylating agent (methanol/1.25M H(.'1) After two hours 
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FIG-4.1 Analytical Techniques and Detection Limits for the 
measurement S-phenylmercapturic acid in urine. 
METHOD OF METHOD OF LIMIT OF REFERENCE 
SEPARATION DETECTION DETECTION 
Partition Amino acid 2nmol/ml Stommel (1989) 
analysis 
HPLC UV 6nmol/ml Jongeneelen (1987) 
HPLC Fluorescence ln.mol/ml Norpath (1991) 
HPLC ECD 20pmol/ml Norpath (1991) 
GO MS-SIN 50pmol/ml Stommel (1989) 
GO MS-SIN lOpmol/ml Norpath (1991) 
CC MS-SIN 4pmol/ml Van Sittert (1993) 
at room temperature the methylating agent is evaporated and the 
sample dried as above. The residue is resuspended in dicloromethane 
for analysis by CC/MS. 
The methylester of S-PNA is analysed by mass spectrometry in an 
electron impact mode (El) with selective ion monitoring (SIN). Under 
these conditions the most abundant ion has an m/z of 194. 
In order to avoid misinterpretation of the spectra due to minor 
interferences by other components, a qualifier ion (another 
fragment of lesser abundance or specificity than the selected ion) 
is monitored along side the 'selected ion. It should be checked 
that the qualifier ion' has the same retention time in the 
chromatographic system as the selected ion, and that its abunciancy 
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in comparison with the selected ion matches its relative abundancy 
in the mass spectrum of the pure compound. The methylester ion (m/z 
253) was chosen as the qualifier ion. 
Van Sittert et al (199:3) used the GC/HS method described above to 
measure levels of urinary S-PMA in three industrial settings where 
benzene exposure can occur: oil refineries, chemical manufacturing 
and natural gas production plants. They confirmed that S-PHA is a 
sensitive and specific marker of benzene exposure, allowing 
exposures down to 0.3ppm 8 hour TWA to be determined. Depending upon 
matrix effects the limit of detection of the assay was l-Sug/l when 
S-henzylmercapturic acid (S-BMA) was used as an internal standard. 
In highly concentrated urine samples the S-PHA peak could appear a 
few milliseconds later in the chromatograph compared to the internal 
standard. Because of this, the S-PNA peaks from concentrated 
samples, with S-PNA values of >Sug/l, could not always be attributed 
with certainty. In addition, S-BMA is found in the urine of toluene 
exposed workers. Toluene and benzene are commonly used co-solvents 
and co-exposure may occur. The presence of S-BMA in the urine of 
toluene exposed workers interferes with the S-BMA internal standard. 
Recently, Boogaard and Van Sittert (1995) have described the use of 
S-(pentadeuterophenyl) mercapturic acid (d5-S-PtIA) as an internal 
standard. D5-S-PHA was synthesised from d5-aniline and N-
acetylcysteine according to the Gattemann reaction. Using d5-S-PHA a 
detection limit of lug/l could he guaranteed. Using d5-S-RIA 
background levels of S-PHA could be detected in non-exposed 
populations. 
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A limition of the S-PIIA method is that determination by GC/MS 
requires a complex work-up prior to assay and the sensitivity of the 
procedure is limited by the purity of the sample. The development of 
an effective single step immunoextraction procedure to replace this 
may both facilitate and improve the sensitivity of the quantitative 
MS analysis of S-PMA. 
In addition GC/MS analysis restricts this method to use in 
laboratories with sophisticated analytical equipment. The use of an 
immunoaffinity column to enrich S-PMA may permit the analysis of 8-
PMA by HPLC which at present lacks the sensitivity for application 
in biomonitoring. 
4.3 IIIMUNOAFFINITY CHROMATOGRAPHY 
Affinity chromatography is a method of fractionation in which the 
molecule to he purified is specifically and reversibly bound by a 
complementary binding molecule (the ligand) attached to a solid 
support (the matrix). 
In immunoaffinity chromatography either an antibody or an antigen 
can be immobilised to form the adsorbent (immunoadsorbent or 
immunosorhent). With the development of monoclonal antibody 
technology the use of antibodies as ligands has become widespread. 
Using monoclonal antibodies, adsorbents of defined specificity and 
affinity can be prepared. With antibody adsorbents, rapid 
separations (which would be difficult and time-consuming by other 
techniques) and purification factors of several thousand are 
possible. Immunoaffinity chromatography has been reviewed by Goding 
(1986) and Jack and Wade (1987)- 
4.4 ANTIBODY PURIFICATION 
Protein A and protein G are two proteins of staphylococcus origin 
Protein A binds immunoglobulins IgG (IgG1 poorly) and 1gM, whilst 
protein C binds IgG only. Protein C binds immunoglohulins with a 
greater avidity than protein A. Supernatants can be loaded directly 
on to protein A and G columns. Antibody can be eluted with pH 4 
buffer from protein A Antibodies are generally stable under these 
conditions. To elute antibodies from protein G harsher elution 
conditions are needed. Antibodies are normally eluted at pH 2 but 
prolonged exposure at pH 2 is detrimental to the immunoglohulins and 
the samples must he immediately neutralised. For optimum performance 
the sample load should he approximately half of the column capacity, 
minimum flow rates allowing for maximum interaction. 
4.5 PREPARATION OF AN IMMUNOAFFINITY COLUMN WITH 3G9 
CHOICE OF SOLID PHASE 
When preparing an immunoadsorbent the first decision is the choice 
of solid support. A range of solid supports are available and these 
have been reviewed by Narayanan and Crane (1990). The ideal matrix 
exhibits high specificity, contains no hydrophobic binding sites, 
possesses good chemical stability, excellent mechanical rigidity, 
high binding capacity, has a low cost and good reproducibility is 
yet to be synthesized (Naravanan and Crane 1990) Beaded agarose 
comes closest to these ideals. Beaded agarose has high porosity, 
1133 
hydrophilicity and chemical stability. Sepharose is a bead formec 
agarose gel. It possesses an open pore structure which is available 
even to large molecules- The exclusion limit of sepharose 413 in gel 
filtration studies is 64 20 X 106 (Pharmacia). it can tolerate 
undiluted ethanol, methanol, hutanol, acetone, thoxane, 80% v/v aq, 
pyridine and 50% L't'IF. its surface is relatively inert, and contains 
hydroxyl groups which can he easily activated- However, there are 
disadvantages. It cannot withstand high pressure which limits the 
column flow rate, it has a relatively low binding capacity and is 
susceptible to microbial degradation Freezing causes irreversible 
changes in structure. 
Many different coupling methods are available (for a review see 
Narayanan and Crane, 1990). The use of CNBr activated sepharose to 
couple antibodies is very popular. Preparation of CNBr activated 
sepharose is simple and inexpensive, but uses a volatile and toxic 
chemical cyanogen bromide). Pre-activated agarose is available as a 
stable lyophilized powder. CNBr activation increases the number of 
crosslinIs between the polysaccharide side chains improving the 
stability of the agarose. After activation and coupling the solid 
support can withstand high concentrations of salt, urea, guanidine-
HC1,SDS, deoxycholate and Triton X. 
4.16 CNBR ACTIVATED SEPHAROSE 
Antibody coupling is achieved by the nucleophilic attack of the 
epsilon amino group of lysine on CNBr activated sepharose forming a 
stable isourea bond. Maximum binding occurs under slightly alkaline 
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conditions when the amine group is unprotonated. Minor competing 
reactions lead to the formation of carbamate and cyclic 
imiclocarhamate (fig. 4.2). Suitable buffers for coupling are PBS, 
0. IM sodium borate and 0.1M sodium carbonate pH 7.5--8.5- The 
presence of Tris, ammonium and azicte ions will inhibit coupling. 
Protein binding capacity varies with the degree of activation, pH 
and antibody. CNBr activated sepharose 4B has a binding capacity of 
10-15mg of protein per ml of wet gel. 
The total amount of protein reacted with activated gel is important 
Coupling efficiencies of 100% are possible but generally undesirable 
for maximum antibody activity. Optimum results appear to be achieved 
when 80%-90% of the antibody is coupled to activated gel 	Pfeiffer 
et a]. 199'z-'). This seems to he due to the number of points of 
attachment. Over-attachment leads to a loss of tertiary structure 
necessary for antigen-antibody interactions. Westen and Scuver 
(1977) found 3-4mg of IgO coupled per gram of sepharose give maximum 
binding capacities. At higher antibody densities binding capacity 
was diminished, possibly due to steno hindrance and the 
inaccessibility of the antibody in the pores of the support. 
After coupling, unreacted cyanate or imidocarbamate groups (fig. 
4.2) are blocked. Blocking can he performed with glycine, ammonium 
hydroxide or ethanolamine. Ulyc inc and ethano lamine introduce other 
ion ical ly charged groups into the matrix. tqon-specificaliy adsorbed 





















Fire 4.2 CNBr Activated Sepharose - antibody coupling chemistry 
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4.7 USE OF IMMUNOAFFINITY CHROMATOGRAPHY COLUMNS 
Individual monoclonal antibodies possess different chemical and 
physical properties. Optimised chromatography conditions will 
therefore vary between immunoaffinity columns prepared with 
different antibodies. 
For binding, the antigen should be soluble and free of aggregated 
material or debris which would block the column. Insoluble 
impurities can be removed (pre-col-Lunn clarification) by filtration 
or centrifugation. With small columns a flow rate of 1-2m1/min is 
customary. Cross-linked matrices give better flow rates, compress 
less and maintain better flow characteristics. With solid supports 
of a porous nature diffusion within the structure and antibody 
accessibility may limit the flow rates which can be achieved. 
Column efficiency, or performance capability in terms of purity and 
yield, will he determined by the affinity constant of the column (or 
antibody). Affinity constants can be determined by equilibrium 
experiments (Scatchard analysis). Both temperature and pH can have 
an effect on the affinity constant (Eveleigh and Levy 1977). High 
(370C) and low (40C) temperatures lead to a decrease and increase 
in the affinity constant respectively. The effects of temperature (.a 
factor of 2 in the above range) is negligible compared to the effect 
of pH. Affinity constants are greatest at pH 6-8 and fall rapidly 
outside these two values Binding was therefore performed at about 
pH 7. 
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After binding, columns are washed, usually with 5-20 column volumes 
of binding buffer. Care should be taken with low affinity antibodies 
that excess washing does not elute the antigen. Non-specific binding 
is a property of the matrix and individual molecules. Electrostatic 
effects are largest at low salt concentrations. They can he pH 
sensitive. Hydrophobic interactions can also occur. These tend to 
occur with hydrophobic spacer arms. Hydrophobic effects are 
increased at high salt concentrations. The effect of salt and pH 
vary with different antibodies. 
Elution of antigen from the column should be undertaken with the 
mildest conditions if biological reactivity is to he preserved. High 
affinity antibodies usually, but not always require the strongest 
elution conditions (Parham, 1983). 
Elution is generally brought about by the induction of a 
conformational change. Changes in pH (eg. glycine-HC1 buffer pH2.2-
2.8), polarity lowering agents (eg. dioxane, ethylene glycol), 
dissociating agents (eg. 5-8M urea, 4-611 guanidine-HC1) and 
chaotrophic agents (eg. thiocyanate) have all been commonly used. 
Antigens with conformations that depend on enviromental conditions, 
such as temperature or the presence/absence of cofactors, may he 
bound in one conformation and eluted in another by changing the 
column environment (eg. temperature). Combinations of reducing and 
denaturing conditions are likely to dissociate the antibody light 
and heavy chains, destroying the columns. 
The development of an imrnunoaffinity procedure to concentrate and 
purify S-PHA from the urine of benzene exposed workers will greatly 
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facilitate the hiomonitoring of benzene exposure. A monoclonal 
antibody, :3G9, which specifically binds S-PHA, has been generated 
(chapter 3). This chapter describes the immobilisation of 3G9 to 
the solid support CNBr activated sepharose, enabling the production 
of an irnunoaffinity column- Immunoreactivity after coupling was 
assessed by monitoring binding of S-PMA applied to the column in 
aqueous buffer and urine. The performance of the imrni.moaffinit.y 
column was validated against the solvent extraction GC/NS method 
described by Boogaard and Van Sit.tert (1995). The potential of 
immunoaffinity chomatography/HPLC to determine urinary S-PHA is 
investigated. 
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MATERIALS AND METHODS 
MATERIALS 
REAGENTS 
Protein S sepharose Fast Flow and CNBr activated sepharose 4B was 
supplied by Pharmacia Ltd, Milton Keynes, UK. Sodium acetate (GPR, 
Hopkin and Williams Ltd., Essex. UK), sodium azide (Sigma Chemical 
Co, Dorset.. UK). d5-S--PMA (Shell Biomedical Laboratory, Rotterdam, 
Netherlands). 
Am icon Centriprep 30 (Amicon Ltd., Stonehouse. UK). 
BUFFERS 
Coupling buffer consisted of 0..1M sodium carbonate buffer pH 8.3 
containing 0L5M NaCl. 
Glycine buffer consisted of 02M glycine adjusted to pH 8 with 0.2M 
NaOH, containing 05M NaCl 
Acetate buffer consisted of 01M sodium acetate adjusted to pH 4 
with 01M acetic acid, containing 05M NaCl 
1M Tris-HC1 consisted of 1M Trizma base adjusted to pH 9 with 1M HC1 
PBS sodium azide consisted of PBS containing 0.02% w/v sodium azide 
WORKING STANDARDS 
EUISA standards (0-2. 5ug/ml) in PBS and HPLC standards (0-1ug/ml) in 
mobile phase (17% acetonitrile, 0L3M phosphate buffer pH2.1) were 
prepared from a 852ug/ml solution in 1% methanoi:PBS. 
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METHODS 
4.8 ANTIBODY PURIFICATION - PROTEIN G AFFINITY CHROMATOGRAPHY 
Antibody 3G9 was affinity purified using Protein G sepharose 4 Fast 
Flow from Pharmacia. A 25m1 settled bed volume column was prepared 
and stored in 20% methanol water at 40C until use. The column has a 
binding capacity of approximately 150-300mg of antibody. Before use 
the column was equilibrated with PBS at 40C. 
Cell culture supernatant (1500m1) was pooled and centrifuged at 
4000g for 10 minutes at 40C to remove cell debris. The supernatant 
was loaded onto the column and chromatographed in the cold at 
approximately 2m1/minute. The column was washed with 120ml of PBS 
and the antibody was eluted with llOml of 0.1M glycine-HC1 pH 2.7. 
Fractions (lOmi) were collected into vials containing 600u1 of 
neutralising buffer (iN Tris-HC1 pH 9). The pH of the neutralized 
fractions was approximately 7.5-8.0. Protein concentration in the 
collected fractions was determined from optical density measurements 
at 280nm. 
4.9 ANTIBODY CONCENTRATION 
Antibody was concentrated (according to the manufacturer's 
instructions) using an Amicon Centriprep-30 concentrator, a 
filtration unit containing a membrane (molecular weight cut-off of 
30,000), through which buffer is forced by centrifugation. 
Briefly, 10-15m1 of antibody solution (076mg/ml) was centrifuged at 
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2500rpm for 20 minutes at 250C. The buffer was decanted and the 
concentration step repeated. Antibody concentration was repeated 
three times. Concentration of the immunoglobulins was monitored 
spectrophotometrically at 280nm. Immunoreactivity was assessed by 
preparing antibody titration curves. 
4.10 PREPARATION OF flIMUNOAFFINITY COLUMN 
Antibody was covalently attached to a solid support (cyanogen 
bromide activated sepharose 4B) by a modification of the method 
described by Pharmacia. Freeze-dried CNBr activated-sepharose 4B 
(0.21g) was gently mixed with 1mM HC1 (15m1) for five minutes at 
room temperature. The gel which formed was sedimented by 
centrifugation (2000g for 1 minute), and the supernatant discarded. 
The rehydration step was repeated three times. The swollen sepharose 
was washed quickly with coupling buffer (lSml) to remove excess 
acid - 
Immunoglobulin solution (3m1, 1.51 mg/ml) was added to the sepharose 
and the suspension gently mixed for three hours at room temperature. 
The sepharose was washed with coupling buffer (iSmi), resuspended in 
glycine buffer (25m1) and gently mixed overnight at 400 to block any 
remaining active groups on the solid support. The sepharose was 
washed with coupling buffer (15ml) and acetate buffer (15m1.) 
alternately three times to remove any protein non-covalently bound 
to the matrix. The gel was washed twice with PBS and a column of 
approximately 0.5m1 settled bed volume was prepared. Finally, the 
PBS was replaced with PBS containing sodium azide (U.02% w/v) and 
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the column stored at 40C until use. Antibody uptake was monitcecO 
spect.rophotomet.rically at 280nm - 
411 IMMUNOAFFINITY CHROMATOGRAPHY 
Before use. the immunoatilnity column was ;iil.:: 
temperature and equilibrated WI -  
at a flow rate 	 :0 	- 
j 	1f. 	 : 	
r 	 -. 	. 
- 	
. 
e:-te1 The fractions 
.......i--  PMA by ELISA_ 
alec cii lwt,ed to a concentration below the limit of 
detection of the ELISA (BOug/l) and applied (lOml) to the 
immunoaffinity column. The column was washed and the retentate 
eluted as described above. The concentration of S-PMA in the 
retentate was determined by ELISA. 
Mid-stream urine (5, 10 and 20ml) dosed with S-PMA (50, 25 and 
5ug/1) were applied to the column for immunoextraction- The 
retentates were analysed by ELISA and HPLC 
4.12 HPLC ANALYSIS OF S-PMA 
HPLC analyses were performed using a ClO reversed phase 
chromatography column (Hichrome column 10cm x 4.9mm). Mobile phase 
consisted of 17% acetortitrile. 0.03N phosphate bufter. 111-t 2. 
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Samples were chromatographed at a flow rate of imi/minute. S-PtIA was 
detected spectrophotometrically at 256nm (Gilson model 116)_ A 
calibration plot (0Ll2bmg-1Omg/l) was prepared in mobile phase. 
Prior to analysis, the imim.rnoaffinity column retentates were 
concentrated by evaporation and diluted in mobile phase. 
4.13 VALIDATION OF THE INNUNOEXTRACTION PROCEDURE AGAINST A GC/11S 
NETHOD 
Chemical workers of the Shell International Petroleum Lompa:v 
routinely monitored for exposure to benzenc S:.:: 	IS determined 
by 	the measurement. .J. S -PtA 	end cl chitt ur.Ln. 
are collected in pc lythene  
s ve.iiST.ed against 
cc:cnibed by Boogaarc( and Van Sittert 
containing 12 to lhbug/l determined after solvent 
extraction) were determined after immunoextraction using a 
modification of the procedure described by Boogaard and Van Sittert 
(1995). UC/1IS analysis was performc( at the Shell Biomedical 
Laboratory, Rotterdam 
174 
DETERMINATION OF S-PNA IN THE URINE OF BENZENE EXPOSED WORKERS 
To Sml of urine was added 0112ug of internal standard d5-S441A. 
Before immunoaffinity chromatography the pH of each urine sample was 
adjusted, to between pH 33-69. The pH was adjusted by the addition 
of 2 drops of 6N sodium hydroxide plus 4-12 drops of IN sodium 
hydroxide solution-  
Before use, the immunoaffinity columns were allowed to reach room 
temperature and equilibrated with PBS. The urine sample was applied 
to the immunoaffinity column and chromatographed with a flow rate of 
approximately 2m1/minute. This flow rate was achieved by placing the 
columns under a low vacuum The column was washed with PBS (6ml) and 
dried under a gentle stream of air The column retentate was eluted 
with 95% methanol water (2ml). The concentration ofJ'-PMA and db B-
PHA in the sample was determined by CC/MS. 
DERIVATIZATION OF S-PMA FOR CC/MS DETERMINATION 
For CC the mercapturic acids were derivatised as follows. The 95% 
methanol/water was evaporated under a gentle stream of nitrogen at 
450C, and the residue dried by warming above an infra red lamp for 1 
hour. The dry sample was methylated by the addition of 2m1 of 
methanol/1.25M HC1 Methylating agent was prepared by bubbling 46g 
of HC1 gas through 1 litre of methanol, and the pH checked by 
titration with sodium hydroxide. Following met.hylation at room 
temperature for 30 minutes the sample was evaporated to dryness 
under a gentle stream of nitrogen at 45oC The residue was dissolved 
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in lOOul of dichloromethane and analysed by GC/NS with selective ion 
recording. 
GC/NS DETERMINATION OF S-PtIA-NETHYESTER 
It was not possible to analyse the samples using the conditions 
described by Boogaard. The modified GC/MS conditions were as 
follows: the column was a fused silica capillary column (60m x 
0.22mm) coated with DB-1 (Durabond, film thickness 0.1 micrometres). 
Helium was used as the carrier gas, 170kPa (flow rate of 
approximately lml/minute)- The injector temperature was initially 
1500C. After the sample was loaded this temperature was held for I 
second then increased to 250C by 1290/second. The injection volume 
was lul splitless. The oven programme was initially 5000 for 1 
minute followed by a 100C/minute increase to 3000C. This temperature 
was held for 7.5 minutes. 
Electron impact ionisation was performed with the following 
conditions: ion source temperature 18000.  ionisation potential 70eV 
and multiplier voltage autotune plus 800 eV. For quantification of 
S-PHA and d5-S-PtIA the ions at m/z 194 and 199 (fragment of S-
PNA/d5-S-PHA methyl ester) were monitored. Qualification ions at m/z 
253 and 254 respectively were also recorded. 
A calibration curve (fig. 4.3) was prepared in blank urine (0-
100ug/1). The ratio of the methyl esters of S-PMA and d5-S-PIIA 
internal standard was plotted against the response ratio of m/z 194 
and m/z 199- 
1% 
The concentration of the S-PNA in a urine sample (C) was calculated 
from the equation: 
C~.i=N-i-x-CB-
AB X F 
F. 	a factor of relative sensitivity (m/z 194 : m/z 199) 	is 
approximately 1 and can be calculated from the linear equation: 
A 	xCB = CP XF± Apo 	XCB 
(AB ABC)) 	 (AB 
when 
AB = area/peak height of m/z 199 in calibration or unknown urine 
ABO= area/peak height of m/z 199 in blank calibration urine without 
internal standard 
A, = area/peak height of m/z 194 in calibration urine 
Apo:::: area/peak height of m/z 194 in blank calibration urine with 
internal standard 
A= area/peak height of m/z in the unknown urine 
CB= concentration of internal standard d5-S-PMA in calibration or 
unknown urine. 
concentration of S-PNA in the calibration urine 
c= concentration of S-PNA in the unknown urine 
4.14 IN1UNOAFFINITY CHRONATOGRAPHY/HPLC ANALYSES OF URINARY S-PNA 
Finally, the concentration of S-PNA in urine samples collected from 
benzene exposed workers was determined by immunoaffinity 
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chromatography/HPLC. The concentration of S-PHA in the urine samples 
(30-1152ug/1) had been determined previously by GO/MS (method of 
Boogaard and Van Sittert 1995). 
Urine samples (1-5m1) were applied to the immunoaffinity column and 
chromatographed as described above. Prior to analyses by HPLC, the 
iminunoaffinity chromatography retentates were concentrated by 
evaporation, under a stream of nitrogen gas, and diluted in mobile 
phase (500u1 ) - 
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RESULTS 
4.15 ANTIBODY PURIFICATION AND CONCENTRATION 
Protein G purification yielded 30ug of 3G9 per ml of supernatant. 
From the immunoreactivity studies, this corresponded to a 16 fold 
increase in concentration (table 4.1). A further 25 fold increase in 
3G9 concentration was achieved with the Amicon Centriprep 30. It was 
calculated from OD measurements that 96% of the antibody was 
recovered after membrane filtration. 
Table 4.1 Antibody 3G9 Purification v Immunoreactivity 
FRACTION 	 TITRE 
CULTURE SUPERNATANT 	 1:2500 
AFTER PROTEIN 0 
PURIFICATION 	 1:40000 
AFTER CONCENTRATION 	 1:1000000 
4.16 PREPARATION OF IHMUNOAFFINITY COLUMNS 
4.06mg (89%) of 3G9 was coupled to 0.21g (0.75m1 of swollen gel) of 
CNBr activated sepharose. No protein was detected in the final 
coupling/acetate washes (0.D. readings at. 280nm) indicating that all 
the antibody was covalently attached to the solid support. 
4.17 IHNIJNOAFFINITY CHROMATOGRAPHY 
The immunoaffinity column had a maximum binding capacity of l.Sug of 
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S-PMA. No S-PMA was observed in the final washes when the fractions 
were analysed by EL1SA. 0.54ug (108%) of the S-PHA was recovered 
after immunoenrichment of a solution (lOmi) containing 50ug/l of 
analyte. Recoveries of 80% (SD6.7, nz6) were obtained after 
immunoaffinty chromatography of a 5m1 urine sample containing 5Oug/l 
of S-PI'IA. Recoveries of 94% and 80% were obtained after 
immunoaffinity chromatography of 10 and 20m1 of urine containing 25 
and 5ug/l of S-P1A respectively. 
4.18 DETERMINATION OF S-PtIA BY GC/MS 
The S-PMA and the internal standard (d5-S-PIIA) selected ions 	(m/z 
194 and 199) and qualifier ions (m/z 253 and 258) had a ratio of 
10 to 1. A typical calibration, the ratio of methyl ester of S-PHA 
and d5-S-PMA internal standard plotted against the response ratio 
m/z 194 and 199, is shown in figure 4.3. 
Twenty three urine samples containing 12-168ug/1 S-PI'IA analysed by 
the 	method of Boogaard were analysed by immunoaffini ty 
chromatography - GC/MS. The correlation coefficient between the two 
methods was 0.98, figure 4.4. Recovery of S-PNA after acidification 
and neutralization of the urine was 28.3% (SD=6.2, n=23). GC,tlS 
chromatograms of immt.moextracted samples contained fewer peaks than 
those analysed by the method of Boogaard. 
Typical examples of the fragmentographs obtained from immtmoaffinity 
prepared samples are shown in figures 4.5 to 4.8. FranentographS of 
the same samples prepared by the method of Boogaard ae shown in 
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Figure 4.4 Correlation between antibody method and GC/MS method. 
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Figure 4.5 
Fraentograph of a urine containing 0.7ug/l of S-PNA. Sample was 
prepared by immunoaffinity chromatography. The upper right panel 
shows the fragnentograph of the main ion for S-PMA-methyester (m/z 
194) and the lower right panel the ion m/z 253 which serves as a 
"qualifier ion. The upper left panel shows the main ion (m/z 199) 
and the lower left panel the qualifier ion (m/z 258) for the 
internal standard d5-S-P11A-methyester. 
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Figure 4.6 
Fragmentograph of a urine containing 7ug/1 of S-PNA. Sample was 
prepared by irnmurioaffinity chromatography. The upper right panel 
shows the fragmentograph of the main ion for S-Pt1A-methyester (m/z 
194) and the lower right panel the ion m/z 253 which serves as a 
"qualifier ion. The upper left panel shows the main ion (m/z 199) 
and the lower left panel the "qualifier ion (m/z 258) for the 
internal standard d5-S-PNA--methyester. 
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Figure 4.7. 
Fragmentograph of a urine containing 18ug/1 of S-PNA. Sample was 
prepared by immunoaffinity chromatography. The upper right panel 
shows the fragmentograph of the main ion for S-PMA-methyester (m/z 
194) and the lower right panel the ion m/z 253 which serves as a 
1. 
qualifier ion. The upper left panel shows the main ion (m/z 199) 
and the lower left panel the 'qualifier ion (m/z 258) for the 
internal standard d5-S-Pt"IA-methyester. 
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Figure 4.8. 
Fragmentograph of a urine containing lOOug/l of S-PNA. Sample was 
prepared by immunoaffinity chromatography. The upper right panel 
shows the fragmentograph of the main ion for S-PMA-methyester (m/z 
194) and the lower right panel the ion m/z 253 which serves as a 
1. 
qualifier ion. The upper left panel shows the main ion (m/z 199) 
and the lower left panel the qualifier ion' (m/z 258) for the 
internal standard d5-S-PMA-methyester. 
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Fragmentograph of a urine containing 0.7ug/l of S-PNA. Sample was 
prepared by the method of Boogaard. The upper right panel shows the 
fragmentograph of the main ion for S-PNA-methyester(m/z 194) and the 
lower right panel the ion m/z 253 which serves as a "qualifier ion". 
The upper left panel shows the main ion (m/z 199) and the lower left 
panel the "qualifier ion" (m/z 258) for the internal standard d5-S-
PNA-methyester. 
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Figure 4.10. 
Fraientograph of a urine containing 7ug/l of S-PNA. Sample was 
prepared by the method of Boogaard. The upper right panel shows the 
fraentograph of the main ion for S-PNA-methyester (m/z 194) and 
the lower right panel the ion m/z 253 which serves as a qualifier 
ion. The upper left panel shows the main ion (m/z 199) and the 
lower left panel the qualifier ion" (m/z 258) for the internal 
standard d5-S-PNA-methyester - 
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Figure 4.11. 
Fraentograph of a urine containing 18ug/l of S-PNA. Sample was 
prepared by the method of Boogaard. The upper right panel shows the 
fraentograph of the main ion for S-PMA-methyester (m/z 194) and 
the lower right panel the ion m/z 253 which serves as a qualifier 
ion. The upper left panel shows the main ion (m/z 199) and the 
lower left panel the qualifier ion (m/z 258) for the internal 
standard d5-S-PNA-methyester. 
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Figure 4.12 
Fragmentograph of a urine containing lOOug/l of S-PNA. Sample was 
prepared by the method of Boogaard. The upper right panel shows the 
fragmentograph of the main ion for S-PMA-methyester (m/z 194) and 
the lower right panel the ion m/z 253 which serves as a 'qualifier 
ion'. The upper left panel shows the main ion (m/z 199) and the 
lower left panel the "qualifier ion" (m/z 258) for the internal 
standard d5-S-PMA-methyester. 
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non-exposed person, the background level of S-PHA is 0. 'lug/i. 
Figures 4.6-4.8 and 4.10-4.12 are from urines containing 7, 18 and 
looug/l of S-PtIA. The retention times of the S-PHA and d5-S-PMA 
methyl ester ions, m/z 194 and 199, are between 17.37-17.41 and 
17.35-17.37 minutes respectively. The 'qualifier ions', m/z 253 and 
258, are also shown. 
HPLC DETERMINATION OF URINARY S-PMA 
A linear calibration plot (0.125-1.0mg/1) was obtained with 
standards prepared in mobile phase. The HPLC limit of detection was 
SOug/L The results of the HPLC analyses of immunoaffinity column 
eluates from the urine of workers exposed to benzene are shown in 
Table 4.2. The corresponding data obtained by GC/NS are also 
presented. The concentration of urinary S-PHA ranged from 30 to 
1152ug/i. The correlation coefficient was 0.964 (n=6). A typical 
HPLC chromatograph is illustrated in figure 4.13. S-Pt'IA has a 
retention time of 14 minutes under the HPLC conditions employed. A 
mixed injection of sample and authentic S-PMA co-eluted. 
Table 4.2 Comparison of S-PMA Concentrations Determined by GC/MS 
and Immunoaffinity Chromatography (IAC)/}IPLC in the Urine 
of Benzene Exposed Workers 







Figure 4. 13 I-{PLC chromatogram of S-PtiA after immunoextraction 
from the urine of a benzene exposed worker. The urine 
contained 1152ug/1 of S-PMA determined by GC/NS. 
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DISCUSSION 
A monoclonal antibody, 309, which specifically binds S-PMA, has been 
generated. 3G9 retains its irnmunoreactivity after coupling to a 
solid support, enabling the production of an immunoaffinity column. 
The chromatography column can be used to selectively extract low 
levels of S-PNA (07ug/1) from urine. The performance of the 
immunoaffinity column at low urinary concentrations of S-PMA (12-
168ug/1) has been validated in a comparative study with the method 
of Boogaard and Van Sittert (1995). The two methods show excellent 
agreement. The correlation coefficient was 0.98 (n=23) over this 
range of S-PMA. Furthermore, bioconcentration of S-PIIA from the 
urine of benzene exposed workers has permitted the quantification of 
S-PMA by HPLC at 8 hour TWA airbourne exposures of around lppm. 
Immunoreactivity was assessed by monitoring binding of S-PMA applied 
to the column in aqueous buffer. The column adsorbed 1.5ug of S-PtIA 
and the analyte did not appear to leach from the column during 
washing. High recoveries (up to 100% of the load) were obtained 
where the retentate was eluted from the column with methanol. 
Moreover, the column retained functionality even after a very high 
percentage (95%) solvent elution step. With repeated use (10 times) 
there was no noticable loss in column performance. Observations show 
no evidence of changes in the antibody binding characteristics with 
time. 
The column also proved to be effective in selectively adsorbing and 
concentrating S-PNA from mid-stream urine. Loading analyte in this 
matrix appeared to have no detrimental effect on column performance. 
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Furthermore, recovery of analyte appears to be independent of sample 
volume. At present urine samples are collected in polythene bottles 
and acidified to pH 2, at this pH S-PHA has been shown to he stable 
for at least one month (Van Sittert et al, 1993). Acidification and 
neutralisation of urine exercisd a strong effect on column 
performance. Recovery of S-PIIA (28.3%) was lower than expected and 
is probably due to high levels of salt disrupting antigen antibody 
binding- Improving sample recovery will further improve assay 
sensitivity. Recovery may be improved if urines are desalted prior 
to extraction. Alternatively, samples may be stored frozen rather 
than at acidic pH after collection. 
The amount of antibody coupled to the solid support (54ug/ml gel) 
was less than the quoted binding capacity (8-10mg/mi gel). However 
antibody uptake (89%) is in the optimum range (80-90%) described by 
Pfeiffer et al (1992). In this study, no further attempts have been 
made to optimise the antibody coupling chemistry or the 
chromatography conditions and additional improvements in assay 
performance may be possible. 
We have shown that 3G9 is predominantly reactive with S-PMA. GC/NS 
chromatograms of immunoextracted samples contained fewer peaks than 
those samples analysed by the method of Boogaard. Due to the loss of 
sample matrix it was necessary to modify the reported GC conditions. 
Changes were made to the injection protocol in order to prevent loss 
of sample during the solvent purge. 
After immunoextraction background levels of S-PIIA could be measured 
(fig. 4.5 ). In non-exposed populations the concentration of S-PIIA 
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is in the range 0.7-2.3ug/1. To compensate for differences in 
individual kidney filtration rates the amount of S-PMA is normally 
expressed per grain of creatinine. Figures 4.6, 4.7 and 4.8 are of 
urines containing 7, 18 and lOOug/l S-PMA respectively. Creatinine 
concentrations have previously been determined. The concentrations 
of S-PMA per gram of creatinine are 4, 31 and 44ug/g respectively. 
The mean urinary levels of S-PMA in smokers and non-smokers are 3.61 
and 1.99ug/g of creatinine. End of shift urine samples from workers 
exposed to lppm of benzene, 8 hour TWA, have an average S-PMA 
concentration of 47ug/g creatinine. 
The limit of detection of the present assay for S-PUA is 0.3ppm, 8 
hour TWA, of benzene (Boogaard and Van Sittert 1995). The 
sensitivity of the GO/MS assay is limited by the purity of the 
sample. Immunopurification reduces the background noise in the MS 
fraientographs (figures 4.6-4.8 and 4.10-4.12) and, therefore, the 
data demonstrates the potential of immunoaffinity chromatography to 
increase GO/MS assay sensitivity. It is estimated that 
immunoaffinity chromatography gives a ten fold increase in GO/MS 
assay sensitivity. 
Bioconcentration has facilitated the measurement of S-PMA by HPLC 
from the urine of benzene exposed workers. Results obtained by 
immunoaffinity chromatography/HPLC correlate (correlation 
coefficient 0.964) with those obtained by GO/MS (Table 4.2) over a 
range of values (30-1152ug/1). GC/NS has shown that 3G9 is 
predominantly reactive with S-PMA. The excellent agreement between 
the data derived by post-immunoenrichment HPLC and those obtained by 
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'snc i .c 	 nc endogenone. components of urine 
me 	ceocni sen hv 	cr interfere with antmbodyanalyte binding. 
IbC chromatogram (figure 4.1.3) is free from interfering peaks. 
Sensitivity could be further improved by increasing the volume of 
urine subjected to immunopuri f icat ion - 
Immunoaffinity chromatography/HPLC analyses are simple and easy to 
perform compared with GC/MS. it is estimated that 75 samples per a 
day can be analysed by IAC/HPLC. In addition, HPLC determination can 
be readily performed in many laboratories, unlike GC/NS analyses 
which restrict the method to use in sophisticated laboratories. Our 
data demonstrares the potential utility of immunoaffinity 
chromatography/HPLC in monitoring exposure to benzene. 
Further improvements in the immunoaffinity/HPLC analysis of urinary 
S-PHA were made by changing the HPLC mobile phase to 
water:methanol:acetic acid, 70:30:1. This eliminates sample 
preparation after immunoextraction and allows the direct 
determination of S-PIIA in column eluants, thereby reducing both the 
number of stages where sample loss may occur and assay time. In 
addition, to improve assay reliability an internal standard - S--
phenyl-N-trifluoroacetyl-L-cysteine - has been synthesised. 
Preliminary studies indicate S-phenyl-N-trifluroacetyl-N-cysteine is 
bound by antibody 3G9 and can he extracted from a spiked urine by 
immunoaffinity chromatography. The retention time of S-PHA and S-
phenyl-N-trifluroacetyl-L-cysteine was 11 and 22 minutes 
respectively when water:methanol:acetic acid was used as the mobile 
phase. 
196 
Having developed and validated a simple laboratory assay for the 
measurement of urinary S-PMA, future investigations will focus on 
the production of a field kit which will enable simple and rapid 
tests for exposure monitoring by operators in the field. 
CHAPTER FIVE 
THE DETERMINATION OF HAEMOGLOBIN ADDUCTS 
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INTRODUCTION 
Compounds which directly or indirectly give rise to mercapturic 
acids are also able to react with the nucleophilic centres in 
protein molecules. The determination of protein adducts is therefore 
an alternative approach to determining mercapturic acids. Due to the 
difficulties encountered in raising useful monoclonal antibodies to 
2-HEMA (chapters 2 and 3) the determination of 2-(hydroxyethyl) 
adducted proteins was investigated 
5.1 PROTEIN ADDUCTS AND RISK ASSESSMENT 
Proteins are macromolecules which contain nucleophilic centres (eg. 
the sulphydryl group of cysteine, methione sulfurs, the Ni and N3 
atoms of histidine, the amino group in lysine, the aspartic and 
glutamic carboxylates and the N terminal amino group) which are able 
to react with electrophiles. In 1974, Ehrenberg et al first 
suggested the use of proteins as nucleophiles for use in dose 
monitoring studies and demonstrated that alkylation of tissue 
proteins could he used to measure the genetic risk from 
electrophiles in the environment. Mice were exposed to air 
containing ethylene oxide and the hydroxyethylation of protein and 
DNA in several tissues was measured. The level of binding was very 
similar in the tissues examined and the ratio of protein and DNA 
binding was consistently 22-28 : 1. 
Furthermore, Ehrenberg and his colleagues translated tissue dose 
into risk equivalents by expressing the genetic risks of 
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environmental chemicals in the framework of low LET (Low energy 
transmission) radiation- Quantifying risks from various sources in 
the same unit - the rad-equivalent- Ehrenberg facilitated the 
comparison of risks, of alternatives in risk-benefit evaluations and 
the summation of risks of various origins. On the basis of dose-
effect curves of ethylene oxide and X-rays, in barley, a tissue dose 
of lmMh of ethylene oxide equals 80 rads of low LET radiation. For 
a review of the rad-equivalence concept see Tor'nqvist et a! 
(1991). 
5.2 HAEMOGLOBIN ADDUCTS 
For applications in human tissue dosimetry the chosen adduct must be 
stable and determinable by non-nuclear methods. The protein should 
also be abundant and readily available for sampling. Haemoglobin 
fulfils these criteria and has been shown to be suitable for the 
evaluation of genetic risks of alkylating agents (Osterman-Golker et 
al 1976). 
Exposing mice to either ethylene oxide or dimethylnitrosamine, a 
carcinogen which needs metabolic activation, Osterman-Golker 
demonstrated that haemoglobin alkylation could be used to measure 
exposure to both primary alkylating agents and compounds that are 
metabolised to alkylating agents. They also demonstrated that the 
life time of haemoglobin (about 4 months in man) was not affected by 
alkylation making it suitable for monitoring both acute and chronic 
exposure. Several direct and indirect alkylating agents have been 
shown to give rise to hydroxyethylated haemoglobin: ethene 
(Ehrenberg et al 1977), vinyl chloride (Osterman-Golker et al 1977) 
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and ethyl methanesulfonate (Truong et al 1978). The analysis of 
haemoglobin as a dose monitor for alkylating and arylating agents 
has been reviewed by Neumann (1984). 
53 DETERMINATION OF HAEMOGLOBIN ADDUCTS 
In their initial studies, Ehrenberg et al (1974) determined the 
number of adducted histidine molecules in haemoglobin by GO/MS 
(after protein hydrolysis and adduct enrichment)- The method is very 
sensitive and background levels of adducted histidine were reported 
in populations not exposed to alkylating agents (Van Sittert. 1985). 
However, these methods were laborious, expensive and not suitable 
for monitoring large populations. More suitable methods for 
biomonitoring are based on the determination of adducts formed by 
reaction with the amino groups of the N-terminal valine residues of 
the cA. and chains of haemoglobin. (For a review see Britton et al, 
1991)- 
5.4 THE EDMAN DEGRADATION REACTION 
The N-terminal adducted valines of the oL. and 3 chains of 
haemoglobin are the major haemoglobin adducts formed on exposure to 
alkylating agents Adducted N-terminal valines can be quantified by 
the Edman degradation reaction. Edman degradation sequentially 
removes one residue at a time from the amino terminus of a peptide.. 
In an Edman degradation reaction, phenyl isocyanate is reacted with 
uncharged terminal amino groups to form a phenyithiocarbamoyl 
derivative which is liberated under mildly acidic conditions as the 
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cyclic phenylthiohydantoin amino acid (Figure 5.1). The 
phenylthiohydantoin derivative can he quantified after separation by 
GO. In 1984 Jensen et al showed that the alkyated N-terminal valine 
was selectively split off from haemoglobin under neutral-alkaline 
conditions leaving unadducted valine attached to the protein. The 
method was rapid but detection of the phenyl isocyanate conjugate 
lacked the desired sensitivity for biomedical monitoring (due to the 
low response of the flame ionisation or electrochemical detectors.). 
5.5 THE MODIFIED EDNAN DEGRADATION REACTION 
A breakthrough came two years later when N. Tornqvist et al (1986) 
substituted the conventional sequencing reagent, phenyl 
isothiocyanate, with pentafluorophenyl isothiocyanate (PFPITC, 
Figure 5.2). Pentafluorophenyithiohydantoin (PFPTH) derivatives 
(Figure 5.2) could he detected by GO/MS (negative ion chemical 
ionisation) with a sensitivity of l-lOpmol hydroxyethylvaline/g Rb. 
This detection limit corresponds to a degree of alkylation obtained 
from exposure to ethylene oxide at an average level of 0.01 ppm 
40hour/week for four months, the life span of haemoglobin in man 
(Tornqvist 1985). 
With the modified Edman degradation procedure it has also been 
possible to monitor epoxide doses from exposure to ethene. For 
example, ethene is used to ripen bananas and workers in this area 
had adduct levels elevated by 25 pmol/g globin. Similarly, ethene in 
cigarette smoke raised the number of hydroxyethylvaline adducts, on 
average, by 85 pmol/g globin for people smoking 10 cigarettes per 























F 	 =s 
PENTAFLUOROPHENYL ISOTHIOCYANATE (PFPITC) 
1 -(2-HYDROXYETHYL)-5-I SOPROPYL-3 -PENTAFLUORO-
PHENYL-2-THIOHYDANTOIN 
Figure 5.2 The derivatisation agent PFPITC used in the modified 
Edman degradation procedure and the PFPTH adduct 
monitored by GC/11S 
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In addition to its high sensitivity, the Modified Edman degradation 
reaction has several advantages over early methods based on total 
protein hydrolysis: - 
The method is 20-50 times faster. 
Mild work up procedures reduce the risk of artefact formation 
during isolation of adducts from glohin samples. 
The method is adaptable to the determination of unknown adducts 
as fractionation of samples is not involved. All the substituted 
valines cleaved as PFPfHs and extracted, can he kept in one 
fraction to be subjected to GC/MS analysis. 
However, a further increase in sensitivity is still desirable 
(Tornquist 1991). Furthermore, the method is taxing and involves a 
lengthy work-up prior to assay. Also, N-alkyl Edman Degradation - MS 
needs expensive equipment and can be carried out only in specialised 
laboratories. 
(Kautialnen and Tornqvist (1990) reported a more generally applicable 
method determining hydroxyethyl and hydroxypropyl N-terminal valine 
adducts by GC analysis with ECD. Their results correlated 
excellently with the MS determinations but the pulsed ECD detector 
employed was significantly less sensitive. GC-ECD necessitates 
purification of the PFPTHS prior to analysis, which is carried out 
on Sep-Pak cartridges. The limit of detection of the ECD-GC method 
at present is 100 pmol/g globin which permits the detection of an 
increase in hydroxyethylvaline in smokers smoking 10 cigarettes a 
day, or an increment after exposures of 50ppb for ethylene oxide and 
ippra for ethene for 40 hours per week.) 
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5.6 A RADIOIHMUNOASSAY FOR 2-(HYDROXYETHYL)HEpTAPEPrIDE 
In this laboratory a specific and sensitive RIA has been developed 
for monitoring exposures to ethylene oxide and ethene (Wraith et al 
1988). Polyclonal antibodies were raised to adducted N-terminal 
heptapeptides of the 	chain of haemoglobin released from glohin 
by the action of trypsin (fig. 5.3). The immunoassay could measure 
adducted heptapeptide in the presence of a lO  fold excess of non-
adducted heptapeptide, and had a sensitivity of 0.14 pmol/g globin 
comparable to the GC-MS method described above. The RIA has been 
validated in a comparative study with the G("-MS method, and the 
results from samples analysed by the two procedures were in good 
agreement (correlation coefficient = 0.97). 
Recently, the RIA has been converted to an ELISA. The ELISA has been 
used at the Shell Biomonotoring Laboratories and found to correlate 
well with the GC/MS procedure used there. However, high background 
values make the assay unsuitable for routine use (personal 
communication with H. Van der Waal, Shell Biomonitoring 
Laboratories). Polyclonal antibodies have a broad substrate 
specificity and problems associated with a high background may be 
overcome with a more specific monoclonal antibody. 
5.7 IMMUNOAFFINITY CHROMATOGRAPHY 
To determine adduct levels at low concentrations it is necessary to 
concentrate the adducts. The production of a monoclonal antibody 
which binds 2-(hydroxyethyl)heptapeptide will allow the development 
of immunoaffinity chromatography systems. Immunoconcentration may 
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Figure 5.3 The N-terminal heptapeptide released from the alpha-chain of ethylene oxide 
treated haemoglobin by trypsin hydrolysis. 
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Concentration should be at the earliest stage and by the gentlest 
methods possible to avoid artefact formation. The optimum would be 
the quantification of adducted valines in whole haemoglobin or 
globin samples. The production of an immunoaffinity column which 
bound hydroxyethylatecl valine in whole haemoglobin or globin would 
greatly facilitate the assay of N-terminal adducted valines. 
The aim of this aspect of the study was to produce a monoclonal 
antibody which recognises 2-(hydroxyethyl)I-ieptapeptide in whole 
haemoglobin and to develop an immunoaffinity column to complement 
the GC/NS analysis of N-terminal adducted haemoglobin. 
Due to the inaccessibility of the adducted N-terminal valines in 
whole haemoglobin adducted N-terminal heptapeptide from the alpha 
chain of haemoglobin was chosen for immunisation. The production of 
a monoclonal antibody which binds 2-(hydroxyethyl)heptapeptide, the 
development of an ELISA for measurement of 2-(hydroxyethyl) 
heptapeptide and antibody characterisation studies are described. 
Binding of adducted valine in whole haemoglobin is under 
investigation and the preliminary results are discussed. Finally, 
initial studies in to the development of an immunoaffinity procedure 
to facilitate biomonitoring studies is described. 
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METHODS AND MATERIALS 
MATERIALS 
REAGENTS 
Ammonium hydrogen carbonate, haemoglobin, 2-( N-morphoiino )-ethane 
suiphonic acid (MEB) and trypsin type Xlfl (cat. no. T8642) were 
purchased from Sigma Chemical Co. Ltd. (Poole, Dorset. UK)- Ammonium 
hydroxide, ethylacetate (analysed grade), ethyl ether (anhydrous, 
analysed grade) were purchased from J.T. Baker Philipsburg, USA). 
Formamide (puriss), pentafluorophenyl isothiocynate (PFPITC, purim), 
n-pentane (UV spectroscopy) 2-propanol (p.A) were purchased from 
Fluka Biochemika (Gillingham, Dorset. UK) Acetone (p.A), sodium 
carbonate (anhydrous, p.A.), sodium hydroxide (pA.), toluene. (p.A.) 
were available from B..D.H Merck (Merck Ltd., Dagenham, Essex. UK) 
N-terminal hydroxyethylated heptapeptide and non-adducted 
heptapeptide was prepared by Cambridge Research Biochemicals Ltd. 
using solid phase peptide synthesis. After peptide synthesis the 
heptapept ides were analysed by HPLC and found to be homogeneous on 
two stationary phases. In addition, FAB-MS gave molecular weights 
consistent with those expected for the adducted (MW 772) and non-
adducted heptapeptide (MW 728). 
Hydroxyethylated heptapeptide coupled to horse serum albumin (HSA), 
hydroxypropy adducted heptapeptide and whole adducted haemoglobin 
was supplied by Shell Research Ltd. (Sittingbourne, Kent. UK). 
Adducted heptapeptide was coupled through its carboxyl and amino 
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functions of aspartic acid and lysine to amino and carboxyl groups 
on horse serum albumin (HSA) using 1-ethyl-3-(3-dimethylamino 
propyl)carhodiimide. Approximately 16 moles of adducted heptapeptide 
was conjugated per mole of HSA. 
Hydroxypropy adducted heptapeptide was released from whole 
haemoglobin after adduction with propylene oxide. The mono- and di-
substituted heptapeptides were not separated. 
Adducted haemoglobin prepared by the reaction of human haemoglobin 
with 140 labelled ethylene oxide. From the incorporation of C14 it 
was estimated that each haemoglobin molecule contained at least one 
N-terminal modification. 
BUFFERS 
MES buffer consisted of 20mM 2-(N-morpholino)-ethanesulphonic acid 
pH 6.3 
METHODS 
5.8 PRODUCTION OF MONOCLONAL ANTIBODIES TO HYDROXYETHYL 
HEPTAPEPTI DE 
IMMUNISATION PROTOCOL 
Three female, 10-12 week old Balb/c mice were used for immunisation. 
Primary immunisations (day 1) and secondary immunisations (day 21) 
were given sub-cutaneously. Each mouse received lOOug of 2-
(hydroxyethyl)heptapeptide conjugated to horse serum albumin in 
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200u1 of a 50:50 v/v hapten adjuvant emulsion. Primary immunisations 
were prepared in Freurids complete adjuvant whilst secondary 
immunisations were prepared using Freunds incomplete adjuvent. Nice 
were bled (approx. 150u1) from the retro-orbital plexus (day 30). 
Serum was separated from the blood samples by centrifugation 
(2200rpm for 5 minutes), and stored frozen at -700C. 
SCREENING ANTISERA 
Antibody titre was determined by the preparation of antibody 
titration curves (1:30 to 1:7680). Relative affinity was determined 
by the preparation of standard calibration plots (1x10 11 to 1x10 9  
moles/ml 2-(hydroxyethy)heptapeptide) with a limiting concentration 
of antibody Ovaibumin-2-(hydroxyethyl)heptapeptide (lug/ml) and 
ethylene oxide derivatised haemoglobin (2.5ug/ml) were used for 
plate coating in the screening assays. Assay protocols are desribed 
in chapter 2. 
CELL FUSIONS 
Prior to fusion, mice were immunised with lOOug of immunogen in 
lOOul sterile PBS, intraperitonealy, on two consecutive days. Two 
days after the final pre-fusion immunisation, the mice were 
sacrificed by asphyxiation in diethyl-ether. The spleens were 
immediately removed from the mice and the spleen cells fused with 
the myeioma cell line Sp 2/0. Ag 1-4. as deecribed in chapter 3. Two 
fusions were performed. 
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Fusions were screened by ELISA. Derivatised haemoglobin was used for 
plate coating (25ug/ml). Wells were recorded as positive in the 
screen with an O.D. of greater than two times background. Binding of 
free hapten was detected in binding inhibition studies with 
500pmol/ml of 2-(hydroxyethyl)heptapeptide. 
59 CHARACTERISATION OF MONOCLONAL ANTIBODY 4D3 
Optimum plate coating concentration and antibody dilution were 
determined by chequer-board assays. Antibody affinity and 
specificity was determined from calibration curves Cross-reactivity 
studies were peformed with non-adducted heptapeptide, 
hydroxyethylheptapeptide and hydroxypropyiheptapeptide. Calibration 
curves in the range lx1Er6 to 1x10 2 pmol/ml were prepared in the 
cross-reactivity studies. 
5.10 BINDING STUDIES WITH WHOLE HAEMOGLOBIN. 
Binding of adducted heptapeptide in whole haemoglobin was 
investigted by the preparation of calibration curves (1x10 6 - 1x10 
12 pmol/ml) of adducted haemoglobin, non-adducted haemoglobin and 2-
(hydroxyethyl)heptapeptide. Calibration curves were prepared in 
PBS/I'ween - 
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5.11 DETERMINATION OF ADDUCTED 2-(HYDROXETHYL)HEPrAPEPrIDE IN WHOLE 
HAEMOGLOBIN BY ELISA AFTER TRYPSIN HYDROLYSIS 
GLOBIN PREPARATION - METHOD 1 
Globin was extracted from whole adducted and non-adducted 
haemoglobins as follows. Haemoglobin solution was added dropwise 
with vigorous stirring to 20m1 of 1% lH HC1 in acetone at -20C. A 
freezing mixture of 3:1 (w/w) crushed ice:sodium chloride was used 
to generate a -200C bath. The precipitated globin was separated from 
the haem by centrifugation (1720g for 10 minutes at -200C). The 
supernatant was discarded. To avoid irreversible denaturation of the 
globin it was essential that in subsequent manipulations the protein 
was kept at -200C. The globin was dissolved in lml of distilled 
water and reprecipatated by adding dropwise to acid/acetone as 
above. After centrifugation the precipitate was washed once with 
acid/acetone and twice with acetone alone. In later manipulations 
the globin became finer and the centrifugation time had to be 
increased (up to 40 minutes in the final wash). 
After the final wash, traces of acetone were evaporated, initially 
under a gentle stream of nitrogen, and finally by freeze drying. 
TRYPSIN HYDROLYSIS 
Adducted globin, non-adducted globin and non-adducted globin spiked 
with 2-(hydroxyethyi)heptapeptide were hydrolysed as follows. Globin 
(10mg) was dissolved in distilled water (3m1). To this solution was 
added lOOul of 2mg/mi aqueous trypsin solution, followed by 600ul of 
0.5M ammonium hydrogen carbonate. After mixing, the final pH was 
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checked (should be pH 8.5 +/- 0.2), and the solutions were reacted 
at 370C for 2 hours. The pH of the solutions were adjusted to 6.5 by 
the addition of 02M HC1 and made up to a final volume of 5m1 with 
distilled water. The core peptides and the trypsin were precipitated 
by heating at 980C for 10 minutes. After cooling the solution was 
clarified by centrifugation (2400rpm, 20 minutes at room 
temperature). The clear supernatant was decanted and an accurate 
volume freeze dried. 
ASSAY OF TRYPSIN HYDROLYSED GLOBIN 
The concentration of hydroxyethyl heptapeptide was determined by 
ELISA. Calibration plots were developed with the monoclonal antibody 
designated 4D3. Freeze dried samples were resuspended in distilled 
water. Resuspending the samples in 300ul of water gives a ten fold 
increase in adduct concentration. 
5.12 DETERMINATION OF ADDUCTED N-TERMINAL VALINES BY 
THE MODIFIED EDMAN DEGRADATION REACTION 
GLOBIN PREPARATION - METHOD 2 
Haemoglobin samples were thawed on the day of use and mixed to 
ensure homogeneity. An aliquot (2.5m1) of haemoglobin was added 
dropwise to a freshly prepared solution 50mM HC1 in 2-propanol with 
continuous stirring. The haem was separated from the globin and 
removed by centrifugation at 4500g for 10 minutes at room 
temperature. The supernatant, containing the globin, was decanted 
and the dark brown residue discarded. Ethyl acetate (25ml) was added 
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to the supernatant and the supernatant ethyl acetate mixture was 
allowed to stand for 30 minutes at room temperature. The globin 
precipitates were collected by centrifugation at 2000g for 10 
minutes at room temperature. The supernatant was carefully decanted 
and discarded. The residue was resuspended in a further 25m1 of 
ethyl acetate and the precipitation step repeated as described 
above. The globin was then resuspended in 25ml of n-pentane and the 
washed globin was centrifuged at 4500g for 10 minutes at room 
temperature to remove any traces of water from the sample. The 
supernatant was discarded and the globin was dried in a desiccator 
under vacuum overnight. 
DERIVATISATION OF GLOBIN SAMPLES 
50mg of dry globin was accurately weighed and dissolved in l.bml of 
formamide in a screw capped tube. Calibration standards containing 
0-1800pmol HOEtValine/g globin were prepared in formamide from 
ethylene oxide treated globin containing an assessed 18nmol/mg 
globin. To each sample and standard was added 50u1 of an internal 
globin standard solution. Glohin standard was prepared from globin 
treated with perdeuterated ethylene oxide containing approximately 
2.5nmol 2H4 OETValine/mg globin. Internal globin standard solution 
consists of 400ug of internal standard globin and 5mg of carrier 
globin per ml of formamide. Addition of 50ul of this solution to 
50mg of sample corresponds to 1000 pmol 2H4 OETValine/g globin. 
After addition of internal standard the pH of the samples and 
standards was adjusted to 6.3 by the addition of iN NaOH. The 
derivatisation reagent PFPITC was added (7u1) to each tube, the 
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tubes were capped, mixed and left in the dark overnight at room 
temperature. In order to complete the derivatisatjon the samples 
were finally warmed at 40C for 1.5 hours. 
CLEAN-UP OF SAMPLES 
Deionised water (imi) was added to each sample and the sample was 
extracted with 2ml of ethyl ether. After separation a further imi of 
deionised water was added and the sample extracted a second time 
with 3ml of ethyl ether. The etherial phases were combined and the 
ether evaporated under a gentle stream of N2 gas. The residue was 
redissolved in lml of toluene. 
The toluene solution was extracted with 2m1 of deionised water to 
remove any traces of formamide. The toluene solutions were extracted 
twice with 2m1 0.111 aqueous sodium carbonate solution to hydrolyse 
any by-products. The toluene was extracted again with 2m1 of water, 
the aqueous phase was separated from the toluene by brief 
centrifugation and discarded. Finally the toluene extract was 
evaporated to dryness at 500C in a water bath under a gentle stream 
of N2. The residue was redissolved in 50u1 of toluene and analysed 
by GC/NS. 
GC/NS ANALYSIS OF DERIVATISED 2-(HYDROXYETHYL)VALINE 
GC/NS analysis was performed by the Department of Analytical 
Chemistry, Shell Research Ltd., Sittingbourne. Briefly, separation 
was achieved with a fused silica capillary column (30mxO.33mm, DB5 - 
Durabond) on a Finnigan Ilat9O GC. The sample was loaded in toluene 
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and methane was used as the mobile phase. Detection was by mass 
spectrometry with selective ion monitoring (m/z 348 and 352). 
Methane was used as the reagent gas. 
5.13 ANTIBODY PURIFICATION AND CONCENTRATION 
Cation exchange chromatography:- 
Cation exchange HPLC was performed with a Hydropore SCX column (10cm 
x 4.6mm). Before use the column was equilibrated with 20mM tIES pH 
63. Antibody solutions were diluted in tIES buffer and filtered 
through a 0.2um low protein binding membrane. Antibodies (lOml) were 
loaded onto the column at a flow rate of lml/minute, and the column 
washed with 15m1 of tIES buffer. Antibody was eluted with a gradient 
of 0-0.35M NaCl in 20mM tIES pH 6.3 developed at 2m1/min over 10 
minutes. Elution of protein from the column was monitored 
spectrophotometrically at 280nm. Fractions (2m1) were collected, and 
antibody activity was determined by immunoassay (preparation of 
antibody titration curves). 
Protein G - affinity chromatography:- 
Purification of antibody by cation exchange chromatography resulted 
in a. loss in antibody binding. Therefore, antibody was also purified 
by protein G affinity chromatography and concentrated by membrane 
filtration. Membrane filtration was performed with an Amicon 30 
centriprep filtration unit. Affinity purification and membrane 
filtration is described in 4.8 and 4.9 (pages 171-172). 
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5.14 PREPARATION OF AN IMNUNOAFFINITY COLUMN 
COUPLING ANTIBODY TO CNBR ACTIVATED SEPHAROSE 4B 
Antibody was coupled to CNBR activated sepharose (4.10, page 172). 
For coupling, concentrated antibody (1.5m1) was diluted in coupling 
buffer (1.5ml). Antibody uptake was determined from absorbance 
readings at 280nm. 
5.15 AFFINITY CHROMATOGRAPHY 
Before use, the immunoaffinity chromatography column was allowed to 
reach room temperature and equilibrated with PBS. Samples were 
chromatographed at a flow rate of approximately 0.5ml/minute. 
2-(hydroxyethyl)heptapeptide was diluted in PBA (lug/ml) and loaded 
(lml) onto the immunoaffinity column. The column was washed with PBS 
(Sml) and eluted with methanol (2m1). Fractions, load (imi), wash 
(imi) and retentate (imi) were collected. Methanol was removed by 
evaporation under a gentle stream of nitrogen. After evaporation the 
volumes were made up to imi by adding PBS. All the fractions were 
assayed for the presence of 2-(hydroxyethyl)heptapeptide by ELISA 
(3.91-1000ng/ml calibration curves were prepared). 
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RESULTS 
5.16 MONOCLONAL ANTIBODY PRODUCTION 
SCREENING ASSAY 
Nice were bled 14 days after the second immunisations, yielding 50-
150ul of serum per mouse. All the sera (x3) contained antibodies 
which bound both the ethylene oxide treated haemoglobin and adducted 
heptapeptide-ovalbumin conjugate coated plates in the screening 
assays. The antibody titre varied between the mice. The highest 
titres were observed with the derivatised haemoglobin coated plates 
(Table 5.1). All the sera contained antibodies which bound free 2-
(hydroxyethyl)heptapeptide (Table 5.1). Binding to whole adducted 
haemoglobin was inhibited with 2-(]ydroxyethyl)heptapeptide. The 
sera did not cross-react with non-adducted heptapeptide at 1000 pmol 
ml-1. 
Table 5.1 Screening results for 2-(hydroxyethyl)heptapeptide-
ovalbuinin immunised mice. 
HOUSE 	 TITRE 
Plate coating 
Oval-Rb-OH d}{b 
1 	 1:100 	1:300 
2 1:100 1:300 







* inhibition studies were performed with 500pmol/ml 
of 2- (hydroxyethyl )heptapeptide 
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Fusion 1 
Spleen cells from mouse 1, immunised with hydroxyethylated 
heptapeptide conjugated to HSA, were successfully fused with the 
myeloma cell line Sp 2/0. Ag 1-4. On the day of screening 50-100% of 
the wells per plate contained 1 or more viable hybrid colonies. In 
the ELISA screen 37 supernatants were positive. No supernatants 
contained antibody which bound free hapten in the binding inhibition 
studies. 
Fusion 2 
Spleen cells from mouse 2 were successfully fused with the Sp 2/0. 
Ag 1-4 myeloma cell line. The hybrid colonies grew very rapidly and 
the fusion was screened after 7 days. On the day of screening all of 
the wells on the fusion plates contained 1 or more viable clones. 
The supernatants were screened by ELISA and 24 positive wells were 
obtained. Inhibition studies showed 6 supernatants contained 
antibodies which hound free hydroxethylheptapeptide (500 pmol-ml 2-
(hydroxyethyl)heptapeptide). The fusion plates were screened a 
second time, 7 days later, for slower growing hybridoma clones. 34 
new positive wells were detected, none of which contained antibodies 
which bound free hapten. 
Wells 1C8, 4D3, and 5F2, demonstrated the greatest inhibition in the 
binding inhibition studies (81%, 57% and 77% respectively). 
However, 1C8 supernatant also bound the non-adducted heptapeptide in 
the cross-reactivity studies and no further work was therefore 
carried out on this cell line. 
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Wells 4D3 and 5F2 were cloned and expanded as described in the 
methods. The results are summarized in table 52. Monoclonality was 
confirmed for well 4D3F3. 
Table 52 Fusion 2 clone plate results 
CLONED WELL 	 CLONE PLATE RESULTS 
NOS. WELLS 	NOS. +VE WELLS 	NOS. MONOCLONAL 
CONTAINING IN SCREENING WELLS +VE IN 
HYBRIDOI4AS 	ASSAY 	 SCREENING ASSAY 
4D3 	 79 	 12 	 5 
5F2 84 0 0 
5.17 CHARACTERISATION OF MONOCLONAL ANTIBODY 4D3 
Assay conditions were optimised in chequer-hoard assay studies. 
The most sensitive assay conditions were achieved with 1:100 culture 
supernatant and either 0. 25ug/ml 2-(hydroxyethyl )heptapeptide-
ovalbumin or lug/nil adducted haemoglobin coated plates. Under these 
conditions 2-(hydroxyethyl)heptapeptide could be measured in the 
range 2x10 12 to 1x10 9 moles/ml (figure 5.4). The limit of 
detection was the same with both coating materials. 
The antibody did not cross-react with non-adducted heptapeptide or 
hydroxypropylheptapeptide in the measuring range of the assay. 
Cross-reactivity did occur when non-adducted heptapeptide and 
hydroxypropyl heptapeptide were present in a 1250 fold excess. IC50 
values for hydroxyethylheptapeptide, non-adducted heptapeptide and 
hydroxypropylheptapeptide were 8x10 1, 1x10 7 and lx10 7 moles/ml 
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developed with 4D3 in microtitre plates coated 














I 	 ... 	 j•'I 	 _•. 	
.. 	 -.1-.-T- 	
_[ 
0 	1 	W 	1 11 	I-gi ll 	1490- 	F 
to 	 too oOO 
	
%0~00 	too 0010 	 Qø 
' 	N-(2-HYDROXYETHYL) —0----- HEPTAPEPTDE 
HEPTAPEPTIDE 
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5.18 BINDING OF 2-(HYDROXYETHYL)HEPTAPEPTIDE IN WHOLE HAEMOGLOBIN 
Calibration curves were prepared with whole adducted haemoglobin, 
non-adducted haemoglobin and hydroxyethylheptapeptide. The antibody 
was able to distinguish adducted and non-adducted haemoglobin in the 
ELISA (figure 5.6). Assuming each haemoglobin molecule contains one 
adducted N-terminal valine then binding to whole haemoglobin was 
observed in the range 2x10 8 to 5x10 10 moles/ml of haemoglobin. 
This binding is approximately 0.6% of that expected (1050 values 
obtained with adducted haemoglobin and adducted heptapeptide were 
7x10' and :3x10 9 moles/ml respectively). 
5.19 DETERMINATION OF ADDUCTED 2-(HYDROXYETHYL)HEPTAPEPTIDE IN 
WHOLE HAEMOGLOBIN BY TRYPSIN HYDROLYSIS 
56mg of globin was extracted from lOmi of 10mg/mi solution of 
adducted haemoglobin. After freeze drying the globin appeared as a 
white-pale brown solid. The N-terminal heptapeptide was released 
from the globin by trypsin hydrolysis. No adducted heptapeptides 
were detected in the control (non-adducted) haemoglobin. 90% of the 
2-(hydroxyethyl)heptapeptide added to a non-adducted globin was 
measured in the ELISA. The adducted haemoglobin contained 
25.2pmol/mi of adducted heptapeptide. After correction for loss of 
sample during preparation this corresponds to 28000pmol of adducted 
heptapeptide per gram globin. This was 0.2% of the expected value if 
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Figure 5.6 Adducted whole haemoglobin and adducted heptapeptide 
calibration plots developed with 4D3. Plates were 
coated with whole adducted haemoglobin. 
5.20 DETERMINATION OF ADDUCTED 2-(HYDROXYETHYL)VALINE IN WHOLE 
HAEMOGLOBIN BY GC/NS (Modified Edman Degradation) 
The adducted haemoglobin showed an increase in 2-
(hydroxyethyl)heptapeptide from 70pmol/g globin in the background 
sample to 26745 pmol/g globin. The level of C14 equivalent peak at 
m/z 350 remains constant at 17-19%. It appears that the amount of 
C14 cannot he quantified at this level of activity. 
5.21 PROTEIN PURIFICATION AND CONCENTRATION 
Salt fractionation and cation exchange chromatography yielded 17mg 
of antibody from 500m1 of cell culture supernatant (34ug/mi 
supernatant). A loss in antibody immunoreactivity was observed in 
binding studies after HPLC purification (table 5.3). 
Protein G purification yielded 11.79mg of antibody (23.5ug of 
antibody per ml of culture supernatant). Antibody remained 
immunoreactive after protein G purification. The antibody titration 
curves demonstrate an 8 fold increase in 4D3 concentration. Antibody 
was concentrated a further 20 fold by membrane filtration. After 
membrane filtration 90% of the immunoglobulin was recovered 
(6.1mg/mi). 
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Table 5.3 Immunoreactivity (1050 values) during 
antibody purification. 
FRACTION 	 TITRE 
HPLC 	PROTEIN G 
PURIFIED PURIFIED 
Culture supernatant 	 1:500 	1:400 
Purified antibody 	 1:60 	 1:3000 
Concentrated antibody 	 1:300 	1:60000 
COUPLING TO SOLID PHASE 
7.78mg (85%) of 4D3 was coupled to 0.38g (1.33m1 of swollen gel) of 
CNBr activated sepharose. No protein was detected in the final high 
and low pH washes indicating that the antibody was covalently hound 
to the solid support. 
522 II'iMUNOAFFINITY CHROMATOGRAPHY 
The immunoaffinity column had a maximum binding capacity of 4.7ug of 
hydroxyethylheptapeptide (66x10 9 moles). No hydroxyethyl 
heptapeptide was observed in the final washes when the fractions 
were analysed by ELISA. 
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DISCUSSION 
Three mice were immunised with 2-(hydroxyethyl)heptapeptide 
conjugated to HBA. Antibodies which hind free hapten were induced in 
all the mice (table 5.1) Sera from mice 1 and 3 demonstrated the 
highest titres and relative affinity in the screening assay. Spleen 
cells from these two mice were successfully fused with the Sp2 
myeioma cell line. 
Six supernatants containing antibody which bound free hapten were 
detected when fusion 2 was screened by ELISA Supernatant from well 
4D3 demonstrated the greatest relative affinity and specificity for 
2-(hydroxyethyl)heptapeptide. Well 4D3 was successfully cloned. The 
monoclonal cell line was cultured in stationary flasks and the 
supernatant harvested at regular intervals. 
An ELISA has been developed with 4D3 which has a limit of detection 
of 2pmol/ml of adducted heptapeptide (Figure 54). The assay appears 
to be specific for 2-(hydroxyethyl)heptapeptide 	Cross-reactivity 
with hydroxypropyl heptapeptide and non-adducted heptapeptide was 
observed only when present in a 1250 fold excess. The monoclonal 
assay should permit the quantification of approximately 0.6pmol of 
adducted N-terminal valine per gram of globin. 
The ELISA developed with 4D3 is less sensitive than the assay of 
Wraith et al (1988) developed with a polyclonal antisera 
(sensitivity 0.14pmol/9 globin). However the sensitivity compares 
favourably with the sensitivity of the GC/MS modified Edman 
Degradation procedure (sensitivity 1-10pmol/g globin). The 
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sensitivity of the ELISA is suitable for biomonitoring and it 
should he possible to determine the level of background adducts in 
man (0.3nmol/g glohn, Tornqvist 1986). However, assay performance 
is yet to he validated with an alternative analytical procedure. 
This is essential if the utility of the monoclonal based assay is to 
he discussed. Validation will demonstrate if the problems associated 
with the polyclonal assay, high background and low adduct values at 
high concentrations, can he overcome with 4D3. 
It is advantageous to detect antibodies which bind free hapten at 
the earliest possible moment after fusion. The first fusion was 
therefore, also screened by RIA. For the RIA 2-
(hydroxyethyl)heptapeptide was labelled with 1251 using Bolton and 
Hunters reagent (Figure 5.9'. No antibodies which bound free hapten 
were detected with RIA, confirming the results of the EL1SA. 
Radiolabelled assays have a number of disadvantages. The stability 
of the isotope may limit the shelf life of the reagent. 1251 has a 
short half-life (64 days) and the labelling therefore must be 
repeated at regular intervals. Radioactivity is hazardous and 
radioactive waste must he disposed of. As a result, an alternative 
labelling strategy was investigated. 
The use of a chemiluminescent label attached to an antibody has 
enabled the development high sensitivity assay systems (Collins 
1985). In a novel approach, 2-(hydroxyethyl)hepatapeptide was 
chemilumilahelled with the acr±dinium ester 4-(2-succinimidyl- 
oxycarhonylethyl )phenyl-lO-methylacridiflium9carhOxylate 	(figure 
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Figure 5.10 The acridinium ester 4-('2-succinimidyloxycarbonylethyl 
phenyl- 10-methy1acridinium-9-carbow1ate 
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in the presence of dilute hydrogen peroxide. The chemiluminescent 
reaction involves hydrolysis of the ester bond by the hydroperoxide 
ion and the formation of the electronically excited N-
methylacridone. Consequently, the chemiluminescent moeity is 
released from the hapten prior to excitation. This reduces the 
quenching of labels associated with proteins, leading to a 
relatively high quantum yield. Proteins can he labelled with high 
specific activity and chemiluminescence has the potential of 
increasing assay sensitivity. In addition, chemiluminescent 
immunoassays can be readily converted into assay kits. 
The integrity of the lumilabelled heptapeptide was demonstrated by 
the development of a calibration plot (2-250pmoles/ml) with the 
polyclonal antisera of Wraith (1988). At present this assay is five 
times less sensitive than the RIA/ELISA developed with the 
polyclonal antisera. The low sensitivity of the assay was due, in 
part, to the sensitivity of the detector which necessitated the use 
of high concentrations of label and antibody. Furthermore, when 
compared to the ELISA as a screening assay after fusion it was 
difficult to distinguish positive and negative supernatants due to 
high levels of non-specific binding. Although the assay remains to 
be optimised the application of this labelling procedure to 2-
(hydroxyethyl) heptapeptide has been demonstrated. If the monoclonal 
based assay is successfully validated the development of a 
chemiluminescent assay, with a potentaial for improved assay 
sensitivity, will be investigated. 
The recognition of adducted N-terminal valines in whole haemoglobin 
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was investigated. In initial studies comparable results were 
obtained when sera were screened against 	ovalbumin-adducted 
heptapeptide and ethylene oxide adducted haemoglobin coated plates. 
Also, 	no 	differance 	was 	observed 	between 	2- 
(hydroxyethyl)hePtaPePtide calibration plots developed against 
adducted heptapeptide and ovalbumin heptapeptide coated plates. 
Next, 2_(hydroxyethyl)hePtaPeptide, adducted and non-adducted 
haemoglobin calibration plots were developed with 4D3. The antibody 
could distinguish between adducted and non-adducted haemoglobin but 
the concentration of adduct was less than expected (approximately 
06%) assuming every haemoglobin molecule contains at least one 
adducted N-terminal valine. 
The number of adducted N-terminal valines in whole haemoglobin was 
estimated from the incorporation of radioactivity after the reaction 
of haemoglobin with radiolabelled ethylene oxide. The number of 
adducted N-terminal valines was therefore determined more 
accurately. Determination of the concentration of adducted 
heptapeptide by ELISA after release by trypsin hydrolysis from 
whole globin found only 28nmol of adduct per gram of globin. This 
was 0.2% of the expected value. To confirm this result the number of 
2-(hydroxyethyl)valifles was determined using the modified Edinan 
Degradation reaction and GC/NS analysis. The concentration 
determined by GC/NS analysis (27rirnol/9 globin) confirms the value 
obtained by ELISA. This data strongly suggests that 4D3 is able to 
quantitatively bind N-terminal 2-(hydroxyethyl)valifle whole in 
adducted haemoglobin. 
The aim of this part of the investigation was to develop an 
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immunoenriebment method to complement the Edman degradation 
procedure. The addition of an effective immunoenrichment to enrich 
whole adducted haemoglobin may reduce background interferences 
thereby enhencing the sensitivity of detection. It has been 
demonstrated that 4D3 retains its immunoreactivity after coupling to 
a solid support (CNBr activated sepharose) enabling the production 
of an immunoaffinity column. Immunoreactivity was assessed by 
monitoring binding of adducted heptapeptide applied in aqueous 
buffer. The column adsorbed 47ug of 2-(hydroxyethyl)heptapeptide 
and the analyte did not appear to leach from the column during 
washing. The column maintained its functionality after elution with 
solvent (95% methanol:water) allowing the same column to be used 
repeatedly Purification of N-terminal adducted haemoglobin by 





The major aim of this project was to generate monoclonal antibodies 
which recognize mercapturic acids for application in the detection, 
identification and exposure monitoring of genotoxic carcinogens. 
This has been achieved. 
A carefully designed hapten-protein conjugate and a judicious 
screening strategy has enabled the generation of a monoclonal 
antibody (3G9) which specifically binds S-PMA. Urinary S-PMA is a 
highly specific and sensitive marker of benzene exposure (Van 
Sittert et al 1993). 
Benzene is an important industrial chemical and a group 1 
carcinogen. Current occupational exposure limits (8 TWA) in the 
United Kingdom (MEL) and United States (PEL) are 5 and lppm 
respectively. Until now only GC/NS determination of 5-PIIA possessed 
the required sensitivity for application in biomonitoring programmes 
(0.3ppm 8 hours TWA, Boogaard and Van Sittert 1995). 
Immobilized antibody retains immunoreactivity and can be used to 
enrich low levels of S-Pt1A (0.7-168ug/1) from the urine of benzene 
exposed workers. Bioconcentration of S-PNA from the urine of benzene 
exposed workers has permitted the quantification of S-PMA by HPLC at 
8 hour TWA of less than lppm (background levels of urinary S-PMA can 
be detected). Furthermore, the performance of the immunoaffinity 
column has been validated against the solvent extraction GC/MS 
method of Boogaard (range 12-168ug/l, corr. coeff.098, n23). 
Immunoaffinity chromatography/HPLC analysis is simple and easy to 
perform, unlike the GC/MS method which requires a complex work-up 
prior to assay and is restricted to use in sophisticated 
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laboratories. In addition, the sensitivity of the GC/MS procedure is 
limited by the purity of the sample. Immunoaffinity chromatography 
results in a cleaner sample than solvent extraction and as a result 
the sensitivity of the GC/MS analysis has been improved at least 10 
fold - 
Results obtained with 3G9 validate the immunochemical approach. The 
development of a rapid cost effective field assay to determine 
urinary S-PtIA may improve human health exposure monitoring and 
permit more effective human health risk assessments-
Immunoanalytical methods lend themselves to the development of field 
kits. The development of an antibody based test kit which will 
enable simple and rapid tests for benzene exposure to be carried out 
by operators in the field is now been investigated. 
The development of simple methods to determine mercapturic acids 
will also have applicatioms outside of industrial biomonitoring. 
Metabolism of benzene via benzene oxide leads to excretion of S-PtIA 
in urine. Formation of benzene oxide is catalyzed by the cytochrome 
P450 system. Sex dependent differences and genetic polymorphism in 
the cytochrome P450 system exist and higher rates of metabolism may 
increase the susceptability of individuals to benzene toxicity 
(Kenyon et al 1996). Similarly, phenotypic variation can also be 
found in the glutathione_S_traflsferases (GSTs) and cancer 
susceptibility has been linked to phenotype. Polymorphisms may 
therefore have important implications in risk assessmemt. A simple 
immunoanalytical/HPLC method for the quantification of S-PMA should 
facilitate studies in this field. 
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In man 2-HEMA is a common urinary metabolite of a number of 
important industrial chemicals (eg. ethylene oxide, vinyl chloride 
and acrylonitrile). At present assays for 2-HENA lack the desired 
sensitivity for application in hiomonitoring programmes (Van Welie 
et al 1992). A second aim of this project therefore was to generate 
monoclonal antibodies which bind 2-HEMA for application in exposure 
monitoring programmes. 2-HEMA coupled to KLH was weakly antigenic 
and did not elicit a strong immunogen response. In a novel approach 
2-HEMA was coupled to NSA. Using an homologous protein as the 
carrier molecule focused the immune response on the hapten. However 
the antibodies which we generated were generally of too low affinity 
for application in exposure monitoring studies. 
Using a homologous protein carrier the practical possibility of 
producing class-specific antibodies to mercapturic acids has also 
been demonstrated. A low affinity, class-specific, antibody has been 
generated using acetylcysteine conjugated through its sulfhydryl 
group to NSA. Antibodies which bind mercapturic acids per se can be 
used to detect exposures to unknown genotoxic agents. Application of 
class-specific antibodies in an immunoextraction mode to concentrate 
unknown mercapturic acids should greatly facilitate the 
identification of unknown exposures using physico-chemical methods. 
Antibodies which bound low molecular weight mercapturic acids formed 
a very small percentage of the total response. It would be expected 
therefore that the number of B lymphocytes secreting antibody which 
recognised these mercapturic acids will also form a very small 
percentage of the total. Cell fusion is inefficient, the genetic 
information of only about 1:10000 lymphocytes is fixed in the 
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hybridoma cells. Furthermore, hybridoma cells can be easily lost 
before monocionality is reached. Using hybridoma technology the 
isolation of hybridoma cells secreting antibody which bound low 
molecular weight mercapturic acids has proved very difficult. - 
Molecular biology techniques are increasingly been used to generate 
monoclonal antibodies (Owens and Young 1994). Using recombinant 
technology the entire gene reportiore is saved and expressed. 
Application of this technology should greatly increase the chances 
of isolating antibodies to small mercapturic acids. In addition, 
with mutagenesis it may be possible to alter the genetic framework 
of a low affinity antibody to give a high affinity antibody. 
The framework of immunoglohulins has been used to generate 
recombinant libraries of proteins able to bind ligands of wide 
chemical diversity. Napolitano et al (1995) have demonstrated that 
the GST framework can also he used to generate a binding library. 
GSTs are able to bind molecules of low molecular weight and this 
novel approach may generate proteins capable of binding low 
molecular weight compounds. Mercapturic acids may be suitable and 
exciting substrates for the development of novel binding proteins. 
Reactive intermediates which gave rise to mercapturic acids may also 
give rise to protein conjugates. Haemoglobin adducts are commonly 
used in biomonitoring studies. We have demonstrated that monoclonal 
antibodies can be generated to adducted heptapeptide released from 
the alpha chain of haemoglobin by trypsin hydrolysis. To determine 
adduct levels at low concentrations it is necessary to concentrate 
the adducts. Concentration should be at the earliest possible stage 
and by the gentlest method possible to avoid artefact formation. 
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Initial studies strongly suggest antibodies can hind N-terminal 
adducted valines in whole haemoglobin. The development 	of 
immunoextraction procedures which recognize N-terminal valines in 
whole haemoglobin may facilitate the quantification of low adduct 
concentrations- 
For the ultimate carcinogen to bind covalently to haemoglobin it 
must be sufficiently stable to diffuse out of the cell in which the 
carcinogen is metabolised and into an erythrocyte This involves 
crossing two cell membranes. Serum proteins are more readily 
available and as a result adduct formation should be more efficient. 
In addition, serum proteins are synthesized in hepatocytes and it is 
in hepatocytes that many carcinogens are metabolised (Skipper 1990). 
The benzene metabolite, benzene oxide, not only undergoes reaction 
with glutathione but may also react with cysteine groups in other 
protein molecules (Bechtold, 1992). Serum albumin of man contains 
only one cysteine molecule (at position 34) with a reactive 
sulfhydryl group which is known to bind xenobiotics. Bechtold has 
demonstrated a linear response between benzene exposure and 5-
phenylcysteine formation, and was able to measure S-phenylcysteine 
in occupationally exposed humans. After protein hydrolysis Bechtold 
determined trifluoroacetyl derivitised S-phenylcysteine by GC/NS. 
The method is time consuming and the sensitivity is limited by the 
purity of the sample. Antibody 3G9 binds S-phenyl-N-
triflouroacetylcysteine. Immunoaffinity chromatography has the 
potential to improve the sensitivity and facilitate the 
determination of this adduct in albumin. This should be 
investigated. 
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Determination of adducts in albumin, like haemoglobin, is generally 
laborious and time consuming. The determination of adducts in whole 
albumin may greatly facilitate biological monitoring and metabolism 
studies. These studies have shown that antibodies can be generated 
that bind adducted NSA but which show no cross-reactivity with non-
adducted albumin. Furthermore, these antibodies demonstrate 
exquisite specificity, and are suitable for detecting low molecular 
weight (eg. hydroxyethylation) conjugates. Determination of albumin 
adducts formed by exposure to small molecular weight compounds (eg. 
butadiene and isoprene) may be rewarding. 
Nercapturic acids are a record of exposure in the last 24 hours. 
Serum albumin and haemoglobin have half-lifes of 20-25 days and 120 
days respectively in man and are a record of chronic exposure. 
However, exposures over a life-time determine an individuals risk to 
cancer. Some proteins have very long life-times (eg. collagen) and 
may prove to be lifetime dosimters (Skipper 1990). Antibodies are 
induced with one protein conjugate and screened against a second 
protein conjugate. Antibodies which recognize adducted proteins per 
se may have applications in this field of study. 
In 1895 Wohier wrote Organic chemistry nowadays almost drives me 
mad. To me it appears like a primeval forest full of the most 
remarkable things. a dreadful endless jungle into which one does not 
dare enter for there seems no way out'. Today that jungle still 
exists and remains largely unexplored. Although monoclonal 
antibodies give us one tool with which to travel, this study 
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